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ABSTRACT

Autotaxin in Central Nervous System Development and Disease
By Natalie A. Wheeler
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2016
Advisor: Babette Fuss, Ph.D., Professor, Department of Anatomy and
Neurobiology
During development, oligodendrocytes (OLGs), the myelinating cells of the central
nervous system (CNS), undergo a stepwise progression during which OLG progenitors,
specified from neural stem/progenitor cells, differentiate into fully mature myelinating
OLGs. This progression along the OLG lineage is characterized by well-synchronized
changes in morphology and gene expression patterns. The studies presented in this
dissertation identified the extracellular factor Autotaxin (ATX) as a novel upstream
signal modulating HDAC1/2 activity and gene expression in cells of the OLG lineage.
Using the zebrafish as an in vivo model system, as well as rodent primary OLG cultures,
this functional property of ATX was found to be mediated by its lysoPLD activity, which
has been well-characterized to generate the lipid signaling molecule lysophosphatidic
acid (LPA). LPA binds to Gprotein-coupled LPA receptors (LPARs) on the surface of
OLGs to initiate downstream signaling events. ATX’s lysoPLD activity was found to
modulate HDAC1/2 regulated gene expression during a time window coinciding with the
transition from OLG progenitor to early differentiating OLG. When looking further
downstream of the ATX-LPA axis, down-regulation of LPA receptor 6 (LPA6) was found

xi
to reduce the expression of OLG differentiation genes as well as the overall process
network area of OLGs. Thus, LPA6 plays a role in both the gene expression and
morphology changes seen in OLG differentiation. These findings prove useful for future
therapeutic targets needed for demyelinating diseases of the CNS such as Multiple
Sclerosis (MS), in which OLGs fail to differentiate into mature OLGs, needed for
remyelination.
Additionally, white matter injury has been frequently reported in HIV+ patients.
Previous studies showed that HIV-1 Tat (transactivator of transcription), a viral protein
that is produced and secreted by HIV-infected cells, is a toxic factor to OLGs. We show
here that Tat treatment reduces the expression of OLG differentiation genes and the
overall process network area of OLGs. Additionally, Tat-treated OLGs have reduced
ATX lysoPLD activity and there is a physical interaction between Tat and ATX.
Together, these data strongly suggest functional implications of Tat blocking ATX’s
lysoPLD activities and thus the ATX-LPA signaling axis proves to play a significant role
in the development of OLGs.

CHAPTER 1
Introduction to Myelin, Oligodendrocytes and Influential factors
Myelin and its functional significance
Communication throughout the brain relies on electrical signals between
neurons. Just as wires need insulation, neurons require the lipid rich multilamellar
myelin membrane for proper conduction. The highly insulated myelin membrane
provides support for brain conductivity and can be considered a defining characteristic
of vertebrates, though myelin-like sheaths have been found in invertebrates.
Oligodendrocytes (OLGs) and Schwann cells are the cells responsible for producing
myelin in the central nervous system (CNS) and peripheral nervous system (PNS),
respectively.
To ensure electrical signals are maintained and transmitted throughout the body,
ions pass through axons at areas of myelin gaps or so called “nodes of Ranvier.” This
passage of ions helps to retain electrical signals, as they appear to “jump” from one
node to another, and is therefore termed, saltatory conduction (Baumann and PhamDinh, 2001). Evolutionarily, myelin was one of the later structures of the nervous system
to evolve (Baumann and Pham-Dinh, 2001; Hartline and Colman, 2007). As animals
developed more sophisticated behaviors, the ability to act fast to capture or escape prey
was needed and rapid conductance of nerve impulses became a high priority for the
nervous systems of animals (Hartline and Colman, 2007). To allow for increased speed
of conductance, larger axons could be used to decrease the overall resistance of the
electrical signal and allow for faster conduction. This proves to be an impractical
solution for mammals, however, as the conduction speed needed would result in a large
1

distribution of nerve fibers that would be disproportionate to their body size. The myelin
membrane proved to circumvent this problem by allowing insulation to the axons,
thereby increasing the resistance of the electrical field (Hartline and Colman, 2007). The
myelin membrane serves as an integral part of the nervous system. Additionally, not
only does myelin act as an insulator of axons, it is now known that myelin also provides
axonal support (Saab et al., 2013). This idea becomes important when considering the
consequences of myelin loss on axons in pathology. The significance of myelin
becomes increasingly evident in pathological conditions where the myelin membrane is
disrupted, such as in the demyelinating disease Multiple Sclerosis (MS).
Multiple Sclerosis (MS)
Multiple Sclerosis (MS) is the most common demyelinating disease, for which
there is no present cure, and is usually seen in patients ranging from 20 to 50 years old,
although it has been reported in individuals as young as 2 and as old as 75. Currently,
there are approximately 2.3 million people worldwide affected by MS (Multiple Sclerosis
Society, 2016). MS proves to be the leading cause of non-traumatic disability with
symptoms encompassing vision loss, pain, fatigue, cognitive dysfunction and impaired
coordination (Fox et al., 2006). Both the diagnosis and treatment of MS is difficult as the
symptoms, severity and duration of MS can vary from person to person.
It is not clear as to the cause of MS, however, both genetic and environmental
factors have been argued to play a role in the development of the disease (Hauser and
Oksenberg, 2006). One of the environmental factors that may contribute to the disease
is a deficiency in vitamin D, which is produced when the body is exposed to natural
sunlight. The idea of a vitamin D deficiency in relation to MS was initially theorized when
2

an epidemiological study showed that MS cases tend to occur less frequently in
populations of people living closer to the equator. This goes along with the idea that by
living closer to the equator, a person would have more sun exposure and thus would
make more vitamin D than those living farther away from the equator (Freedman et al.,
2000; Raghuwanshi et al., 2008).
The genetic prolife of MS remains unknown and has not been strictly linked to
heredity. Those who have a first-degree relative (parent or sibling) with MS, however,
are more at risk of developing MS than the general population. Researchers have also
speculated that individuals can be born with a genetic predisposition that makes them
more sensitive to environmental agents that can cause the disease (Multiple Sclerosis
Society, 2016). Genome-wide association studies have identified over a hundred
polymorphisms with modest individual effects in MS susceptibility and confirmed the
main individual effect of the Major Histocompatibility Complex (Burrell et al., 2011;
Hoppenbrouwers and Hintzen, 2011). Additional immunological relevant genes were
found significantly overexpressed (Gutierrez-Arcelus et al., 2016). These studies,
however, involve patients diagnosed with MS and as such use blood or cerebrospinal
fluid (CSF), thus, the result obtained cannot be used to address any potential genetic
associations with parenchymal gene expression. Nonetheless, it is generally accepted
that the genetic contribution to MS susceptibility remains to be defined. Additionally,
there are certain risk factors including age, sex, race, smoking, infections, etc., that
have been linked to MS (Mayo Clinic, 2016). Though the exact cause of MS is
unknown, it is plausible that responsibility lies on the combination of genetic and
environmental risk factors.
3

There are four main clinically defined forms of MS that can be classified as:
relapsing remitting, primary progressive, secondary progressive and progressiverelapsing. RRMS is the most common form as 85% of patients start with this disease
course. Patients with RRMS have periods of MS “attacks,” called relapses, followed by
partial or complete recovery periods, known as remission. During remission, patients
display improved symptoms with no apparent progression of the disease. Interestingly,
patients suffering from RRMS have more brain lesions (plaques or scars) containing
inflammatory cells. As time progresses, patients with RRMS may transition to secondary
progressive MS (SPMS) (Multiple Sclerosis Society, 2016).

Another form of MS,

primary progressive MS (PPMS) is seen in roughly 10-15% of patients. PPMS is
characterized by a steady, but gradual, worsening of neurologic functioning, without any
distinct relapses or periods of recovery. People with PPMS tend to have more spinal
cord lesions than cortical lesions (Multiple Sclerosis Society, 2016). Lastly the rarest
form of MS is progressive relapsing (PRMS), with only 5% occurrence in the population.
PRMS is characterized by a steady worsening disease course from onset with
additional attacks of more severe neurological symptoms. Some PRMS patients
experience times of remission, although this is not true for all patients (Multiple
Sclerosis Society, 2016). Due to the capricious symptoms, severity and progression of
MS, it is sometimes difficult to classify as well as treat patients with MS.
As MS is classified as an autoimmune disease, current therapies target the
inflammation side of the disease. These therapies, however, fail to treat the loss of
myelin or any axonal damage caused by the disease. Though these treatments help
patients short term, remyelination by OLGs and axonal repair is needed to correctly
4

cure the disease. In this therapeutic paradigm, remyelination of axons, by OLGs, will
reinstate the proper neural circuitry needed for normal brain activity. Interestingly, OLG
progenitor cells (OPCs) are found in MS lesions, however, they are limited in their ability
to remyelinate or remyelinate sufficiently (Bradl and Lassmann, 2010; Chang et al.,
2002a; Goldschmidt et al., 2009). Therefore, with the notion that regeneration of the
myelin sheath follows the same mechanisms present during development, obtaining a
better understanding of OLG development from a progenitor cell to a fully myelinating
cell is integral to target specific mechanisms that are altered in demyelinated conditions.
Oligodendrocyte specification in the Central Nervous System (CNS)
OLGs were originally discovered by Rio Hortega in 1921 (Iglesias-Rozas and
Garrosa, 2012). Though the cellular origins of this myelinating cell in the brain and
spinal cord have been debated, research advances using transgenic mouse models
have given us insight into OLG specification (Richardson et al., 2006). CNS cell
initiation and proliferation develops within distinct layers and zones, of neuroectodermal
origin, where each zone comprises distinct cell types and morphologies (Brazel et al.,
2003; Marshall et al., 2003; Pringle et al., 1996; Richardson et al., 2006; Woodruff et al.,
2001). The ventricular zone of the brain is the first to develop and houses the origin of
neurons, as well as some astrocytes. This zone is made of pseudostratified epitheliallike tissue consisting of neuroectodermal tissue (Kettenmann and Ransom, 2013). As
development progresses, a new proliferative area, the subventricular zone, begins to
thicken and remains actively proliferative during early postnatal development (Brazel et
al., 2003). Cortical progenitor cells follow a developmental sequence in which cell types
develop in temporally distinct, yet overlapping patterns beginning with neuronal
5

development, followed by astrocyte development, and lastly OLG development
(Sauvageot and Stiles, 2002; Spassky et al., 1998, 2000).
During development, OPCs are generated in sequential waves from specific
germinal regions. OPCs arise from the ventricular zone of the spinal cord and the
ventral forebrain of the developing brain (Baracskay et al., 2007; Brazel et al., 2003;
Kettenmann and Ransom, 2013; Levison et al., 1993; Marshall et al., 2003; Privat and
Leblond, 1972) (Kessaris et al., 2006). Research conducted in the rat elucidated that
there are multiple areas along the ventral and dorsal axes of the spinal cord that
produce OLGs and that OLGs originate in subventral regions and later move to more
dorsal regions. Starting around E12.5, the pMN (motor neuron progenitor) domain of the
spinal cord produces 85-90% of the OPCs (Miller, 1996; Pringle and Richardson, 1993;
Pringle et al., 1996; Richardson et al., 1988, 2006; Woodruff et al., 2001). This is
followed by a second wave of OPC genesis emanating from more dorsal progenitor
domains starting at E15.5 (Cai et al., 2005a; Fogarty et al., 2005). Dorsally-derived
progenitors only contribute 10-15% of adult OLGs.
In the developing forebrain, OPCs also migrate in a series of waves. At about
E12.5 in mice (E5-6 in chicks), the initial wave of OPC production unfolds in the medial
ganglionic eminence and the closely associated enteropeduncular area of the ventral
telencephalon (Olivier et al., 2001; Spassky et al., 2001; Tekki-Kessaris et al., 2001).
These ventrally-derived OPCs then migrate into the cortex (Kessaris et al., 2006;
Richardson et al., 2006) and can be observed throughout the cortex around E18
(Kessaris et al., 2006; Richardson et al., 2006; Woodruff et al., 2001). The second and
third wave of OPCs emanating from the lateral and caudal ganglionic eminences, at
6

E15.5 and from the cortex after birth, give rise to the majority of adult OLGs in mice
(Brazel et al., 2003; Kessaris et al., 2006; Richardson et al., 2006; Woodruff et al.,
2001). Additionally, OLGs origin in the brain surfaces in the medial and lateral
ganglionic eminences, which are considered to be transient and only appear present
during embryonic development (Brazel et al., 2003; de Castro and Bribián, 2005;
Kessaris et al., 2006; Richardson et al., 2006; Woodruff et al., 2001). Though some
differences are seen, the overall spatiotemporal specification of OLGs originate in the
ventral regions of the brain and spinal cord, and as development continues, these cells
migrate in a radial dorsolateral migration pattern (Cai et al., 2005b; Emery, 2010;
Fogarty et al., 2005; Richardson et al., 2006; Vallstedt et al., 2005). Specification of
OPCs is highly regulated and requires the expression of essential transcription factors.
Sox9 and Olig2 are two early transcription factors that are necessary for specification
into the OLG lineage (Ben-Hur et al., 2003; Stolt et al., 2003; Zhou and Anderson,
2002). Olig2 then induces the expression of Sox10, Nkx2.2, and platelet-derived growth
factor (PDGFR)-alpha (Cai et al., 2005b; Liu et al., 2007; Vallstedt et al., 2005; Zhou et
al., 2001).
OLG specification, development and myelination in the zebrafish share many
similarities with the mammalian system (Buckley et al., 2008; Czopka, 2016; Preston
and Macklin, 2015; Sidik and Talbot, 2015). The development of the transient,
embryonic midline structure, the notochord, is essential for OLG specification in the
spinal cord (Stemple, 2005). The notochord is required for the formation of the dorsalventral axis of the overlying neural tube, which includes the specification of the floor
plate, the ventral-most portion of the spinal cord (Dodd et al., 1998; Placzek and
7

Briscoe, 2005; van Straaten and Hekking, 1991; van Straaten et al., 1989). OPCs are
generated adjacent to the floor plate in the same location that gives rise to motor
neurons, named the motor neuron progenitor domain (Noll and Miller, 1993; Pringle and
Richardson, 1993; Warf et al., 1991; Yu et al., 1994) and specification of OPCs begins
when motor neuron production has ended (Park et al., 2004; Zhou and Anderson,
2002).
Oligodendrocyte development
OLG differentiation is an essential part of overall OLG development, with the
notion that many progenitor cells are present at lesion sites in MS, but fail to properly
differentiate and develop further along the lineage (Kuhlmann et al., 2008a). This crucial
step is highlighted throughout my dissertation, as it is the main focus of my studies
regarding overall OLG development. OLG development can be characterized by four
different stages identified by both the expression of specific cell markers (surface
antigens, transcription factors, etc.) as well as changes in cellular morphology
(Baumann and Pham-Dinh, 2001; Bradl and Lassmann, 2010; Pfeiffer et al., 1993).
These markers display specific functions and are needed for proper development along
the lineage (Fig.1.1)
Early stages of OLG development can be recognized by the presence of certain
genes, cell surface gangliosides, as well as mitogens. Both Olig2 and Sox10 are
expressed early in OLG development and remain expressed throughout the lineage in
rodents (Liu et al., 2007). In addition to these early markers, in the rodent model
system, the antibody A2B5 can be used to identify cell surface gangliosides found on
OPCs. The lipids recognized by A2B5 are down-regulated as the cell differentiates into
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a more mature OLG (Baracskay et al., 2007; Baumann and Pham-Dinh, 2001; Bradl
and Lassmann, 2010; Pfeiffer et al., 1993; Raff et al., 1983, 1984). In the early stages of
OLG development, mitogens, specifically platelet-derived growth factor (PDGF) and
basic fibroblast growth factor (bFGF), are present in order to increase cell survival, aid
in cell migration and proliferation, and prevent cell differentiation (Fok-Seang and Miller,
1994; Gard and Pfeiffer, 1993; Hart et al., 1989a, 1989b; Pringle and Richardson, 1993;
Richardson et al., 1988). Platelet derived growth factor receptor alpha (PDGFRα) is
specifically expressed in immature OPCs, but its expression is rapidly extinguished as
OPCs undergo terminal differentiation (Gard and Pfeiffer, 1993; Pringle and Richardson,
1993; Richardson et al., 1988).
As OLG development progresses, there is a decline in mitogenic factors and
OLGs are instead introduced to the differentiating factor thyroid hormone (TH). Both the
removal of mitogens and TH are necessary for OPC differentiation (Barres et al., 1994;
Franco et al., 2008). At this stage, OLGs start to display a multipolar morphology that
can be identified by the mouse monoclonal antibody O4, which binds to an
uncharacterized surface antigen (POA) and sulfatide (Bansal et al., 1989, 1992). Cnp,
Ugt8, Mbp and Plp are induced immediately after mitogen withdrawal and TH exposure
(Dugas et al., 2006). CNP (2',3'-cyclic nucleotide 3'-phosphodiesterase) activity appears
to be one of the earliest events in OLG differentiation and thought to play a critical role
in the events leading to myelination. It has also been seen in uncompact myelin in the
paranodal loops (Nave and Trapp, 2008; Wells and Sprinkle, 1981). When CNP is
overexpressed in mice, premature and abnormal myelination is observed and when
overexpressed in vitro, it promotes process outgrowth (Lee et al., 2005; Nave and
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Trapp, 2008). Cnp1 null mutant mice, although fully myelinated, develop progressive
axonopathy and die prematurely (Edgar et al., 2009; Lappe-Siefke et al., 2003), thereby
suggesting

its

role

in

axonal

support.

UGT8

(UDP-

galactose

ceramide

galactosyltransferase 8) is an endoplasmic reticulum-localized enzyme (Kapitonov and
Yu, 1997; Schulte and Stoffel, 1993; Sprong et al., 1998) that is responsible for the
synthesis of galactosylceramide, the major glycosphingolipid of myelin produced by
OLGs (Marcus and Popko, 2002). A knock-out (KO) mouse model lacking UGT8
revealed that galactosylceramide, together with sulfatide, is involved in myelin function
and stability, but not in myelin biogenesis (Bosio et al., 1996; Coetzee et al., 1996;
Dupree et al., 1999).
Two extensively studied myelin genes that encode major myelin protein
components in the CNS are Mbp (myelin basic protein) and Plp (proteolipid protein).
Membrane associated MBP is abundant in myelin, representing 30% of the total myelin
protein and is significantly involved in the compaction and binding of opposing
cytoplasmic myelin membranes (Readhead et al., 1990). In the shiverer mouse line, in
which MBP is absent, hypomyelination and the formation of uncompact myelin is
apparent in the CNS (Readhead and Hood, 1990; Readhead et al., 1990; Shine et al.,
1990), therefore solidifying its significance in the generation of myelin. PLP, a 4-pass
transmembrane protein, is thought to mediate adhesion between the outer membranes
of the myelin sheath (Baumann and Pham-Dinh, 2001; Popot et al., 1991). Interestingly,
PLP has a splice variant with the name DM20 (Campagnoni, 1988; Nave and Trapp,
2008; Timsit et al., 1995) that is expressed earlier in OLG development and is later
followed by the expression of PLP (Timsit et al., 1995). Mice harboring the jimpy
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mutation, the first Plp mutation identified, express a reduction in OLGs and display thin
myelin, ultimately leading to premature death (Duncan et al., 1989; Knapp et al., 1986).
The phenotypic response seen in the jimpy mice is a result of protein misfolding in the
mutant PLP (Griffiths et al., 1998a, 1998b). Conversely, and similar to what is seen in
Cnp1 null mutant mice, Plp1-null mice, in which the Plp1 gene is inactivated, show no
signs of OLG or myelin loss, however, older age mutant mice develop progressive
axonopathy throughout the CNS, with transport defects, swellings and widespread
axonal degeneration. Since the prominent axonal transport defects in Plp1 null mutant
mice (Edgar et al., 2004) resemble those observed in mitochondrial disorders
(Ferreirinha et al., 2004; Tarrade et al., 2006), it is suggested that OLGs require PLP to
support the axonal energy metabolism.
OLG development in the zebrafish
As seen in the mammalian system, gene regulation plays a large role in the timely
development and differentiation of OLGs. To start, olig1 and olig2 are expressed in cells
of the motor neuron domain, containing both OPCs and motor neurons (Zhou and
Anderson, 2002; Zhou et al., 2001). It has been shown, in both mice and zebrafish, that
olig2 is necessary for the specification of both motor neurons and OLGs (Park et al.,
2002; Takebayashi et al., 2002; Zhou and Anderson, 2002). Additionally, olig1
expression in the zebrafish is important in OLG differentiation and can activate MBP
transcription as seen in the mouse (Li et al., 2007; Xin et al., 2005). Near the end of
embryogenesis and during postnatal stages, many OPCs stop dividing and differentiate
to become mature myelinating cells, whereas others persist as nonmyelinating cells.
The expression of nkx2.2a (NK2 transcription factor 2a) was found to be a prominent
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factor in this fate determining step as OPCs that express nkx2.2a were found to
differentiate as OLGs, whereas those that did not express the gene mostly remained
nonmyelinating OPCs (Kucenas et al., 2008). Thus, nkx2.2a promotes the specification
and differentiation of a myelinating subset of OLG lineage cells (Kucenas et al., 2008).
In order for differentiation of OLGs to occur in the zebrafish, the expression of
genes such as cldnk (claudink) and plp1b (proteolipid protein) are needed. Genechip
analysis studies revealed cldnk and plp1b to be among 119 genes predicted to be
expressed at elevated levels in differentiating OLGs (Takada and Appel, 2010).
Additionally, microarray screen analysis studies indicated that these genes are highly
elevated in mature OLGs (Chung et al., 2011). Thus, both genes prove important in the
crucial differentiation stage of OLG development, and remain expressed into mature
stages. The relevance of cldnk in OLG maturation can be inferred as it encodes a
protein that is a member of a family of tight junction components and is expressed
specifically in OLGs and Schwann cells associated with the lateral line (Takada and
Appel, 2010). Likewise, plp1b encodes proteolipid protein 1b, whose importance has
been extensively studied in the mammalian system with regards to OLG development
and myelination. In addition to these genes, mbp and p0 appear later in OLG
development showing initial expression at 48hpf in cells of the ventral medial hindbrain
and at 72hpf in cells of the spinal cord (Brösamle and Halpern, 2002; Buckley et al.,
2010). The overall functions of the above stated genes have not been thoroughly
studied in the zebrafish, however, conservation of their predicted protein sequences
with those of the mammalian sequences and their overall expression patterns make it
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likely to predict they serve similar functions (Brösamle and Halpern, 2002; Buckley et
al., 2008, 2010).
All together, in both mammalian and zebrafish systems there are many steps
along the developmental pathway of OLGs. The timing of gene expression and
extracellular factors alike contribute to the precise maturation of these cells. It is crucial
that the mechanisms behind each stage of development be understood to the highest
degree, so that progenitor cell maturation can be obtained. As previously discussed,
OPCs are present and recruited to MS lesions initially, however, they become depleted
over time and fail to develop into mature cells (Kuhlmann et al., 2008b). The limitations
of remyelination seen in MS lesions suggests that though myelination is possible, OPCs
need to be stimulated in order to become fully myelinating cells and this action must
remain consistent. One molecule known to stimulate OLG differentiation is the
extracellular protein, Autotaxin (ATX) (Dennis et al., 2005, 2008; Fox et al., 2003; Fuss
et al., 1997; Nogaroli et al., 2009a; Yuelling and Fuss, 2008; Yuelling et al., 2012). Its
importance in MS became increasing interesting when ATX expression was found
reduced in MS lesions (Comabella and Martin, 2007). Thus, further investigation of this
extracellular protein in OLG development could pave the way towards potential targets
for MS treatment.
Autotaxin
Autotaxin

(ATX),

also

known

as

ecto-nucleotide

pyrophoshatase/phosphodiesterase (ENPP)2, was first introduced as a cell motilitystimulating factor in human melanoma cells (Stracke et al., 1992), and has since been
extensively studied in different areas of research. Though initially ATX did not exhibit
13

any significant homologies to characterized motility and growth factors, ATX was found
to contain a domain that displayed high homology with the enzymatically active domain
of proteins known to possess nucleotide phosphodiesterase and pyrophosphatase
activity (Buckley et al., 1990; Culp and Butler, 1985; van Driel and Goding, 1987;
Murata et al., 1994). It was later discovered, through recombinant forms of ATX, that the
catalytic domain of ATX is crucial for motility stimulation (Lee et al., 1996). This
enzymatic activity led to the inclusion of ATX into the family of nucleotide
pyrophosphatase/phosphodiesterase (NPP)-type ectophosphodiesterases and was
additionally termed (E)NPP2 (Bollen et al., 2000; Goding et al., 2003; Stefan et al.,
2005). The idea that ATX possessed enzymatic activity prompted the finding that all
(E)NPPs hydrolyze both pyrophosphate and phosphodiester bonds present in
nucleotides and their derivatives (Bollen et al., 2000). Although at the time the
physiological substrates of (E)NPPs remained unidentified, it was later uncovered that,
though structurally related, (E)NPPs differ in their enzymatic substrate specificities
(Cimpean et al., 2004; Gijsbers et al., 2001; Stefan et al., 2005). A turning point in
research related to ATX later revealed that ATX’s enzymatic activity catalyzed the
conversion of extracellular lysophosphatidylcholine (LPC) to the lipid mediator,
lysophosphatidic acid (LPA), and displayed molecular identity to the extracellular
lysoPLD (Ferry et al., 2003; Tokumura et al., 2002; Umezu-Goto et al., 2002; Xie and
Meier, 2004). Moreover, the affinity for ATX towards LPC was significantly greater than
its affinity towards nucleotides (Tokumura et al., 2002; Umezu-Goto et al., 2002).
Currently, the phosphodiesterase activity of ATX is considered unlikely (Gijsbers et al.,
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2003; van Meeteren et al., 2006). The lysoPLD properties of ATX remain the focus of
my research with regard to the effects of ATX on OLG differentiation in the CNS.
ATX is synthesized as a pre-pro-enzyme and, after N-glycosylation and
proteolytic maturation, is secreted as an active lysoPLD along the classical secretory
route (Jansen et al., 2005; Koike et al., 2006). Additionally, ATX is seen present in the
circulation where it accounts for maintaining plasma LPA levels. This circulating ATX
has a short half-life as it is rapidly cleared by the liver (Jansen et al., 2009). The brain
displays relatively high expression levels of ATX, especially in the choroid plexus, along
with the spinal cord, ovary, lung, intestines, kidney and lymphoid organs, and CSF
(Kanda et al., 2008; Koike et al., 2010; van Meeteren et al., 2006; Nakamura et al.,
2009; Nakasaki et al., 2008; Tanaka et al., 2006). Currently, three splice
variants/isoforms of ATX have been identified in both human and mouse, referred to as
ATX α, β, and γ, that do not seem to display any major functional isoform differences,
although show characteristic expression patterns (Fuss et al., 1997; Giganti et al., 2008;
Lee et al., 1996).
It wasn’t until the creation of ATX knockout (KO) mice (Enpp2-/-mutants) that the
physiological importance of ATX was revealed. Enpp2-/- mice displayed embryonic
lethality (E9.5–E11.5) due to prominent vasculature and neural tube defects (van
Meeteren et al., 2006; Tanaka et al., 2006). Intriguingly, mice expressing ATX with
inactivated lysoPLD activity displayed the same embryonic lethality that was previously
observed in Enpp2-/- mice (Ferry et al., 2007). Heterozygote Enpp2-/+ mice survived until
adulthood and, interestingly, revealed to have LPA plasma levels that were half that of
wild-type mice; thus confirming the notion that ATX activity is the major source of LPA in
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plasma. Accordingly, the ATX-LPA signaling axis is essential for the formation of the
vasculature and neural tube and proper embryonic development, though these effects
may be secondary to the vasculature effects.
ATX: enzymatic activity via the catalytic lysoPLD active site
The cell motility effect of ATX was originally thought to be due to ATX’s reported
function as a nucleotide phosphodiesterase (Bollen et al., 2000), however, it later
became clear that the cell motility-stimulating activity of ATX is mediated, at least in
part, via the production of LPA and its action on its respective LPA receptors (Hama et
al., 2004; Lee et al., 1996; Okudaira et al., 2010). ATX's NPP activity was known to be
dependent on a single threonine residue located within the enzymatic active site (Clair
et al., 1997), which was ultimately found to be the same residue critical for ATX’s
lysoPLD activity (Gijsbers et al., 2003; Koh et al., 2003). In addition to the threonine
residue, it was revealed that the lysoPLD activity was also stringent upon sequences
within the N- and C-terminal domains of ATX, a finding unique to ATX (Cimpean et al.,
2004; Gijsbers et al., 2003; Stefan et al., 2005). Since these initial findings, a number of
studies have set forth to further characterize the functions of ATX’s lysoPLD active site.
ATX’s enzymatic lysoPLD activity has been shown to play a large role in
biological processes related to development, as well as those in pathological conditions.
The best-known cellular responses to LPA include the stimulation of cell migration,
proliferation, and survival, although inhibitory responses have also been implicated
(Jongsma et al., 2011; Oda et al., 2013). The ATX-LPA signaling axis has been
implicated in a variety of physiological and pathological processes, including lymphocyte
homing, pulmonary fibrosis, neuropathic pain, cardiovascular disease, cholestatic
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pruritus, tumor progression, Alzheimer's disease, chronic Hepatitis C, obesity and
rheumatoid arthritis, and as outlined in this dissertation, Multiple Sclerosis (Bai et al.,
2013; Boucher et al., 2005; Ferry et al., 2003; Hammack et al., 2004; Inoue et al., 2011,
2004, 2008a, 2008b; Kanda et al., 2008; Kremer et al., 2010; Oikonomou et al., 2012;
Santos et al., 1996; Smyth et al., 2014; Tager et al., 2008; Watanabe et al., 2007a,
2007b; Zhang et al., 2012; Zhao et al., 2008). Importantly, LPA has also been described
to be a regulator of epigenetic modifications, specifically histone deacetylase (HDAC)
regulation, at least in cancer cell lines (Ishdorj et al., 2008). In an attempt to link ATX’s
lysoPLD activity with the known epigenetic changes seen throughout OLG
development, I investigated the gene regulatory mechanisms controlled by ATX’s
lysoPLD activity during OLG differentiation.
Epigenetic Regulation in OLG Development
Epigenetics refers to the study of changes in gene expression, that may or may
not be heritable, without changing the sequence of DNA. Epigenetic modifications
include DNA methylation, post-translational modification of histone tails, nucleosomal
remodeling, and modifications by small non-coding RNAs (Berger, 2007; Goldberg et
al., 2007). Post-translational modifications include acetylation/deacetylation, methylation
(Shilatifard, 2006), phosphorylation of serine and threonine residues (Dyson et al.,
2005), sumoylation (Iñiguez-Lluhí, 2006), ubiquitination of lysine residues(Shilatifard,
2006; Weake and Workman, 2008), and citrullination of arginine residues (Mastronardi
et al., 2006), as well as ADP- ribosylation and isomerization of prolines (Kouzarides,
2007). These modifications make up the “histone code” that is cell-type specific. A
dynamic balance of these modifications dictates the transcriptional state of chromatin,
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as some histone changes confer a more open and transcriptionally competent state and
others silence gene activation by chromatin compaction.
Epigenetic regulation of gene expression during OLG development has recently
been recognized as a fundamental contributing player in (re)myelination. It is anticipated
that insights into the epigenetic regulation of myelin formation and repair will provide
novel targets for therapeutic intervention (Copray et al., 2009). OLGs need to go
through several steps of development before ultimately producing myelin. A large
network of transcriptional activators and repressors are known to control each stage
(Miller, 2002; Wegner, 2008). With regard to differentiation, Olig1, Olig2, Sox10 and
more recently myelin gene regulatory factor (Myrf) are needed in order to terminally
differentiate and activate myelin protein expression (Ben-Hur et al., 2003; Emery et al.,
2009; Liu et al., 2007; Stolt et al., 2002; Xin et al., 2005). In addition, inhibitors of OLG
differentiation are needed in order to fine-tune this transcriptional network and prevent
precocious differentiation. These inhibitors include Hes5 (Kondo and Raff, 2000a; Liu et
al., 2006), Sox11 and Tcf4 (He et al., 2007a), and Id2 and Id4 (Kondo and Raff, 2000b;
Marin-Husstege et al., 2002; Samanta and Kessler, 2004). Selective expression or
silencing of genes at each stage of OLG development is ultimately controlled by
epigenetic

regulatory

mechanisms,

which

determine

the

accessibility

of

the

transcriptional machinery to the chromosomal territories containing the specific genes
(Copray et al., 2009).
Though increasing evidence points to the substantial role for HDACs in OLG
development, which will be further elucidated, methylation serves to play a fascinating
role as well. Histone methyltransferases (HMTases) are histone-modifying enzymes that
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catalyze the transfer of methyl groups to lysine and arginine residues. Distinct enzymes
mediate methylation of specific residues. A prominent HMTase that catalyzes histone
H3 lysine 27 trimethylation (H3K27me3) is enhancer of zeste homologue 2 (Ezh2). It
has been shown that methylation at H3K27 by Ezh2 plays a role in the specification of
the OLG lineage. Ezh2 is completely down-regulated during specification towards
neurons and astrocytes allowing transcription of these programs (Sher et al., 2012).
Ezh2 expression is present in the early proliferating OPCs up to the stage of
premyelinating OLGs. Ezh2 expression is down-regulated, however, in mature OLGs at
the onset of myelination
Introduction to HATs and HDACs
One of the best-characterized histone modifications that modulate OLG
development is the equilibrium between histone acetylation and deacetylation (Copray
et al., 2009). Histone acetyltransferases (HATs) and histone deacetylases (HDACs)
finely tune cellular acetylation, targeting not only histones, but also numerous proteins
with key roles in cell metabolism, signaling and death (Kazantsev and Thompson, 2008;
Langley et al., 2005; Saha and Pahan, 2006). HATs provide for acetylation of the
conserved N-terminal histone tails, resulting in relaxation of the nucleosomes by
decreasing the interaction of the positively charged histone tails with the negatively
charged phosphate backbone of DNA. HATs have been shown to play an important role
in neural stem cell differentiation (Asklund et al., 2004; Hsieh et al., 2004; Song and
Ghosh, 2004), however, the role of HATs in OLG differentiation is less pronounced. In
fact, deacetylation by HDACs has been shown to play a more critical role in the
progression of progenitor cells toward the OLG lineage.
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In most cases, HDACs remove the acetyl groups from histone lysine residues
favoring condensed chromatin that prevents access of transcriptional activators to their
target sites and results in transcriptional repression. The mammalian members of the
HDAC family are, based on their structures, subdivided into four main classes: Class I
(HDAC1, 2, 3, and 8), Class II (HDAC4, 5, 6, 7, 9, and 10), Class III (SIRT1-7) and
Class IV (HDAC11). The classical, class I, II and IV, HDACs are structurally related and
need the presence of Zn+2 to be active (de Ruijter et al., 2003), whereas class III
HDACs, the sirtuins, are a group of enzymes dependent on NAD+ and are structurally
unrelated to the classical HDACs (Michan and Sinclair, 2007).
OLG specification is unique in that it is initiated by a global histone deacetylation
program. During the early stages of OLG specification, HDACs mediate the suppression
of alternative lineages and, later in development, regulate the repression of inhibitors of
myelin specific genes. HDAC inhibition by trichostatin A (TSA) in neural stem cells
favors the neuronal fate, while inhibiting specification into OPCs. The loss of HDACs
also reprograms OPCs into neural stem-like cells capable of neurogenesis (Aixiao Liu,
2007; Kondo and Raff, 2004; Lyssiotis et al., 2007a). More specifically, HDACs block
critical transcription factors of alternative lineages such as the stem cell marker Sox2
(Lyssiotis et al., 2007a; Shen and Casaccia-Bonnefil, 2008). Taken together, HDAC
inhibition results in the reactivation of other genes that mark the stem cell state, along
with the silencing of OLG lineage-specific genes (Lyssiotis et al., 2007b). The
importance of histone deacetylation in determining the direction of neural stem cell
specification is further supported by evidence in which HDAC inhibitors cause a
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noticeable reduction in OPCs on the account of a larger population of astrocytes and
neurons (Aixiao Liu, 2007; He et al., 2007a; Siebzehnrubl et al., 2007; Ye et al., 2009).
Once specification has taken place, HDACs continue to serve a crucial role in the
differentiation stage of OLG development. The timely differentiation of progenitor cells is
indispensable for development. With that in mind, investigators demonstrated
deacetylation of histone H3 is a critical mechanism for myelination onset in vivo as it is
required for the down-regulation of differentiation inhibitors and early progenitor
markers. During the first 10 postnatal days in rats, administration of valproic acid (VPA,
a Class I HDAC inhibitor) resulted in significant hypomyelination, while administration of
VPA after onset of myelination had no effect on myelin gene expression. During the
time after the onset of myelination, a more stable repression of the transcriptional
inhibitors of the myelin genes is carried out by methylation at H3K9 (Shen and
Casaccia-Bonnefil, 2008). This methylation is coupled with increased association of
HP1, a protein that directs chromatin compaction by binding to adjacent H3K9 sites.
These results thereby indicate that histone deacetylation is the molecular link of the
transition between cell cycle exit and differentiation onset (Shen and Casaccia-Bonnefil,
2008). Additionally, pharmacological inhibitors of HDACs increase histone acetylation
and prevent differentiation of OLG progenitors in vitro (Hsieh et al., 2004; MarinHusstege et al., 2002) and in vivo (Aixiao Liu, 2007; Shen et al., 2005). Accordingly, in
the rodent model, HDACs prove to be necessary for OLG development, not only for
OPC specification, but also for differentiation.
As just described, HDAC inhibition is correlated with the induction of Sox2 and
increased neurogenic capacity from treated OPCs (Kondo and Raff, 2004; Lyssiotis et
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al., 2007a). Unlike rodent OPCs, however, acutely isolated human OPCs express both
Sox2 protein and mRNA (Sim et al., 2011) and are neurogenic in the absence of
reprogramming (Tripathi et al., 2010). These observations led to the idea that the role of
HDACs on OLG development may differ between species. This was further tested by
treatment with HDAC inhibitors, TSA and sodium butyrate, on human primary OPCs.
HDAC inhibition (HDACi) resulted in significant dose-dependent inhibition of O4+ OLG
cell differentiation, reduction of OLG morphological maturation and down-regulation of
Mbp mRNA (Conway et al., 2012). Along with these results, HDACi treatment prevented
down-regulation of Sox2, Id4 and Tcf4/Tcf7l2 mRNAs, but did not regulate Hes5
(Conway et al., 2012). Thus, suggesting that HDAC activity plays an essential role in the
specification of OPCs (rodent), as well as the differentiation of progenitor cells into
OLGs (rodent, human). Interestingly, studies describing the role of the ATX-LPA axis in
epigenetic modulation of OLGs, presented in this dissertation, are limited to OPCs
committed to the lineage and have no effect on specification. These data parallel what
is seen in the human and further signifies the importance of ATX in OLG differentiation.
Pharmacological inhibition of HDACs provided for a clear proof of concept that histone
deacetylation is crucial for OLG development, however, the identification of individual
members of the HDAC family was, and partly remains, the next step into understanding
the role of HDACs in OLG differentiation.
Regulation by HDAC1 and HDAC2
HDAC1 and HDAC2 are of particular interest in OLG development as they have
been reported to be recruited to the promoters of inhibitory molecules of myelin specific
genes to initiate OLG differentiation (Dewald et al., 2011; He et al., 2007a; Shen and
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Casaccia-Bonnefil, 2008; Ye et al., 2009). The RE1-silencing transcription factor
(REST) recruits HDAC1 and HDAC2 to stimulate OPC differentiation by repressing
several neuronal genes and thereby favoring glial cell specification (Dewald et al.,
2011). In mice, conditional ablation of Hdac1 and Hdac2 results in the stabilization and
nuclear translocation of β-catenin, which negatively regulates OLG specification by
repressing Olig2 expression (Ye et al., 2009). A severe impairment in the formation and
differentiation of OPCs was observed in these double KO mice. Furthermore, mouse
genetic approaches identified Yin Yang1 (YY1) as the essential transcription factor that
facilitates the recruitment of HDAC1 to the promoters of the transcriptional inhibitors,
Tcf4 and Id4, allowing for expression of myelin specific genes (He et al., 2007a). These
data indicate that HDAC1 and HDAC2 are required for both specification and
differentiation of OPCs.
Moreover, the role of HDAC1 activity in OLG development appears to be conserved
across a wide range of species. In hdac1 zebrafish mutants, specification of OPCs fails,
but persistence of neural progenitors in the hindbrain ventricular zone is independent of
hdac1 activity (Cunliffe and Casaccia-Bonnefil, 2006). zHDAC-1 null neural stem cells
continue to express Sox2 and fail to express Olig2 required for specification into the
OLG lineage. In addition, sonic hedgehog (Shh) is normally expressed in the zHDAC-1
mutant hindbrain, however, it’s signaling is inefficient in inducing Olig2 expression
(Cunliffe and Casaccia-Bonnefil, 2006). Thus, the global deacetylation program initiated
by HDACs, especially specific isoforms of Class I HDACs, enables expression of the
OLG transcriptional profile.
In a different study, Nkx2.2 recruited the HDAC1/mSin3a complex to repress the
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MBP promoter in immature OLGs (Wei et al., 2005). In addition, Nkx2.2 binds to and
represses the promoter of the class III HDAC Sirt2 in CG4 cells, an oligodendroglial
precursor cell line, and Sirt2 promoted the differentiation of CG4 cells (Ji et al., 2011).
Similarly, HDAC1/2 heterodimers, in association with Sin3B, were detected in complex
with Myt-1 on the proximal region of the PLP promoter (Romm et al., 2005). These
results may appear contradictory to the described functions of HDAC1 in promoting
OLG differentiation, however, it is also conceivable that tightly regulated repression of
precocious differentiation may be a prerequisite to adequate OLG lineage progression
(Jacob et al., 2011).
The Role of Histone Deacetylation on Later Stages of Oligodendrocyte
Development
Not only do HDACS play a crucial role in the actual generation and differentiation of
early OLGs, but they also act on immature OLGs (after established lineage choice) up
to the onset of myelination. Histone deacetylase 11, HDAC11, plays a distinct role in
OLG development. HDAC11 catalyzes deacetylation of lysine 9 and 14 on histone H3
(H3K9; H3K14) and it has been proposed to activate the expression of both, MBP and
PLP genes, possibly by modulating specific regulatory regions (Liu et al., 2009). Indeed,
disruption of HDAC11 expression increased acetylation at the promoter region of both
MBP and PLP and led to a subsequent decrease in their transcript levels (Liu et al.,
2009). In accordance to these studies, in the mouse brain, HDAC11 shows strong
expression in OLGs that increases during postnatal development (Liu et al., 2008).
These studies support an important function of HDAC11 in OLG terminal differentiation
and myelination.
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Histone modifications have been shown to display an important role in OLG
development along the lineage and have such been studied in a more clinical
standpoint by examining modifications in patients suffering from MS. Brain samples
revealed that there is a shift toward histone acetylation in the white matter of the frontal
lobes of aged subjects and in patients with chronic MS (Pedre et al., 2011). These
changes were associated with high levels of transcriptional inhibitors of OLG
differentiation, TCF7l2, ID2 and SOX2, and higher HAT transcript levels, CBP and
P300, in female MS patients compared with non-neurological control and correlated with
disease duration (Pedre et al., 2011). These data suggest that histone deacetylation is a
process that occurs at the early stages of the disease, and displays decreased
efficiency with disease duration. The role of HDACs on OLG development is
increasingly critical to understand, as it proves to be involved in essential stages and
plays a role in disease pathology.
Conclusions
There are many mechanisms that regulate both the specification and
development of OLGs. With regards to MS, it is imperative that we gain a better
understanding of these mechanism in order to stimulate the specification of OPCs or,
and more suitable for lesions in which adult OPCs are present, drive differentiation of
progenitor cells into cells with the capacity to (re)myelinate. To achieve functional
maturity of OLGs needed for (re)myelination, there must be a dynamic chemistry
between extrinsic and intrinsic signals. Epigenetic modifications have been shown to
play a large role in OLG development. The rate and type of these modifications in OLGs
is controlled by many factors and depends on the developmental stage and health of
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the cells (Copray et al., 2009).
The data presented in this dissertation reveal the discovery of the first
extracellular signal, ATX, that regulates HDAC activity in the transition from progenitor
cells to OLGs (differentiation), which is indispensable for proper OLG development. As
OPCs are found in MS lesions, but are limited in their ability to differentiate, this step
becomes a crucial area of investigation when searching for therapeutic advances. The
novel finding that ATX, through its ability to form LPA via the lysoPLD active site,
regulates the epigenetic modifications needed for proper OLG differentiation is a turning
point in the field, and further shows its importance in OLG development. The role that
the ATX-LPA- epigenetic regulatory pathway plays in relation to MS is so impacting,
they may offer to be future therapeutic targets.
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Figure 1.1. The oligodendrocyte lineage. This figure depicts both the changes in
morphology and gene expression/cell surface markers that OLGs undergo as they
develop. OPCs are specified (neural progenitor cell to OPC) in restricted regions of the
central nervous system where they migrate from and proliferate extensively, populating
the brain and spinal cord. Once they have reached their destination, they begin to
develop a complex process network and eventually form membranous structures which
wrap around axons in vivo. OLG differentiation, as denoted in this schematic, is the
main focus of this dissertation. As changes are observed morphologically, OLGs also
undergo changes in gene expression/cell surface markers as shown underneath the
pictures. The genes/cell surface markers listed are used to identify different stages of
the OLG lineage and are delineated for the developing zebrafish (purple) and rat (blue):
oligodendrocyte transcription factor 2 (olig2), ganglioside (A2B5), proteolipid protein
(plp1b), claudink (cldnk), pro-oligodendrocyte surface antigen or sulfatide (O4), 2,3cyclic nucleotide 3-phosphodiesterase (Cnp) and UDP- galactose ceramide
galactosyltransferase (Ugt8).
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Chapter 2
The Autotaxin-LPA Axis Modulates Histone Acetylation and Gene Expression
during Oligodendrocyte Differentiation
(This chapter was accepted as a paper in the Journal of Neuroscience in August of
2015. The work reported for this manuscript is based primarily on my own efforts.
Assistance was provided by Dr. James Lister (CRISPR-Cas9 genome editing Figure
2.1)
Introduction
The differentiation of the myelinating cells of the central nervous system (CNS),
namely oligodendrocytes (OLGs), follows a step-wise program that is characterized by
well-coordinated changes in gene expression and cellular morphology (Bauer et al.,
2009; Mitew et al., 2014; Wegner, 2008). The developmental timing of this
progression along the OLG lineage is finely tuned by extracellular signals and
intracellular pathways. In particular, and at the transition from OLG progenitor to
differentiating

OLG,

epigenetic

mechanisms

associated

with

a

progressive

compaction of chromatin have been found to play a central role (Bischof et al., 2015;
Copray et al., 2009; Jacob et al., 2011; Liu and Casaccia, 2010; Liu et al., 2015;
Mori and Leblond, 1970; Shen and Casaccia-Bonnefil, 2008; Yu et al., 2013). The
current understanding of the above mechanisms affecting the chromatin landscape
involves histone deacetylation via the action of the class I histone deacetylase
(HDAC) members HDAC1 and HDAC2 (Shen et al., 2005, 2008; Wu et al., 2012; Ye
et al., 2009). In general, HDAC1/2 containing complexes are considered to remove
acetyl groups from histone tails, thereby favoring a condensed chromatin structure
and limiting DNA access for transcription factors (Grunstein, 1997). In the case of
the OLG lineage, it has been demonstrated that the target genes affected by
HDAC1/2 deacetylation include clusters of co-regulated genes implicated in
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transcriptional repression (Swiss et al., 2011). Thus, it is deacetylation-mediated
repression of transcriptional inhibitors of OLG differentiation, such as Egr1, Id2 and
Sox11, that is thought to promote progression along the OLG lineage. While the
intracellular aspects of this mechanism have been well-characterized, little is known
about the extracellular signals that may be modulating it (Wu et al., 2012).
In our previous studies, we identified autotaxin (ATX), also known as ENPP2,
phosphodiesterase-Iα/ATX or lysophospholipase D (lysoPLD), as an extracellular factor
that promotes OLG differentiation at various steps along the progression of the lineage
and via the action of two distinct functionally active domains (Dennis et al., 2005, 2008;
Nogaroli et al., 2009b; Yuelling and Fuss, 2008; Yuelling et al., 2012). In this regard,
ATX’s so-called modulator of oligodendrocyte remodeling and focal adhesion
organization (MORFO) domain was found to regulate primarily the morphological
aspects of OLG differentiation (Dennis et al., 2008, 2012; Fox et al., 2003), while its
lysoPLD-active site, which generates the lipid signaling molecule lysophosphatidic acid
(LPA) (van Meeteren and Moolenaar, 2007; Nakanaga et al., 2010; Tokumura et al.,
2002; Umezu-Goto et al., 2002), may be predominantly modulating gene expression
(Nogaroli et al., 2009b). Intriguingly, studies assessing ATX’s functions as a whole and
in vivo in the developing zebrafish revealed a lineage promoting, and likely gene
expression regulatory, role at the transition from OLG progenitor to differentiating
OLG (Yuelling et al., 2012). Thus, we investigated here a possible role of, in
particular, ATX’s lysoPLD activity in modulating histone deacetylation and gene
expression during the early stages of the OLG lineage.
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Materials and Methods
Animals. Zebrafish embryos were obtained through natural matings, raised at 28.5°C
and staged according to morphological criteria and hours post fertilization (hpf) (Kimmel
et al., 1995). Wildtype fish were of the AB strain and Tg(nkx2.2a:megfp)vu17 (Kirby et al.,
2006;

Kucenas

et

al.,

2008),

abbreviated

Tg(nkx2.2a:megfp),

as

well

as

Tg(olig2:dsred2)vu19 (Kucenas et al., 2008), abbreviated Tg(olig2:dsred2), fish were
kindly provided by Sarah Kucenas and Bruce Appel. Sprague Dawley female rats with
early postnatal litters were obtained from Harlan Laboratories (Indianapolis, IN). All
animal studies were approved by the institutional animal care and use committee at
Virginia Commonwealth University.
Antibodies. Supernatants from cultured hybridoma cells (clone A2B5; ATCC,
Manassas, VA) were used for immunopanning. Anti-acetyl-Histone H3 (Lys 9)
antibodies (Cell Signaling Technology, Inc., Danvers, MA) were used for Western blot
analysis as well as immunocytochemistry. Anti-Histone H3 antibodies (Cell Signaling
Technology, Inc., Danvers, MA) as well as IRDye 680RD- and 800CW-conjugated
secondary antibodies (LI-COR Biosciences, Lincoln, NE) were used for Western blot
analysis. Supernatants from cultured hybridoma cells (clone O4; gift from S.E. Pfeiffer),
anti-Caspase 3, active (cleaved) form (EMD Millipore, Billerica, MA), anti-Ki67 (Leica
Microsystems, Buffalo Grove, IL) and Alexa 488- and/or Alexa 568-conjugated
secondary antibodies (Life Technologies, Grand Island, NY) were used for
immunocytochemistry.
Pharmacological

compounds.

Zebrafish

embryos

and

primary

cultures

of

differentiating OLGs were treated with the following compounds: ATX-lysoPLD activity
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inhibitors S32826 and HA130 (Tocris/Bio-Techne, Minneapolis, MN), HDAC1/2/3
inhibitor C1944 and HDAC6 inhibitor Tubastatin A (Selleckchem, Houston, TX) all of
which were dissolved in dimethyl sulfoxide (DMSO) resulting in a final experimental
concentration of 0.1% of DMSO, which is well tolerated in both the zebrafish as well as
the cell culture system (Lyssiotis et al., 2007b; Maes et al., 2012). Lysophosphatidic
acid (LPA; 18:1; Sigma, St. Louis, MO) was dissolved in DMEM containing 0.1% fatty
acid-free bovine serum albumin. Control in all experiments where pharmacological
compounds were used refers to vehicle treatment.
Cell culture. Primary OLG progenitors were isolated from postnatal day 2 (P2) rat
brains by A2B5 immunopanning and cultured as previously described (Barres et al.,
1992; Lafrenaye and Fuss, 2010; Martinez-Lozada et al., 2014). Briefly, immunopanned
OLG progenitors were plated onto fibronectin (10 µg/ml)-coated tissue culture dishes,
glass coverslips or 96-well plates. Plated OLG progenitors were cultured in serum-free
proliferation medium (Dulbecco’s modified Eagle’s medium (DMEM) containing human
PDGF and basic fibroblast growth factor (bFGF) (Gemini Bio-Products, Sacramento,
CA) for 24 hrs, after which cells were allowed to differentiate in serum-free medium
(DMEM containing 40 ng/mL tri-iodo-thyronine (T3; Sigma, St. Louis, MO) and N2
supplement (Life Technologies, Grand Island, NY); DMEM/T3/N2) over the time periods
indicated. Differentiating OLGs were either directly analyzed or treated as indicated.
Typically, at least three independent experiments were performed, whereby an
independent experiment refers to an experiment in which cells were isolated from a
separate P2 rat litter at an independent time point (day) and treated separately from all
other independent experiments.
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CRISPR/Cas9 genome editing. CRISPR target sequences for atx (enpp2), as
depicted in Fig. 1, were identified using the online tools crispr.mit.edu and
chopchop.rc.fas.harvard.edu (Montague et al., 2014). sgRNAs were generated using
the cloning-free/short oligonucleotide approach described by Talbot and Amacher
(2014). Briefly, short-guide oligonucleotides containing a T7 promoter and genomic
target site were synthesized by Eurofins MWG Operon LLC (Huntsville, AL). Guideconstant oligonucleotides were obtained from Life Technologies (Grand Island, NY). Full
length templates for sgRNA synthesis were generated by PCR using short-guide and
guide-constant oligonucleotides, and PCR templates were purified using ISOLATE II
PCR cleanup columns (Bioline, Taunton, MA). The plasmid pT7tyrgRNA (Addgene
46761; kindly provided by Wenbiao Chen) (Jao et al., 2013) was used as a template for
the generation of the tyrosinase (tyr) control sgRNA. sgRNAs were transcribed from
their templates using the MEGAshortscript T7 kit (Life Technologies, Grand Island, NY).
Cas9 mRNA was synthesized from the plasmid pT3TS-nCas9n (Addgene 46757; kindly
provided by Wenbiao Chen) (Jao et al., 2013) using the mMESSAGE mMACHINE T3
Transcription Kit (Life Technologies, Grand Island, NY). 1 nanoliter of a mixture of Cas9
mRNA (100 ng/µl) and sgRNA (80 ng/µl for atx-E2; 95 ng/µl for atx-E7; 100ng/µl for tyr)
was injected per one-cell stage zebrafish embryo. Zebrafish were analyzed at 48 hpf.
Brightfield images of whole embryos were taken using an Olympus SZX12 zoom stereo
microscope (Olympus America Inc., Melville, NY) equipped with an Olympus DP70
digital camera system.
Genomic DNA analysis. Genomic DNA was isolated from control and Cas9
mRNA/sgRNA injected embryos using the DNeasy Blood and Tissue kit (Qiagen,
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Valencia, CA). DNA fragments spanning genomic target sites were amplified by PCR
using the following primer pairs:
atx-E2(ZDB-GENE-040426-1156): forward (5’ AAATTGTTGAAACCATATGCGA 3’), reverse (5’
GCATCCTACTTTTTGAGAGCGA)
atx-E7(ZDB-GENE-040426-1156): forward (5’ TGTTTAGGTGTGTGCTTAGTGC 3’), reverse (5’
AATCTGCAATTAATACATACCGTTG 3’).
To assess for indels generated by CRISPR/Cas9 genome editing, PCR fragments were
sequenced (VCU’s Nucleic Acid Research Facilities) and the Surveyor Mutation
Detection Kit (Integrated DNA Technologies, Inc., Coralville, IA) was used.
ATX-lysoPLD activity assay. ATX-lysoPLD activity was determined using the
fluorogenic assay as described by Ferguson et al. (Ferguson et al., 2006). Whole
zebrafish homogenates diluted in 140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2,
5 mM Tris/HCl (pH 8.0), 1 mg/ml fatty acid-free BSA (Sigma-Aldrich, St. Louis, MO) or
concentrated (40x) conditioned medium from primary OLG cultures grown in phenolred-free DMEM were incubated with 2.5 μM FS-3 substrate (Echelon Biosciences Inc.,
Salt Lake City, UT) for 4 hrs at 37°C. Increase in fluorescence with time was measured
at an excitation wavelength of 485 nm and an emission wavelength of 520 nm using a
PHERAstar multimode microplate reader (BMG LABTECH Inc. Cary, NC.).
RNA isolation and real-time RT-qPCR Analysis. For the isolation of RNA from whole
zebrafish embryos or cultured rodent OLGs, samples were collected in Trizol
(Invitrogen, Carlsbad, CA) and immediately homogenized. RNA was extracted as
described by Chomczynski and Sacci (1987) (Chomczynski and Sacchi, 1987). For the
isolation of RNA from FACS-isolated cells, cells were collected directly in Trizol and
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then immediately processed using the RNeasy Micro Kit from Qiagen (Valencia, CA). All
RNA samples were treated with DNase (DNA-Free Kit; Applied Biosystems/Ambion,
Austin, TX). RNA concentrations were determined using a Nanodrop ND 1000
Spectrophotometer (Thermo Scientific/NanoDrop, Wilmington, DE) and purity was
assessed by the ratio of absorbance at 260 and 280 nm (OD260/280 ≥ 1.8). Oligo(dT)primed cDNAs were synthesized from 50 ng to 1 µg of RNA using the Omniscript or
Sensiscript RT Kit (Qiagen, Valencia, CA) according to the manufacturer’s guidelines.
RNA samples were normalized to the same approximate concentration and the same
amount of RNA was used for all conditions of an individual independent experiment. As
control, cDNA reactions without reverse transcriptase were performed for all samples.
PCR reactions performed with such no-reverse-transcriptase cDNAs as template
yielded quantitation cycle (Cq) numbers that were at least 5 cycles below the lowest Cq
for any of the experimental samples (unknowns), whereby Cq values for unknowns
were within the linear quantifiable range as determined by calibration curves. Genespecific primers were designed and in silico tested for specificity using NCBI/PrimerBLAST (Ye et al., 2012). All primers were designed to amplify all known splice variants.
For each primer pair listed below, amplicon length is noted in bp. In addition, PCR
efficiencies are given in % and correlation coefficients (r2 values) as single numbers,
whereby the latter were determined from calibration curves using RNA samples derived
from species and tissue/cell type equivalent sources.
The following unmodified zebrafish gene-specific primer pairs were used:
atx/enpp2(ZDB-GENE-040426-1156):

forward

(5’-CAATGTATGCAGCATTCAAACGAGTG-3’,

exon 22), reverse (5’CACCATTTTTCTCACTAGCGTAACG-3’, exon 23), 79 bp, 107%,
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0.996
plp1b(ZDB-GENE-030710-6): forward (5’TGCCATGCCAGGGGTTGTTTGTGGA-3, exon 5),
reverse (5’-GGCGACCATGTAAACGAACAGGGC-3, exon 6/7); 143 bp, 96%, 1,000
cldnk(ZDB-GENE-040801-201): forward (5’-TGGCATTTCGGCTCAAGCTCTGGA-3’, exon 1),
reverse: (5’GGTACAGACTGGGCAATGGACCTGA-3, exon 2); 135 bp, 93%, 0.999
inab (gefiltin)(ZDB-GENE-990415-83): forward: 5’-CTCTCCATCCCGGCTGAGCAGCT -3’, exon
1), reverse: (5’AGCCTGGGATGTTGGGGCGGTT-3’, exon 1); 74 bp, 105%, 0,997
gfap(ZDB-GENE-990914-3): forward (5’-TGAGACAAGCGAAGCAGGAGGCCA-3’, exon 5),
reverse (5’GGCGCTCCAGGGACTCATTAGACCC-3’, exon5/6); 102 bp, 101%, 0.997
prph (plasticin)(ZDB-GENE-990415-207): forward (5’-ACTCCTACCGCACCTCTCACCACCG -3’,
exon 1), reverse (5’-TAGCGGCCCCCGATGCGACTG-3’, exon 1); 70 bp, 93%, 0.997
sox10(ZDB-GENE-011207-1): forward (5’-TGGACACCACCCTCACGCTA-3’, exon 3), reverse
(5’-CTGCAGTTCCGTCTTGGGGG-3’, exon 4); 76 bp, 94%, 0.966
β-actin (actb2(ZDB-GENE-000329-3)) (Buckley et al., 2010) was used as reference gene (60bp,
95%, 0.999); eef1a1/1(ZDB-GENE-990415-52) has been assessed as additional reference gene
for the analysis of RNA derived from the developing zebrafish and no pronounced
differences were noted (Yuelling et al., 2012).
The following unmodified rat gene-specific primer pairs were used:
Cnp(NM_012809.2): forward (5’-ATGCCCAACAGGATGTGGTG-3’, exon 3/4), reverse
(5’-AGGGCTTGTCCAGGTCACTT-3’, exon 4); 150 bp, 103%, 0.990
Ugt8(NM_019276.3): forward (5’-AGGAGCTCTGGGGAGATTGC-3’, exon 3), reverse
(5’-TTTGAATGGCCAAGCAGGTCA-3’, exon 4/5); 126 bp, 108%, 0.960
Egr1(NM_012551.2): forward (5’-CCTGACCACAGAGTCCTTTTCT-3’, exon 1/2), reverse
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(5’-AAAGTGTTGCCACTGTTGGG-3’, exon 2); 150 bp, 93%, 0.996
Pgk1(NM_053291.3) (as reference gene): forward (5’-ATGCAAAGACTGGCCAAGCTAC-3’,
exon 8), reverse (5’-AGCCACAGCCTCAGCATATTTC-3’, exon 9), 103 bp, 103%, 0.997
Pgk1 was used as reference gene due to its previously established expression stability
in rat OLGs (Nelissen et al., 2010). In addition, Ppia(NM_017101.1) has been assessed as
additional reference gene for the analysis of RNA derived from differentiating OLG
cultures and no pronounced differences were noted.
RT-qPCR reactions with at least 2 technical replicates per sample were performed on a
CFX96 real-time PCR detection system (BioRad, Hercules, CA) using the iQ SYBR
Green Supermix (BioRad, Hercules, CA). PCR conditions were as follows: 95°C for 3
min followed by 40 cycles of 95°C for 15 s, 58°C for 30 s, and 95°C for 10 s. For all
primer pairs, melting curves were used to ensure specificity. Relative expression levels
were determined using the ΔΔCT method (Livak and Schmittgen, 2001).
Whole mount in situ hybridization. Zebrafish embryos were fixed in 4%
paraformaldehyde in PBS overnight at 4°C and stored in methanol at 22°C for at least 1
day. Colorimetric in situ hybridizations using digoxigenin-labeled antisense cRNA
probes were performed by standard methods and as previously described (Thisse and
Thisse, 2014, 2008; Yuelling et al., 2012). In situ hybridized embryos were mounted in
90% glycerol/PBS and whole mount images were acquired using the extended focus
module of the axiovision software package in combination with an Axio Observer Z.1 or
SteREO Discovery.V20 microscope equipped with an AxioCam MRc digital camera
(Carl Zeiss MicroImaging, Inc., Thornwood, NY). Once captured, images were imported
into Adobe Photoshop and adjustments were limited to cropping and brightness/contrast
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adjustments which were applied equally across the entire image and to controls. In situlabeled cells were counted using the Cell Counter plugin to the ImageJ software
package (Abramoff et al., 2004).
Isolation of OLG progenitors from zebrafish embryos using fluorescent activated cellsorting (FACS). Tg(nkx2.2a:megfp;olig2:dsred2) zebrafish embryos (up to 300 per
sample) were anesthetized with tricaine methanesulfonate (MS-222;

Sigma Aldrich

Corp., St. louis, MO) and subjected to enzymatic (trypsin and DNAse) and mechanical
(20 and 26 gauge needle) dissociation. Cell suspensions were resuspended first in 1ml
and then in 500 µl of ice cold 5% Goat Serum in PBS after centrifugation (at 956xg for
2 min at 4°C) and then subjected once again to mechanical dissociation (26-gauge
needle). Cell suspensions were passed through a 40 micron filter and then through a
fluorescence activated cell sorter (FACS Aria II, BD Biosciences, San Jose, CA) using
an 85 µM nozzle. Cell sorting was performed at room temperature using a 488 nm laser
(>20mW power, Coherent solid-state) for excitation and 530/30 nm and 585/42 nm
bandpass filters for the collection of emission. Settings were carefully determined
empirically and exactly reproduced in each experiment. Gates were demarcated to sort
only mEGFP/DsRed2 double-positive cells. The speed of sorting (usually no more than
1–2 drops per event) was adjusted to obtain a purity of >95%. Cells were suspended in
either PBS (HDAC activity assay) or Trizol (RNA isolation).
HDAC activity assay. FACS-isolated cells were plated into 96-well plates
(1x104 cells/well) and directly assayed. Rodent OLG progenitor cells were cultured and
treated in fibronectin coated 96-well plates (1x105 cells/well) and then assayed. HDAC
activity was determined using the fluorometric HDAC Activity Assay Kit from BioVision
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Inc. (Milpitas, CA). Briefly, the cell permeable HDAC Substrate Boc-Lys(AC)-AMC was
added and cells were incubated for 3 hrs at 37 °C. Subsequent incubation with the
Lysine Developer (30 min at 37 °C) was used to produce a fluorophore from substrate
sensitized through deacetylation. Fluorescence, as a measure of HDAC activity, was
determined using a Spectra Max M5 fluorescent plate reader (Molecular Devices,
Sunnyvale, CA) with excitation/emission at 360/460 nm. In each experiment, triplicates
were prepared for all conditions and treatments.
Immunocytochemistry. For immunocytochemistry using O4 hybridoma supernatants,
cells were fixed in 4% paraformaldehyde/PBS, nonspecific binding sites were blocked in
10% FCS/DMEM, and cells were incubated with the supernatant (1:1 diluted in 10%
FCS/DMEM) overnight. Cells were fixed and in case of dual staining permeabilized
using 0.5% Triton X-100/0.4 M sucrose/PBS and then incubated for 30 min in blocking
solution (10% FCS/DMEM). Subsequently, cells were incubated overnight with antiacetyl-histone H3 (Lys 9), anti-Caspase 3 (active (cleaved) form) or anti-Ki67 antibodies
overnight. Primary antibodies were detected using Alexa 488- or Alexa 568-conjugated
secondary antibodies (Life Technologies, Grand Island, NY) and nuclei were
counterstained using Hoechst 33342 (EMD Millipore, Billerica,MA). For the generation
of representative images, confocal laser scanning microscopy was used (Zeiss LSM
700, Carl Zeiss Microscopy, LLC, Thornwood, NY). Images represent 2D maximum
projections of stacks of 0.5 µm optical sections.
Nuclear histone acetylation analysis. Cells double-labeled for O4 and acetyl-histone
H3 (Lys 9) were imaged using confocal laser scanning microscopy (LSM 700 Carl Zeiss
Microscopy, LLC, Thornwood, NY). Single focal plane images were taken using a
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40x/1.3 n.a. plan-apochromat objective lens. Images were taken from O4-positive cells
and focused on the region of the nucleus as marked by staining with Hoechst. Laser
intensity, detector gain and amplifier offset were optimized and kept constant throughout
the imaging of all samples from one experiment. Fluorescence intensity, i.e. average
pixel intensity, for the anti-acetyl histone H3 (Lys 9) signal, as a measure for the level of
histone acetylation, was determined over the area of the nucleus using IP Lab imaging
software (BD Biosciences Bioimaging, Rockville, MD). Unprocessed confocal images
were used for analysis and threshold settings were kept constant once determined.
Western blot analysis. Cells were homogenized in lysis buffer (150 mM NaCl, 10 mM
KCl, 20 mM HEPES (pH 7.0), 1 mM MgCl2, 20% glycerol, and 1% Triton X-100)
including the complete protease and phosphatase inhibitor cocktail (Thermo Scientific,
Rockford, IL). 5 µg per sample were used for Western blot analysis to detect acetyl
histone H3 (Lys 9) and total H3. Bound primary antibodies were detected using IRDye
680RD- and 800CW-conjugated secondary antibodies (LI-COR Biosciences, Lincoln,
NE). Signal intensities were determined using a LI-COR Odyssey infrared imaging
system (LI-COR Biosciences, Lincoln, NE).
Cell survival and proliferation analysis. Cells were subjected to immunostaining
using O4 hybridoma cell supernatants and antibodies specifically recognizing the active
(cleaved) form of caspase-3 or the Ki67 antigen. To determine the number of caspase-3
or Ki67 immunopositive cells, images of four fields per coverslip were taken with a
20x/0.8 n.a. plan-apochromat objective lens using a confocal laser scanning microscope
(LSM 700 Carl Zeiss Microscopy, LLC, Thornwood, NY). Three coverslips per condition
for each of three independent experiments were analyzed, and Hoechst 33342-positive
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nuclei as well as caspase-3 or Ki67 immunopositive oligodendrocytes were counted
using the Cell Counter plugin to the ImageJ software package (Abramoff et al., 2004).
Statistical Analysis. To determine significance, GraphPad Prism (GraphPad
Software, La Jolla, CA) or SigmaPlot (Systat Software, Inc., San Jose, CA) software
was used. Data composed of two groups were analyzed using the two-tailed Student’s
t-test or the Mann-Whitney U-test and presented in bar graphs depicting means ± SEM
or box and whisker plots depicting medians and quartiles. Data compared to a set
control value lacking variability were analyzed using the one-sample t-test (Dalgaard,
2008; Robert R. Sokal, 2013) and presented in bar graphs.
Results
In the developing zebrafish hindbrain, ATX promotes the timely appearance of
differentiating OLGs via its lysoPLD activity
Our previous studies, using antisense morpholino oligonucleotide-mediated knockdown of atx expression, revealed that in the developing zebrafish hindbrain, ATX
promotes the timely appearance of cells committed to the OLG lineage without affecting
the number of olig2-positive progenitor cells, the overall morphology of the axonal
network or the differentiation of somatic abducens motor neurons (Yuelling et al., 2012).
As recent studies have questioned the correlation between morpholino oligonucleotideinduced and mutant phenotypes in the zebrafish (Kok et al., 2015), we used clustered
regularly interspaced short palindromic repeats (CRISPR)/Cas9 genome editing to
substantiate the above proposed in vivo role of ATX. For these studies, we used the
codon-optimized Cas9 with nuclear localization signals system described by Jao et al.
(2013). This optimized system has been described to lead to an increased frequency of
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biallelic disruption so that injected (F0) embryos phenocopy known mutant phenotypes
(Jao et al., 2013). As shown in Fig. 2.1A-E, injection of guide RNAs against exon 2 or 7
of the atx (enpp2) gene and in vitro transcribed, capped, polyadenylated nls-zCas9-nls
RNA into one-cell stage zebrafish embryos resulted in the generation of indel mutations
over and upstream of the CRISPR targeting sequence. These mutations resulted in
reduced levels of atx mRNA (Fig. 2.1F) (atx-E2, n=4, t-test, p=0.0038; atx-E7, n=6, ttest, P=0.0006), an effect that was not observed when using a guide RNA against
tyrosinase (tyr) (tyr, n=3, t-test, p=0.3468). Most importantly, the CRISPR/Cas9mediated reduction in atx expression was found associated with a decrease in the
transcript levels for the later stage OLG differentiation marker genes claudin K (cldnk)
and proteolipid protein (plp1b) (Fig, 2.1G) (cldnk atx-E2, n=4, t-test, p=0.0188; cldnk
atx-E7, n=5, t-test, p=0.0006; plp1b atx-E2, n=6, t-test, p=0.0155; plp1b atx-E7, n=5, ttest, p=0.0203). As shown in Fig. 2.1H, injection of Cas9 mRNA with either of the guide
RNAs was not found to be associated with changes in the gross morphology of the
embryos. The above described data, therefore, corroborate our earlier morpholino
oligonucleotide-mediated knock-down results and confirm a critical in vivo role of ATX in
the regulation of OLG differentiation.
To assess the extent to which this functional role of ATX may be dependent on its
lysoPLD activity, the inhibitors HA130 and S32826, which have been well-characterized
to block ATX’s lysoPLD activity (Albers et al., 2010; Ferry et al., 2008), were used. Of
these inhibitors, HA130 has previously been demonstrated to effectively block ATX’s
lysoPLD activity in the developing zebrafish at concentrations similar to the ones found
to block human ATX (Lai et al., 2012). Two experimental designs were used (see
42

Figs. 2.2A and 2.3A). First, to determine the effect of an inhibition of ATX’s lysoPLD
activity on OLG differentiation, inhibitors were added to zebrafish embryos at 44 hrs
post fertilization (hpf), i.e. at a time point when OLG progenitors arise in the ventral
hindbrain and start to differentiate (Zannino and Appel, 2009)(Fig. 2.2A). Zebrafish
embryos were analyzed at 48 hpf, a time point at which transcripts for cldnk and plp1b
start to become detectable (Brösamle and Halpern, 2002; Münzel et al., 2012; Takada
and Appel, 2010). As shown in Fig. 2.2B, treatment with either of the inhibitors at both
1µM and 10µM concentrations significantly reduced ATX’s lysoPLD activity (HA130
1µM, n=4, t-test, p=0.0166; HA130 10µM, n=4, t-test, p=0.0132; S32826 1µM, n=6,
t-test, p=0.0008; S32826 10µM, n=5, t-test, p=0.0131). Importantly, both inhibitors
significantly reduced the mRNA levels for cldnk and plp1b at both concentrations used
(Fig. 2.2C,D) (cldnk: HA130 1µM, n=3, t-test, p=0.0144; HA130 10µM, n=3, t-test,
p=0.0413; S32826 1µM, n=3, t-test, p=0.0006; S32826 10µM, n=3, t-test, p=0.0166;
plp1b: HA130 1µM, n=5, t-test, p=0.0038; HA130 10µM, n=5, t-test, p=0.0325; S32826
1µM, n=5, t-test, p=0.0071; S32826 10µM, n=5, t-test, p=0.0031). In contrast, there was
no change in the number of olig2-positive progenitors (Fig. 2.2E,F) (HA130 1µM, n=5,
t-test, p=0.7184; HA130 10µM, n=5, t-test, p=0.5050; S32826 1µM, n=5, t-test,
p=0.7679; S32826 10µM, n=5, t-test, p=0.7277), which at 48 hpf represent early stages
of both motor neuron and OLG lineages (Park et al., 2002; Zannino and Appel, 2009). It
is of note that neither S32826 nor HA130 were found to exert cytotoxic effects when
treating zebrafish embryos or cells in culture at the concentrations used here (Albers et
al., 2010; Ferry et al., 2008; Iyer et al., 2012; Lai et al., 2012, see also description to Fig.
2.7 below). Consistently, no gross morphological defects were noted upon the treatment
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of zebrafish embryos with HA130 or S32826 (Fig. 2.2G) and no noticeable increase in
7-aminoactinomycin D (7-AAD) staining, as a measure for increased cell death (Philpott
et al., 1996), was detected when analyzing single cell suspensions from control and
inhibitor treated whole fish embryos by flow cytometry (data not shown). Hence, the
data shown in Fig. 2 suggest that ATX’s lysoPLD activity, as ATX as a whole (Yuelling
et al., 2012), regulates the progression of olig2-positive progenitor cells into lineage
committed and differentiating OLGs, but not the appearance of olig2-positive
progenitors itself.
To further confirm the above conclusion, ATX-lysoPLD inhibitors were added at a
time point at which olig2-positive progenitors begin to arise in the hindbrain, i.e. at
24 hpf (Zannino and Appel, 2009) (Fig. 2.3A). As shown in Fig. 2.3B-E, treatment with
HA130 had a comparable effect in both experimental designs (ATX activity: HA130
1µM, n=5, t-test, p=0.0051; HA130 10µM, n=4, t-test, p=0.0130; cldnk: HA130 1µM,
n=4, t-test, p=0.0037; HA130 10µM, n=5, t-test, p=0.0167; plp1b: HA130 1µM, n=4,
t-test, p=0.0272; HA130 10µM, n=4, t-test, p=0.0111; olig2: HA130 1µM, n=5, t-test,
p=0.1867; HA130 10µM, n=5, t-test, p=0.8770). Interestingly, treatment with S32826,
when applied at 24 hpf, did not cause a significant effect on ATX’s lysoPLD activity or
cldnk/plp1b mRNA levels when used at 1µM and a much-reduced effect when used at
10µM (Fig. 2.3B-E) (ATX activity: S32826 1µM, n=3, t-test, p=0.0566; S32826 10µM,
n=4, t-test, p=0.0322; cldnk: S32826 1µM, n=5, t-test, p=.3999; S32826 10µM, n=5,
t-test, p=0.0145; plp1b: S32826 1µM, n=3, t-test, p=0.9437; S32826 10µM, n=3, t-test,
p=0.0162; olig2: S32826 1µM, n=5, t-test, p=0.2823; S32826 10µM, n=5, t-test,
p=0.8073). This lack of effective inhibition of ATX’s lysoPLD activity is likely due to the
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known poor in vivo stability and/or bioactivity of S32826 (Ferry et al., 2008; Gupte et al.,
2011). As in the studies to the experimental design shown in Fig. 2.2, no gross
morphological defects (Fig. 2.3G) or noticeable increase in cell death (not shown) were
noted.
Taken together, the above data demonstrate that inhibition of ATX’s lysoPLD activity
mimics the effects on the OLG lineage as seen upon morpholino oligonucleotidemediated knock-down of atx expression (Yuelling et al., 2012) or CRISPR/Cas9mediated genome editing at the atx locus (Fig. 2.1). Thus, they establish that it is ATX’s
lysoPLD activity that is necessary for the timely appearance of differentiating OLGs in
the developing zebrafish hindbrain.
In the developing zebrafish, ATX-lysoPLD promoted progression along the early
stages of the OLG lineage is associated with an increase in HDAC activity
The progression along the early stages of the OLG lineage, as seen regulated by
ATX’s lysoPLD activity, has been well-established to be associated with epigenetic
modifications and in particular with an increase in histone deacetylation (He et al., 2007a;
Liu and Casaccia, 2010; Marin-Husstege et al., 2002; Shen et al., 2005, 2008; Swiss et
al., 2011; Takada and Appel, 2010). In addition, in studies unrelated to ATX, it has been
shown that LPA, for which enzymatic lysoPLD activity represents one of the known
biosynthetic pathways (Aoki et al., 2008a), can increase histone deacetylation in a
number of human cancer cell lines (Ishdorj et al., 2008). Thus, and in an effort to identify
downstream targets of ATX’s lysoPLD activity involved in the regulation of OLG
differentiation, we focused on HDACs and their activity. For these studies, the
experimental design as depicted in Fig. 2.4A was used. In addition, and to enable an
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analysis of HDAC activity explicitly in cells of the OLG lineage, the double transgenic
zebrafish line Tg(nkx2.2a:megfp;olig2:dsred2) was used in which a subset of OLG
lineage cells can be identified by the concurrent expression of mEGFP and DsRed2
(Kucenas et al., 2008) and thus be isolated by fluorescence-activated cell sorting
(FACS). In agreement with an OLG lineage commitment, such sorted and doublepositive cells were characterized under control conditions by an enriched expression of
the OLG marker gene cldnk (Fig. 2.4B) (n=5, t- test, p=0.0262, compared to whole fish
embryo expression). In contrast, there were, if at all, only slight levels of expression
detectable for the radial/ependymal/enteric glia marker gfap (Fig. 2.4B) (n=4, t-test, p=
0.0023, compared to whole fish embryo expression) (Bernardos and Raymond, 2006;
Doodnath et al., 2010; Grupp et al., 2010; Hagström and Olsson, 2010; Lam et al.,
2009) and the neuronal intermediate filament encoding genes gefiltin (inab) (Fig. 2.4B)
(n=4, t-test, p=0.0014, compared to whole fish embryo expression) and plasticin (prph)
(Fig. 2.4B) (n=4, t-test, p=0.0019, compared to whole fish embryo expression) (Leake et
al., 1999). In addition, and similar to the rodent system (Savaskan et al., 2007), such
early stages of the OLG lineage were found to express atx (Fig. 2.4B) (n=4, t-test,
p=0.0464). It is of note that such early, and relatively low, expression during the OLG
lineage remained undetected in our earlier studies (Yuelling et al., 2012) due to the use
of less sensitive detection methods. Upon inhibition of ATX’s lysoPLD activity, and
consistent with the previously observed lack of an effect on the number of olig2
expressing progenitor cells (Fig. 2.2E,F), no change in the number of double-positive
cells was observed (Fig. 2.4C) (HA130, n=4, t-test, p=0.4722; S32826, n=4, t-test,
p=0.3765). To further assess potential effects of ATX-lysoPLD inhibition on progenitor
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marker expression levels, the fluorescence intensities for mEGFP and DsRed2 were
monitored, as they are indicators for nkx2.2a and olig2 promoter activities. A shown in
Fig. 2.4D and E, no changes were observed (n=5, t-test, p=0.5855, mEGFP; n=5, t-test,
p=0.6436, DsRed2). In contrast, and in agreement with our previous findings
(Fig. 2.2C,D), the expression of sox10, which at the developmental stage analyzed
marks olig2/nkx2.2a double-positive cells that are OLG lineage committed and
differentiating (Kucenas et al., 2008), was found to be decreased (Fig. 2.4F) (HA130,
n=4, t-test, p=0.0358). Importantly, such a reduction in the expression of a gene
characteristic for recently specified and differentiating OLGs was associated with a
reduction in overall HDAC activity (Fig. 2.4G) (HA130, n=4, t-test, p=0.0275; S32826,
n=4, t-test, p=0.0106). This effect was found to not be associated with a noticeable
decrease in cell viability as assessed by propidium iodide staining and flow cytometry
(Sasaki et al., 1987) (data not shown).
Taken together, the above data demonstrate that in the developing zebrafish, ATX,
via its lysoPLD activity, promotes the lineage progression from an olig2/nkx2.2a
double-positive progenitor cell to a sox10 expressing fully committed and early
differentiating OLG by a mechanism that is associated with an increase in overall HDAC
activity.
In enriched primary cultures of rodent OLG lineage cells, ATX’s lysoPLD activity
promotes OLG differentiation
To more precisely define the functional correlation between ATX’s lysoPLD
activity and changes in HDAC activity/histone acetylation and to assess evolutionary
conservation of this mechanism, we turned to the well-established culture system of
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enriched primary rodent OLG lineage cells. In this culture system, OLG differentiation
follows the same sequence of events as observed in vivo but provides the advantage of
studying intrinsic cellular mechanisms (Temple and Raff, 1985). In addition, the role of
HDACs and histone acetylation has been well-characterized in this system (MarinHusstege et al., 2002; Swiss et al., 2011). More specifically, an increase in histone
deacetylation as early as 6 hrs post-mitogen withdrawal has been found crucial for the
transition from a proliferating OLG progenitor to a differentiating OLG (Marin-Husstege
et al., 2002). To establish the role of ATX’s lysoPLD activity on OLG differentiation
during this developmental time window, we, therefore, employed the experimental
design as depicted in Fig. 2.5A. First, we established the expression profile of
transcriptional targets previously shown to be regulated by histone deacetylation,
namely 2',3'-Cyclic-nucleotide 3'-phosphodiesterase (Cnp), UDP glycosyltransferase 8
(Ugt8) and the transcriptional regulator Egr1 (Swiss et al., 2011). In agreement with the
findings described by Swiss et al., OLG differentiation was found in our system to be
characterized by an increase in the expression of the OLG marker genes Cnp and Ugt8
and a decrease in the expression of Egr1 (Fig. 2.5B) (Cnp: n=5, t-test, p=0.0134; Ugt8:
n=5, t-test, p=0.0429; Egr1: n=3, t-test, p=0.0362). In addition, there was a slight
increase in the expression of Atx (Fig. 2.5B) (n=5, t-test, p=0.0118). As shown in
Fig. 2.5C, treatment with either of the ATX-lysoPLD activity inhibitors, HA130 or
S32826, significantly reduced ATX’s lysoPLD activity after 4 and 24 hrs (Fig. 2.5C)
(HA130 10µM 28 hrs, n=4, t-test, p=0.0004; HA130 10µM 48 hrs, n=5, t-test, p=0.0001;
S32826 10µM 28 hrs, n=4, t-test, p=0.0078; S32826 10µM 48 hrs, n=5, t-test,
p=0.0095). This inhibition of ATX-lysoPLD activity resulted in an attenuation of both the
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upregulation of Cnp and Ugt8 expression and the downregulation of Egr1 expression
(Fig. 2.5D) (Cnp: HA130 10µM, n=3, t-test, p=0.0224, S32826 10µM, n=3, t-test,
p=0.0159; Ugt8: HA130 10µM, n=3, t-test, p=0.0321, S32826 10µM, n=3, t-test,
p=0.0063; Egr1: HA130 10µM, n=4, t-test, p=0.0051, S32826 10µM, n=3, t-test,
p=0.0345). The above findings demonstrate that ATX, via its lysoPLD activity and
similar to what we have seen in the developing zebrafish (Figs. 2.1-4), promotes gene
expression changes associated with OLG differentiation in primary cultures of rodent
OLGs.
In primary cultures of rodent OLGs, ATX-lysoPLD promoted progression along
the early stages of the OLG lineage is associated with an increase in HDAC
activity
The gene expression changes observed upon inhibition of ATX’s lysoPLD activity
(Fig. 2.5D) mimicked those changes previously described to occur upon inhibition of
HDAC activity (Swiss et al., 2011), thus suggesting that, as in the zebrafish, these
changes may be associated with a decrease in overall HDAC activity. To assess this
possibility, the experimental design as shown in Fig. 2.6A was used. Indeed, HDAC
activity was found to be decreased as early as 4 hrs and up to 24 hrs post-application of
ATX-lysoPLD inhibitors (Fig. 2.6B) (HA130 10µM 28 hrs, n=5, t-test, p=0.0280; HA130
10µM 48 hrs, n=7, t-test, p=0.0001; S32826 10µM 28 hrs, n=3, t-test, p=0.0004;
S32826 10µM 48 hrs, n=5, t-test, p=0.0034). To provide further evidence for a direct link
between ATX’s lysoPLD activity and the regulation of HDAC activity, we performed
rescue experiments in which LPA, the enzymatic product of ATX’s lysoPLD activity, was
added concurrent with ATX-lysoPLD inhibitors. As shown in Fig. 2.6C, addition of LPA
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(10 µM) attenuated the effect of HA130 on HDAC activity (n=7, t-test, p=0.0003).
Consistent with LPA’s thereby suggested HDAC activity promoting role in differentiating
OLGs, LPA treatment alone was found to lead to an increase in HDAC activity (Fig.
2.6D) (n=4, t-test, p=0.0052). Taken together, the above data confirm that, as in the
developing zebrafish, progression along the early stages of the OLG lineage in rodents
is promoted by ATX’s lysoPLD activity via the generation of LPA and a downstream
mechanism that involves an increase in HDAC activity.
ATX-lysoPLD promoted increase in HDAC activity is associated with a decrease
in nuclear histone acetylation
It has been previously shown that HDAC activity in differentiating OLGs is
primarily directed to lysine residues of histones H4 and H3 including the lysine residue
on the tail of histone H3 at position 9 (H3K9) (Swiss et al., 2011). To assess changes in
acetylation at this site, cells treated as depicted in Fig. 2.5A were analyzed at 48 hrs by
immunocytochemistry combined with confocal microscopy. As shown in Fig. 2.7A,
nuclear histone acetylation can be readily detected in O4-positive differentiating OLGs
by this method. Most importantly, inhibition of ATX’s lysoPLD activity led to a significant
increase in the levels of H3K9 acetylation (Fig. 2.7C) (HA130: n=3, Mann-Whitney Utest, p=0.00005; S32826: n=3, Mann-Whitney U-test, p=0.0003). This effect was not
found to be associated with changes in cell survival or proliferation as determined by
immunostaining using antibodies specifically recognizing the active (cleaved) form of
caspase-3 (n=3, t-test, p=0.1355) or the Ki67 antigen (n=3, t-test, p=0.1189). In
addition, no prominent changes in cellular morphology or nuclear appearance were
noted (Fig. 2.7B). The above described increase in H3K9 acetylation upon ATX50

lysoPLD inhibition could be further confirmed by Western blot analysis of cell
homogenates (Fig. 7D) (n=3, t-test, p=0.0442). Taken together, our data so far
demonstrate that attenuation of OLG differentiation via inhibition of ATX’s lysoPLD
activity (Figs. 2.2, 2.3 and 2.5) is associated with a decrease in HDAC activity (Figs. 2.4
and 2.6) and an increase in histone acetylation (Fig. 2.7).
ATX-lysoPLD promoted progression along the early stages of the OLG lineage is
dependent on the activity of HDAC1/2 but not HDAC6
The general requirement of HDAC activity for OLG differentiation has been
previously shown to involve particularly the class I HDAC members HDAC1 and HDAC2
(Shen et al., 2008; Wu et al., 2012; Ye et al., 2009). To investigate the extent to which
ATX’s lysoPLD activity may represent an upstream signal regulating especially the
activity of the class I HDAC members HDAC1 and HDAC2, we used a pharmacological
HDAC1/2/3 inhibitor, namely CI994 (Beckers et al., 2007; Kraker et al., 2003), in the
experimental design as depicted in Fig. 2.8A. It is of note that HDAC3 was found to not
be involved in the regulation of OLG differentiation at the stages analyzed here (Shen et
al., 2008; Wu et al., 2012). In addition, at the concentration used (2.5 µM), CI994 is
considered to effectively inhibit HDAC1 (Beckers et al., 2007). The effectiveness of
HDAC1/2 inhibition in our system is corroborated by the observed reduction in Ugt8
mRNA levels (Fig. 2.8B), as its expression has been previously shown to be regulated
by direct targets of HDAC1/2-mediated histone deacetylation (Swiss et al., 2011).
Furthermore, and as a control, inhibition of HDAC6, which represents a class II HDAC
member, was performed by using the inhibitor Tubastatin A (Butler et al., 2010). At the
concentration used (5 µM), Tubastatin A is considered to effectively inhibit HDAC6 with
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additional but only moderate activity at HDAC8 (Beckers et al., 2007). Neither HDAC6
nor HDAC8 have been found involved in the regulation of gene expression changes
associated with OLG differentiation (Noack et al., 2014; Shen et al., 2005, 2008; Wu et
al., 2012), and HDAC6 has in OLGs functionally been primarily implicated in
contributing to the clearing process of misfolded protein aggregates (Leyk et al., 2015;
Noack et al., 2014). As indicated above and shown in Fig. 2.8, application of CI994, but
not Tubastatin A, attenuated the expression of the OLG differentiation genes Ugt8 and
Cnp to a similar extent as the application of the ATX-lysoPLD activity inhibitor HA130
(Ugt8: HA130, n=3, t-test, p=0.0299; CI994, n=3, t-test, p=0.0176; Tubastatin A, n=3,
t-test, ns; Cnp: HA130, n=3, t-test, p=0.0382; CI994, n=3, t-test, p=0.0270; Tubastatin
A, n=3, t-test, ns). To assess the extent to which HDAC1/2 activity may be required for
the observed ATX-lysoPLD-mediated changes in gene expression, the effect of
HDAC1/2/3 or HDAC6 inhibition on LPA-stimulated rescue was determined. In
agreement with a critical role of HDAC1/2, but not HDAC6, the addition of LPA was
unable to rescue the effect of ATX-lysoPLD inhibition on Ugt8 and Cnp mRNA levels in
the presence of CI994, but not Tubastatin A (Fig. 2.8B,C) (Ugt8: HA130+CI994+LPA,
n=3, t-test, p=0.0033; HA130+Tubastatin A+LPA, n=3, t-test, p=0.0373; Cnp,
HA130+CI994+LPA, n=3, t-test, p=0.0036; HA130+Tubastatin A+LPA, n=3, t-test,
p=0.0325). It is of note that ATX-lysoPLD inhibition could be observed as early as 2 hrs
post-application of HA130 (not shown) and was thus fully effective at the time-point of
HDAC inhibition. Furthermore, no additive or synergistic effects were observed upon
additional inhibition of HDAC1/2/3 or HDAC6 (data not shown). Moreover, CI994
(Kraker et al., 2003), tubastatin A (Parab et al., 2015) and LPA (our own data, not
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shown) have been shown to exert their effects within the first 2 hrs of treatment, thus
largely excluding a timely separation of their actions. Thus, the above data provide
strong support for a crucial role of the class I HDAC members HDAC1 and HDAC2 as
downstream targets mediating the OLG differentiation promoting effect of ATX’s
lysoPLD activity.
Discussion
Our data presented here, suggest a modulatory role of ATX during the transition
from an OLG progenitor to an early stage differentiating OLG as depicted in our
proposed model shown in Fig. 2.9. In this model, LPA, generated via ATX’s lysoPLD
activity, activates one (or more) of its cognate G protein-coupled receptors, which are
referred to as LPA receptors (Choi and Chun, 2013; Chun et al., 2010; Kihara et al.,
2014) and have been found expressed by cells of the OLG lineage (Dawson et al.,
2003; Nogaroli et al., 2009b; Stankoff et al., 2002; Weiner et al., 1998; Zhang et al.,
2014). Activation of the above ATX-LPA axis initiates a downstream signaling cascade
leading to the activation of HDAC1/2, which in turn mediates histone deacetylation and
repression of transcriptional inhibitors of OLG differentiation, thereby promoting gene
expression changes that are associated with the transition from an OLG progenitor to
an early stage differentiating OLG. ATX has been found to be expressed and secreted
by OLG progenitors and differentiating OLGs (Figs. 2.4, 2.5 and Fox et al., 2003; Fuss
et al., 1997; Savaskan et al., 2007) thus suggesting an autocrine signaling mechanism.
However, and during development, paracrine regulation may also occur via the
secretion of ATX by cells of the floor plate (Yuelling et al., 2012). Importantly, the
regulatory mechanism described here appears evolutionarily conserved, at least from
53

zebrafish to rodents.
In the context of histone deacetylation during the early stages of OLG differentiation,
it is of note that HDAC1/2 activity has not only been implicated in modulating the
transition from an OLG progenitor to an early stage differentiating OLG, but also the
specification of an OLG progenitor from a multipotent neural progenitor cell (Copray et
al., 2009; Jacob et al., 2011). However, and based on the data shown here, HDAC1/2mediated regulation of OLG progenitor specification is unlikely to be modulated by ATX
and its lysoPLD activity. First, inhibition of ATX-lysoPLD activity was not found to affect
the expression of nkx2.2.a (Fig. 2.4), which has been described to be upregulated upon
early developmental loss of HDAC1 activity (Cunliffe and Casaccia-Bonnefil, 2006).
Second, ATX and its lysoPLD activity were not found to affect the expression of olig2,
which during OLG progenitor specification has been proposed to be modulated via
HDAC1/2 activity and upstream of sonic hedgehog signaling (Cunliffe and CasacciaBonnefil, 2006; Ye et al., 2009). Hence, it appears that ATX, via its lysoPLD activity,
modulates HDAC1/2-regulated gene expression explicitly during a developmental time
window that coincides with the transition from OLG progenitor to early stage
differentiating OLG and that likely occurs post-sonic hedgehog-modulated HDAC1/2regulated gene expression implicated in OLG progenitor specification. Future work will,
however, be necessary to more precisely define the relationships between the ATX-LPA
axis, sonic hedgehog signaling and their downstream effects on HDAC1/2-regulated
gene expression.
In general, it is becoming more and more clear that histone acetylation and
deacetylation events represent dynamic modifications (Peserico and Simone, 2011).
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Consistent with this notion, histone deacetylation in cells of the OLG lineage has been
found to be transient and reversible (Shen et al., 2005). In a search for more stable
repressive histone modifications, marks of trimethylation of lysine residue K9 on histone
3 (H3K9) have recently been found to coincide with the transition from OLG progenitor
to differentiating OLG (Liu et al., 2015). Thus, it will be interesting to explore in
subsequent studies a potential role of the ATX-LPA axis in modulating H3K9
methyltransferases.
ATX has been demonstrated to possess two functionally distinct domains, the
lysoPLD active site and the MORFO domain. Our data presented here, demonstrate
that ATX’s lysoPLD active site affects epigenetic and gene expression aspects of OLG
differentiation. In contrast, and based on our previous data, the function of ATX’s
MORFO domain, as it relates to OLG differentiation, appears restricted to promoting
cytoskeletal and thus morphological changes (Dennis et al., 2008, 2012; Fox et al.,
2003). This concept that OLG morphogenesis is regulated, at least in part, by
mechanisms distinct from the ones affecting gene expression is supported by
previous findings (Buttery and ffrench-Constant, 1999; Ishii et al., 2012; Osterhout et
al., 1999; Sloane and Vartanian, 2007; Younes-Rapozo et al., 2009). At the same
time, however, it is also well-known that both of the above stated aspects of OLG
differentiation occur well-synchronized during development (Bauer et al., 2009;
Mitew et al., 2014; Wegner, 2008). Taken together, these observations raise the
exciting possibility that ATX, via the concerted action of its two distinct functional
activities, may be one of the critical players coordinating gene expression and
morphological changes during OLG differentiation.
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The functional effects of ATX’s lysoPLD activity have been well-described to be
mediated by signaling through a family of G protein-coupled receptors, the so-called
LPA receptors. To date, there are six receptors that are recognized as bona fide LPA
receptors, all of which appear to be expressed, at least to some degree, in cells of the
OLG lineage (Zhang et al., 2014). Notably, LPA1 has long been known to be present on
OLGs (Dawson et al., 2003; Nogaroli et al., 2009b; Stankoff et al., 2002; Weiner et al.,
1998), and a number of functional roles have been proposed based on tissue culture
studies. Somewhat disappointingly, Lpar1 knock-out mice have initially not been found
to display CNS myelin-related pathologies (Contos et al., 2000, 2002). Myelin defects
were, however, reported in more recent studies analyzing the so-called Málaga variant
(maLpar1 null mice), a stable variant of the original Lpar1 knock-out mouse strain in
which defects are more pronounced likely due to interactions of LPA1 with currently
unknown genetic modifiers (Estivill-Torrús et al., 2008; García-Díaz et al., 2015). In
maLpar1 null mice, impaired transport of one of the major myelin proteins, namely
proteolipid protein, was found to be impaired leading to loss of OLGs most likely due to
stress-induced apoptosis. No deficits in OLG differentiation were noted in these mice.
Thus, and despite its prominent expression in OLGs, LPA1 appears unlikely to play a
major role in mediating the ATX-LPA-HDAC1/2 axis described here.
To our knowledge, null mice have been generated for all currently recognized LPA
receptors with the exception of LPA6 (Contos et al., 2000, 2002; Lin et al., 2012; Liu et
al., 2010; Ye et al., 2005). In addition, knock-down studies have been performed in the
zebrafish and in Xenopus laevis that cover all known bona fide LPA receptors (Geach et
al., 2014; Yukiura et al., 2011). In neither of the studies have myelin defects been
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reported. This does not exclude a prominent role of LPA receptor signaling in OLGs but
rather highlights the complication of functional redundancy and compensation when
eliminating a single LPA receptor. For example, it has been shown that combined
knock-down of lpar1 and lpar4 in the zebrafish leads to vascular defects while single
lpar knock-down has no effect (Yukiura et al., 2011). Similarly, male reproductive
defects have been observed in triple Lpar1/2/3 knockout mice but not any of the single
Lpar knockout mice (Ye et al., 2008). In the context of our studies it is interesting that for
the triple knockout mice no myelin defects have been reported, thus suggesting an
involvement of at least one of the remaining LPA receptors, namely LPA4, LPA5 and/or
LPA6. Out of these, LPA4 has been shown to activate PKA via coupling to the
heterotrimeric G-protein Gαs and increase in cyclic AMP (cAMP) levels (Gardell et al.,
2006). PKA, in turn, has been implicated in regulating HDAC activity via phosphorylation
(Sengupta and Seto, 2004). While LPA5 was found to not couple to Gαs, its stimulation
was nevertheless found to be associated with an increase in cAMP levels possibly
through involvement of G protein βγ subunits (Lee et al., 2006). LPA6 may couple to Gαs,
however with likely much lower potency than LPA4 (Yanagida et al., 2009a). Clearly,
more comprehensive analyses will be necessary to dissect the exact roles for each of
the LPA receptors in the regulation of OLG differentiation and via the ATX-LPA axis.
Our data presented here, reveal a novel functional role for ATX’s lysoPLD activity,
namely the promotion of OLG differentiation via an increase in HDAC1/2 activity and
associated changes in gene expression. In the context of human diseases and in
particular the major demyelinating disease in human, Multiple Sclerosis (MS), it is
worth mentioning that ATX mRNA levels have been found reduced within the MS CNS
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(Raddatz et al., 2014) and that a shift toward a decrease in histone deacetylation has
been implicated in contributing to the limitations in myelin repair seen in MS (Pedre et
al., 2011). These findings further support a critical role of ATX in the regulation of CNS
myelination, and they suggest that misregulation of the ATX-LPA-HDAC1/2 axis may
contribute to the pathology seen in MS.
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Figure 2.1. In the developing zebrafish, CRISPR-Cas9-mediated mutagenesis of atx
leads to a reduction in the mRNA levels for OLG marker genes. A, atx (enpp2) genomic
structure and CRISPR target sequences. ATG and TGA indicate the locations of the
translation start and stop sites. Protospacer adjacent motif (PAM) sequences are
highlighted in red. The sequence encoding T210, the threonine residue shown to be
obligatory for ATX’s enzymatic activity, is underlined. B,D, Representative images of
agarose gels showing DNA fragments upon Surveyor nuclease treatment of control
homoduplexes (c) and control/atx-E2 (B) or control/atx-E7 (D) homo/heteroduplexes.
Numbers on the left indicate DNA sizes in bp. Arrowheads indicate cleaved PCR
amplicon fragments at the expected sizes indicative of indel mutations generated by
genome editing. C,E, Representative images of sequencing traces obtained from
genomic DNA-derived PCR amplicons from control and Cas9 mRNA/sgRNA injected
zebrafish embryos. Arrows at the top of each trace indicate the location of the target
sequence, over and upstream of which a composite sequence trace indicates the
presence of indel mutations generated by genome editing. F,G, Bar graphs illustrating
mRNA levels for atx (F) or the OLG marker genes cldnk and plp1b (G) in whole
embryos as determined by real-time reverse transcription (RT)-qPCR analysis. Control
(uninjected embryos) values were set to 100% (see horizontal line) and experimental
values were calculated accordingly. Data shown represent means ± SEM. nsnot
significant, *p≤0.05, **p≤0.01, ***p≤0.001. H, Representative brightfield images of
control (uninjected) and Cas9 mRNA/sgRNA injected embryos at 48 hpf. Scale bar: 1
mm.
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Figure 2.2. In the developing zebrafish, inhibition of ATX’s lysoPLD activity during early
stages of OLG differentiation leads to a reduction in the levels of OLG-enriched
transcripts without apparent effects on the number of olig2-positive cells. A,
Experimental design. Embryos were treated with the ATX-lysoPLD inhibitors HA130 and
S32826 at a time point when newly specified OLG progenitors start to differentiate. B,
Bar graph depicting ATX-lysoPLD activity in whole embryos as assessed by using the
fluorogenic substrate FS-3. C,D, Bar graphs illustrating mRNA levels for the OLG
marker genes cldnk (C) and plp1b (D) in whole embryos as determined by real-time
reverse transcription (RT)-qPCR analysis. E, Bar graph showing the number of olig2positive progenitors in whole embryos as determined through whole mount in-situ
hybridization. F, Representative extended focus images of whole mount embryos after
in situ hybridization with a probe specific for olig2. Dorsal views over the hindbrain are
shown with anterior to the top. Scale bar: 50 µm. G, Representative brightfield images
of control (vehicle-treated) and ATX-lysoPLD inhibitor treated embryos at 48 hpf. Scale
bar: 1 mm. For all bar graphs, control (vehicle-treated) values were set to 100% (see
horizontal line) and experimental values were calculated accordingly. Data shown
represent means ± SEM. nsnot significant, *p≤0.05, **p≤0.01, ***p≤0.001.
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Figure 2.3. In the developing zebrafish, inhibition of ATX’s lysoPLD activity during the
time window when olig2-positive progenitors arise in the hindbrain leads to a reduction
in the levels of OLG-enriched transcripts without apparent effects on the number of
olig2-positive cells. A, Experimental design. Embryos were treated with the ATXlysoPLD inhibitors HA130 and S32826 during the time window when olig2-positive
progenitors arise in the ventral hindbrain. B, Bar graph depicting ATX-lysoPLD activity
in whole embryos as assessed by using the fluorogenic substrate FS-3. C,D, Bar
graphs illustrating mRNA levels for the OLG marker genes cldnk (C) and plp1b (D) in
whole embryos as determined by real-time reverse transcription (RT)-qPCR analysis.
Note that loss of inhibitory activity as seen for S32826 results in an attenuated effect on
cldnk and plp1b mRNA levels, thus suggesting that ATX, via its lysoPLD activity,
regulates OLG differentiation during a critical developmental window. E, Bar graph
showing the number of olig2-positive progenitors in whole embryos as determined
through whole mount in-situ hybridization. F, Representative extended focus images of
whole mount embryos after in situ hybridization with a probe specific for olig2. Dorsal
views over the hindbrain are shown with anterior to the top. Scale bar: 50 µm. G,
Representative brightfield images of control (vehicle-treated) and ATX-lysoPLD inhibitor
treated embryos at 48 hpf. Scale bar: 1 mm. For all bar graphs, control (vehicle-treated)
values were set to 100% (see horizontal line) and experimental values were calculated
accordingly. Data shown represent means ± SEM. nsnot significant, *p≤0.05, **p≤0.01,
***p≤0.001.
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Figure 2.4. In the developing zebrafish, inhibition of ATX’s lysoPLD activity during early
stages of OLG differentiation leads to a reduction in HDAC activity within cells of the
OLG lineage. A, Experimental design using Tg(nkx2.2a:megfp;olig2:dsred2) zebrafish
embryos, which were treated with the ATX-lysoPLD inhibitors HA130 (10 µM) or
S32826 (10 µM) at a time point when newly specified OLG progenitors start to
differentiate. B, Bar graph illustrating the mRNA expression profile under control
conditions for FACS-isolated mEGFP/DsRed2 double-positive cells as determined by
real-time reverse transcription (RT)-qPCR analysis. mRNA levels in whole fish were set
to 100% for each gene individually (marked by the horizontal line) and the values for
sorted cells were calculated accordingly. C, Bar graph showing the number of
mEGFP/DsRed2 double-positive cells as determined by FACS analysis. Values for
vehicle-treated embryos were set to 100% (see control bar) and experimental values
were calculated accordingly. D,E, Representative single-parameter fluorescence
histograms (x axis: fluorescence intensity, logarithmic scale; y axis: cell number)
depicting mEGFP (D) or DsRed2 (E) intensities of mEGFP/DsRed2 double-positive
cells under control conditions (black line) and upon treatment with HA130 (red line).
Cells within the area marked by the horizontal line were considered mEGFP (D)- or
DsRed2 (E)-positive. Note the high purity (100%) of the sorted cell population. F, Bar
graph depicting sox10 mRNA levels for FACS-isolated mEGFP/DsRed2 double-positive
cells as determined by real-time reverse transcription (RT)-qPCR analysis. Values for
vehicle-treated embryos were set to 100% (see control bar) and experimental values
were calculated accordingly. G, Bar graph depicting HDAC activity as determined by
using the fluorogenic substrate Boc-Lys(Ac)-AMC. Values for vehicle-treated embryos
were set to 100% (see control bar) and experimental values were calculated
accordingly. Data shown in all bar graphs represent means ± SEM. nsnot significant,
*p≤0.05, **p≤0.01, ***p≤0.001.
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Figure 2.5. In rodent OLG cultures, inhibition of ATX’s lysoPLD activity leads to a
reduction in the levels of mRNAs encoding OLG differentiation genes and to an
increase in the level of mRNA encoding the transcriptional OLG differentiation inhibitor
Egr1. A, Experimental design. Timing of histone deacetylation is marked as described
by Marin-Husstege et al. (2002). OPC: OLG progenitor. B, Bar graph depicting mRNA
levels for the OLG differentiation genes Cnp and Ugt8 and the transcriptional inhibitor
Egr1 as well as Atx as determined by real-time reverse transcription (RT)-qPCR
analysis. mRNA levels at 24 hrs were set to 100% for each gene and 48 hrs values
were calculated accordingly. C, Bar graph illustrating ATX-lysoPLD activity as assessed
by using the fluorogenic substrate FS-3. Control (vehicle-treated) values were set to
100% (see horizontal line) and experimental values were calculated accordingly. D, Bar
graph depicting mRNA levels for the OLG differentiation genes Cnp and Ugt8 and the
transcriptional inhibitor Egr1 as determined by real-time RT-qPCR analysis. Control
(vehicle-treated) values were set to 100% (see horizontal line) and experimental values
were calculated accordingly. Data shown in all bar graphs represent means ± SEM.
ns
not significant, *p≤0.05, **p≤0.01, ***p≤0.001.
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Figure 2.6. In rodent OLG cultures, inhibition of ATX’s lysoPLD activity leads a
reduction in HDAC activity. A, Experimental design. Timing of histone deacetylation is
marked as described by Marin-Husstege et al. (2002). OPC: OLG progenitor. B-D, Bar
graphs showing HDAC activity as determined by using the fluorogenic substrate BocLys(Ac)-AMC. Control (vehicle-treated) values were set to 100% (see horizontal line in
B and control bars in C,D) and experimental values were calculated accordingly. Data
represent means ± SEM. nsnot significant, *p≤0.05, **p≤0.01, ***p≤0.001.
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Figure 2.7. In rodent OLG cultures, inhibition of ATX’s lysoPLD activity leads to an
increase in nuclear histone acetylation at lysine residue 9 of histone 3 (H3K9). A,B,
Representative confocal images of differentiating OLGs treated with vehicle (control,
upper panel) or HA130 (lower panel) and immuno-labeled using O4 hybridoma
supernatants (A,B) and anti-acetyl-histone H3K9 antibodies (A). Nuclei are visualized
via staining with Hoechst (A,B). Scale bars: 20 µm in A, 100 µm in B. C, Box and
whisker plot depicting nuclear acetyl-H3K9 levels as assessed by determining
fluorescence intensities shown in arbitrary units (a.u.). The plot depicts medians and
quartiles of three independent experiments. Whiskers represent the 10th and 90th
percentile. ***p≤0.001. D, Bar graph illustrating acetyl-H3K9 levels as assessed by
Western blot analysis. A representative Western blot image is shown in the inset (upper
right). For the bar graph, control (vehicle-treated) values were set to 100% (see control
bar) and experimental values were calculated accordingly. Data represent
means ± SEM. *p≤0.05 (Student’s t-test).
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Figure 2.8. In rodent OLG cultures, LPA rescue of ATX-lysoPLD activity inhibition
requires the activity of class I HDAC members HDAC1 and HDAC2 but not the class II
HDAC member HDAC6. A, Experimental design. Timing of histone deacetylation is
marked as described by Marin-Husstege et al. (2002). OPC: OLG progenitor. B,C, Bar
graphs depicting mRNA levels for the OLG differentiation genes Ugt8 (B) and Cnp (C)
as determined by real-time reverse transcription (RT)-qPCR analysis. Control (vehicletreated) values were set to 100% (see horizontal line) and experimental values were
calculated accordingly. Data represent means ± SEM. nsnot significant, *p≤0.05,
**p≤0.01.
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Figure 2.9. Proposed model for the role of the ATX-LPA axis in OLG differentiation.
ATX, which has been found secreted by OLGs throughout the early stages of the
lineage, generates the lipid signaling molecule lysophosphatidic acid (LPA) via its
enzymatically active lysoPLD site. LPA, in turn, activates one (or more) of its cognate
receptors (LPARs) on the surface of OLG progenitors, which leads to the downstream
activation of histone deacetylase 1 and 2 (HDAC1/2) in the nucleus. Histone
deacetylation mediates the repression of transcriptional inhibitors of OLG differentiation
and thereby promotes gene expression changes associated with the differentiation from
an OLG progenitor (OPC) to an early differentiating OLG (Pro-OLG). Expression
markers identifying individual stages of the OLG lineage are listed below each OLG
stage. Markers in black were used in both the zebrafish and rodent studies, while
markers in light and dark grey are unique for the zebrafish and rodent studies,
respectively.
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Chapter 3
Introduction to Lysophosphatidic Acid (LPA) and their Receptors
Lysophosphatidic acid (LPA)
Lysophospholipids are phospholipid derivatives originating from cell membranes
and one of the best studied lysophospholipids is lysophosphatidic acid (LPA). First
known as a biosynthetic metabolite of cell membrane phospholipids, LPA is now
regarded as an important regulator for diverse biological functions. The molecular
species of LPA encompass diverse ligands that can vary in length and degree of
saturation of their fatty acid chain, which is esterified at the sn-1 or sn-2 position of the
glycerol backbone. The most abundant plasma species of LPA, in humans, is the 16:0
form, which contains a palmityl chain (Choi et al., 2010a). The term LPA, however,
commonly refers to the 18:1 species, which is also the most commonly used research
reagent for LPA signaling studies (Yung et al., 2014). The 18:0 and 18:1 species are the
most common species found in the spinal cord (Das and Hajra, 1989a; Santos-Nogueira
et al., 2015). Remaining LPA moieties reported in serum and plasma are 18:2, 16:1 and
20:4. All known LPA species are synthesized via two major metabolic routes (Fig. 3.1),
and exhibit different functional effects.
LPA species are generated by the conversion of membrane phospholipids to
lysophospholipids, such as LPC, by the action of phospholipase A1 (PLA1),
phospholipase A2 (PLA2), or PLA1 and lecithin-cholesterol acyltransferase (LCAT),
depending on the location of synthesis. ATX’s lysoPLD active site is needed to convert
the lysophospholipids into LPA species (Aoki et al., 2008a; Moolenaar and Perrakis,
2011). Lysophosphatidyl choline (LPC), the main substrate of ATX’s lysoPLD active
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site, is by far the most abundant lysophospholipid, in plasma and serum, and is mainly
found bound to albumin (Croset et al., 2000; Ojala et al., 2006; Tokumura et al., 1999).
The amount of LPC sufficient for ATX to mediate the conversion to LPA, and
subsequently activate LPA receptors, is limited to a few micromolars (Jongsma et al.,
2011; Umezu-Goto et al., 2002). Although ATX is the primary LPA producing
phospholipase in plasma, an alternative, but less common, route of LPA production
requires the hydrolysis of phosphatidic acid (PA) by the membrane- associated
phospholipase A1/A2 (PA-PLA1/2) (Aoki et al., 2002, 2008b; Inoue et al., 2011).
LPA receptors
The pluripotent, lipid signaling mediator, LPA, exerts its widespread functions
through the binding and activation of six distinct G protein-coupled receptors (GPCRs),
which are differentially expressed and show both overlapping and distinct signaling
properties (Chun, 2013; Chun et al., 2010). In 1996, the first LPA receptor, LPA1 was
identified in the ventricular zone of the embryonic brain (Hechtet al., 1996; Chun et al.,
2007). LPA1-6 can be divided into two families and are named in the order in which they
were discovered. The classical receptors, LPA1/Edg-2/vzg-1, LPA2/Edg-4 and
LPA3/Edg-7, belong to the endothelial differentiation gene (Edg) family, which also
includes five GPCRs for the lipid mediator sphingosine 1-phosphate (S1P) (An et al.,
1997; Bandoh et al., 1999; Chun, 2013; Hecht et al., 1996). Three additional LPA
receptors LPA4/ P2Y9/GPR23, LPA5/GPR92 and LPA6/P2Y5/GPR87 are more closely
related to the purinergic receptor (P2Y) family of GPCRs (Kotarsky et al., 2006; Lee et
al., 2009a, 2009b; Noguchi et al., 2003; Tabata et al., 2007; Yanagida et al., 2009b,
2013). These LPARs couple to all four Gα proteins (G12/13, Gq/11, Gi/o, and Gs) and have
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several converging signaling pathways.
Albeit with different potencies, all six LPA receptors can be stimulated by 1-acylLPA. LPA3 and LPA6 stand out as they prefer unsaturated 2-acyl-LPA as a ligand, while
LPA5 exhibits a strong preference for ether-linked 1-alkyl-LPA species (Jongsma et al.,
2011; Williams et al., 2009). Additionally, LPA receptors are expressed in most cell
types of the nervous system, including neural progenitors, primary neurons, astrocytes,
microglia, OLGs and Schwann cells (Noguchi et al., 2009). Due to the complexity of the
LPAR pathways, overall heterogeneity of subtypes and different expression patterns,
the effects of LPA are diverse and extensive, regulating many biological functions
including cell growth, differentiation, survival, motility, and cytoskeletal morphology
(Choi et al., 2010b; Sano et al., 2002).
LPA-mediated effects on cells of the CNS
The initial finding outlining that the brain has the highest tissue concentration of
LPA (Das and Hajra, 1989b), triggered investigative studies of LPA in the CNS. All six
known LPA receptors are expressed at varying levels in the CNS during development
and/or postnatal life (Choi et al., 2010a; Fukushima et al., 2001; Lin et al., 2012;
Noguchi et al., 2009; Pasternack et al., 2009). LPA has been shown to influence myriad
responses in neurons and glia cell types through its cognate receptors. These receptor–
mediated activities have been identified as important factors in disease states, including
fetal hypoxia and hydrocephalus (Herr et al., 2011; Yung et al., 2011), neuropathic pain
(Inoue et al., 2004; Lin et al., 2012; Nagai et al., 2010), ischemic stroke (Li et al., 2008),
neurotrama (Frugier et al., 2011), neuropsychiatric disorders (Mirendil et al., 2015),
developmental disorders, Sandhoff disease and MS (Choi and Chun, 2013).
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With regard to glia cells, astrocytes, microglia and OLGs all express LPA
receptors. Of particular interest to my studies, LPA1-6 receptors are all expressed on
OLGs, though at different levels. Through them LPA can initiate a variety of signaling
cascades in the cell. More specifically, LPA modulates calcium signaling and activates
the ERK1/2 pathway in OLGs , and can increase MBP expression in differentiating
OLGs (Nogaroli et al., 2009a). Additionally, LPA plays a role in the cytoskeletal
maturation of OLGs, as its expression leads to the inhibition of process formation in
OPCs and increased membrane formation of OLGs, revealing a time dependent role for
LPA (Dawson et al., 2003; Nogaroli et al., 2009a; Stankoff et al., 2002). Furthermore,
LPA has been shown to promote OLG cell survival, though these effects were only seen
in an OLG cell line (Li et al., 2003; Matsushita et al., 2005; Stankoff et al., 2002; Weiner
and Chun, 1999).
The LPAR expression profile in astrocytes is quite confusing as cultured
astrocytes have been shown to express Lpar1-5 (Shano et al., 2008; Sorensen et al.,
2008), however, in vivo, astrocytes appear to express few LPA receptor subtypes aside
from low levels of Lpar1 (Cervera et al., 2002; Tabuchi et al., 2000). The expression of
Lpar6 in astrocytes has also yet to be confirmed. Interestingly, LPA has been found to
stimulate astrocyte proliferation (Shano et al., 2008). Studies investigating LPARs in
microglia, the resident immune cells of the CNS, found Lpar1 and Lpar3 expression in
rodents (Möller et al., 2001; Tham et al., 2003), and Lpar1-3 expression in human
microglia cells lines (Bernhart et al., 2010; Möller et al., 2001).
LPAR expression can also be seen in neurons. Both Lpar1 and Lpar2 are
expressed, with Lpar2 more abundantly (Fukushima et al., 2002; Noguchi et al., 2009).
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Additionally, the expression of Lpar5 in sensory and motor neurons of the spinal cord
has been linked to pain, whereby Lpar5 null mice appear to have a reduced pain
phenotype (Lin et al., 2012). Interestingly, LPA promotes cortical neuronal progenitor
cells (NPCs) to commit to the neuronal lineage via LPA1 signaling (Fukushima et al.,
2007; Kingsbury et al., 2003). In regards to neuronal morphology, LPA can alter the
actin cytoskeleton and promote microtubule rearrangement (Fukushima and Morita,
2006; Fukushima et al., 2002), as well as influence the morphology and motility of
young postmitotic neurons (Fukushima et al., 2002). All in all, LPA, and its cognate
receptor signaling pathways, plays an integral role in CNS circuitry and development, as
well as disease pathology, and further investigative studies are needed to uncover the
multitude

of

effects

brought
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Figure 3.1. Biosynthesis of lysophosphatidic acid (LPA). The membrane
phospholipids phosphatidyl choline (PC), phosphatidyl ethanolamine (PE) or
phosphatidyl serine (PS) get converted into their corresponding lyso-forms by the action
of phospholipase A1 and A2 (PLA1/2). Autotaxin (ATX) then generates different LPA
species using the lyso-forms of membrane lipids. Alternatively, PC, PE or PS are
catalyzed into phosphatidic acid (PA) by phospholipase D (PLD). PLA1/2 then acts on
phosphatidic acid (PA) and form LPA. The structures of some common human LPAs
are shown.
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Chapter 4
The role of LPA6 in Oligodendrocyte Differentiation
(This chapter is in preparation as a manuscript to be submitted to Glia. Samantha
Spencer, Minh Nguyen and myself contributed to the work reported for this manuscript.
Samantha Spencer performed the CRISPR/Cas9 injections and Minh Nguyen
performed process network area and H3K9ac analysis)
Introduction
Previously, we have shown that the ATX-LPA signaling axis is necessary to
promote differentiation of OLGs. Since the product of ATX’s enzymatic lysoPLD active
site, the lipid signaling molecule LPA, is well known to exert its function via the
activation of one or more of its cognate signaling receptors, the LPA receptors, these
data suggest a crucial role of LPA receptor signaling in the regulation of OLG
differentiation and myelination. There are six known G protein-coupled, LPA receptors,
all of which are expressed on OLGs (LPA1-6). However, loss of function studies have so
far come up short in providing information regarding their in vivo role in myelination,
potentially due to the redundant functions among LPA receptors and/or compensation
upon the genetic deletion of a single receptor (Contos et al., 2000; Contos et al., 2002).
On the other hand, changes in the molecular mechanisms that govern OLG
development have not been extensively analyzed in these animals, with the exception
of Lpar1 KO mice. Transgenic mice carrying a mutated lpar1 gene (maLPA1-null mice)
exhibit decreased expression of myelin protein MBP, PLP/DM20 and CNPase (GarciaDiaz et al., 2015), however, these studies suggest LPA1 plays a role in the later stages
of OLG development, and not during early OLG differentiation. Our studies, therefore,
sought to further explore the role of LPARs in OLG differentiation.
In the studies presented here, we focused on an LPA receptor about which there
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is still little known, namely, LPA6. LPA6 is the most recently characterized member of the
LPA receptor family. First identified as an orphan GPCR (Kaplan et al., 1993), activation
of LPA6 by LPA has been shown to increase intracellular Ca2+ and ERK1/2
phosphorylation (via Gi/o) and to activate Rho GTPase (via G12/13) (Lee et al., 2009c;
Pasternack et al., 2008, 2009; Yanagida et al., 2009a). Little is known about the role of
LPA6 in cellular physiology, except that it is required for human hair growth (Pasternack
et al., 2008, 2009; Shimomura et al., 2008, 2009).
After initial investigative studies, we report that LPA6 plays a novel role in OLG
differentiation. LPA6 is found in differentiating OLGs, both in primary rat cultures as well
as in the developing zebrafish. LPA6 expression is needed for proper OLG
differentiation as siRNA mediated down-regulation or CRISPR(cas9) mediated mutation
of LPA6 reduces the expression of differentiation genes, Cnp and Ugt8, in primary OLGs
and a myelin specific gene, plp1b, in the developing zebrafish, respectively.
Additionally, down-regulation of Lpar6 does not appear to affect overall OLG process
network area. Therefore, the role of LPA6 appears to mediate the gene regulatory,
rather than the cytoskeletal maturation, portion of OLG development along the lineage.
Interestingly, down-regulation of Lpar6 did not alter specific epigenetic changes seen
affected by the ATX-LPA axis and, therefore, may act in an alternative-signaling
pathway.
Materials and Methods
Cell culture. Primary OLG progenitors were isolated from postnatal day 2 (P2) rat
brains by A2B5 immunopanning and cultured as previously described (Barres et al.,
1992; Lafrenaye and Fuss, 2010; Martinez-Lozada et al., 2014). Plated OLG
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progenitors were cultured in serum-free proliferation medium (Dulbecco’s modified
Eagle’s medium (DMEM) containing human PDGF and basic fibroblast growth factor
(bFGF) (Gemini Bio-Products, Sacramento, CA) for 24hrs, after which cells were treated
with siRNA reagents in antibiotic/FCS free DMEM containing PDGF/bFGF for 3hrs
followed by removal of reagents and incubation in antibiotic/FCS free DMEM containing
PDGF/bFGF for an additional 24hrs before allowed to differentiate in serum-free
medium (DMEM containing 40 ng/mL tri-iodo-thyronine (T3; Sigma, St. Louis, MO) and
N2 supplement (Life Technologies, Grand Island, NY); DMEM/T3/N2) over the time
periods indicated. Typically, at least three independent experiments were performed,
whereby an independent experiment refers to an experiment in which cells were
isolated from a separate P2 rat litter at an independent time point (day) and treated
separately from all other independent experiments.
CRISPR/Cas9 genome editing. CRISPR target sequences for lpar6a and lpar6b as
depicted in Fig. 4.2, were identified as described by Wheeler et al., 2015. sgRNAs were
generated using the cloning-free/short oligonucleotide approach described by Talbot
and Amacher (2014). Briefly, short-guide oligonucleotides containing a T7 promoter and
genomic target site were synthesized as described in Wheeler et al., 2015. 1 nanoliter
of a mixture of Cas9 mRNA (100 ng/µl) and sgRNA (120 ng/µl for lpar6a; 95 ng/µl for
lpar6b) was injected per one-cell stage zebrafish embryo. Zebrafish were analyzed at
48 hpf. Brightfield images of whole embryos were taken using an Olympus SZX12 zoom
stereo microscope (Olympus America Inc., Melville, NY) equipped with an Olympus
DP70 digital camera system.
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RNA isolation and real-time RT-qPCR Analysis. For the isolation of RNA from whole
zebrafish embryos or cultured rodent OLGs, samples were collected and analyzed as
described in Wheeler et al., 2015. Gene-specific primers were designed and in silico
tested for specificity using NCBI/Primer-BLAST (Ye et al., 2012). All primers were
designed to amplify all known splice variants.
atx/enpp2:

forward

(5’-CAATGTATGCAGCATTCAAACGAGTG-3’),

reverse

(5’CACCATTTTTCTCACTAGCGTAACG-3’)
plp1b:

forward

(5’TGCCATGCCAGGGGTTGTTTGTGGA-3),

reverse

(5’-GGCGACCATGTAAACGAACAGGGC-3)
cldnk:

forward

(5’-TGGCATTTCGGCTCAAGCTCTGGA-3’),

reverse:

(5’-

GGTACAGACTGGGCAATGGACCTGA-3)
lpar6a:

forward

(5’-GCGGAGAGGATTGTAACTGCC-3’),

reverse:

(5’-

reverse:

(5’-

TTCGGGCAGTGAGTGACGTT-3)
lpar6b:

forward

(5’-ACGGTGGGCTTCCTGATTCC-3’),

GACTGATGGTCTCGGGGTGG-3)
β-actin (actb2)(Buckley et al., 2010) was used as reference gene; eef1a1/1 has been
assessed as additional reference gene for the analysis of RNA derived from the
developing zebrafish and no pronounced differences were noted (Yuelling et al., 2010).
The following unmodified rat gene-specific primer pairs were used:
Cnp:

forward

(5’-ATGCCCAACAGGATGTGGTG-3’),

reverse

(5’-AGGGCTTGTCCAGGTCACTT-3’)
Ugt8:forward

(5’-AGGAGCTCTGGGGAGATTGC-3’),

(5’-TTTGAATGGCCAAGCAGGTCA-3’)
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reverse

Egr1:forward

(5’-CCTGACCACAGAGTCCTTTTCT-3’),

reverse

(5’-AAAGTGTTGCCACTGTTGGG-3’)
Lpar6: forward (5’-GTAAGCGCCAACGGCTCCA-3’),
reverse (5’-GTAAGCGCCAACGGCTCCCA -3’)
Pgk1 (as reference gene): forward (5’-ATGCAAAGACTGGCCAAGCTAC-3’), reverse
(5’-AGCCACAGCCTCAGCATATTTC-3’)
Pgk1 was used as reference gene due to its previously established expression stability
in rat OLGs (Nelissen et al., 2010). In addition, Ppia has been assessed as additional
reference gene for the analysis of RNA derived from differentiating OLG cultures and no
pronounced differences were noted.
RT-qPCR reactions with at least 2 technical replicates per sample were performed on a
CFX96 real-time PCR detection system (BioRad, Hercules, CA) using the iQ SYBR
Green Supermix (BioRad, Hercules, CA). PCR conditions were as follows: 95°C for 3
min followed by 40 cycles of 95°C for 15 s, 58°C for 30 s, and 95°C for 10 s. For all
primer pairs, melting curves were used to ensure specificity. Relative expression levels
were determined using the ΔΔCT method (Livak and Schmittgen, 2001).
HDAC activity assay. Rodent OLG progenitor cells were cultured and treated in
fibronectin coated 96-well plates (1x105 cells/well) and then assayed as described by
Wheeler et al., 2015.
siRNA-mediate Gene Silencing. OPCs were transfected with ON-TARGETplus
siRNA SMARTpools directed against rat Lpar6 (Thermo Fisher Scientific Inc., Pittsburg,
PA) using Lipofectamine 2000 (Life Technologies Corp., Grand Island, NY). As control,
an ON-TARGETplus non-targeting siRNA pool (Thermo Fisher Scientific Inc., Pittsburg,
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PA) was used. Transfection medium containing siRNA-Lipofectamine complexes was
replaced with serum-free medium (DMEM/PDGF/bFGF) after 3hrs, then the cells were
cultured for 24hrs before replacing with differentiation medium (DMEM/N2/T3) as well
as treatment (LPA, HA130 or vehicle) and was then cultured for an additional 24hrs.
Knockdown of gene expression was assessed by qRT-PCR analysis.
Immunocytochemistry. For immunocytochemistry using O4 hybridoma supernatants,
cells were fixed in 4% paraformaldehyde/PBS, nonspecific binding sites were blocked in
10% FCS/DMEM, and cells were incubated with the supernatant (1:1 diluted in 10%
FCS/DMEM) overnight. Cells were fixed and in cases of dual staining, permeabilized
using 0.5% Triton X-100/0.4 M sucrose/PBS and then incubated for 30 min in blocking
solution (10% FCS/DMEM). Subsequently, cells were incubated overnight with antiacetyl-histone H3 (Lys 9), anti- LPA6, anti-Caspase 3 (active (cleaved) form) or anti-Ki67
antibodies overnight. Primary antibodies were detected using Alexa 488- or Alexa 568conjugated secondary antibodies (Life Technologies, Grand Island, NY) and nuclei were
counterstained using Hoechst 33342 (EMD Millipore, Billerica,MA). For the generation
of representative images, confocal laser scanning microscopy was used (Zeiss LSM
700, Carl Zeiss Microscopy, LLC, Thornwood, NY). Images represent 2D maximum
projections of stacks of 0.5 µm optical sections.
Nuclear histone acetylation analysis. Cells double-labeled for O4 and acetyl-histone
H3 (Lys 9) were imaged using confocal laser scanning microscopy (LSM 700 Carl Zeiss
Microscopy, LLC, Thornwood, NY) as described by Wheeler et al., 2015.
Cell survival and proliferation analysis. Cells were subjected to immunostaining
using O4 hybridoma cell supernatants and antibodies specifically recognizing the active
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(cleaved) form of caspase-3 or the Ki67 antigen. To determine the number of caspase-3
or Ki67 immunopositive cells, images of four fields per coverslip were taken with a
20x/0.8 n.a. plan-apochromat objective lens using a confocal laser scanning microscope
(LSM 700 Carl Zeiss Microscopy, LLC, Thornwood, NY) as described by Wheeler et al.,
2015.
Isolation of OLG progenitors from zebrafish embryos using fluorescent activated cellsorting

(FACS).

OLG

enriched

populations

extracted

from

Tg(nkx2.2a:megfp;olig2:dsred2) zebrafish embryos were collected as previously
described by Wheeler et al., 2015.
Statistical Analysis. To determine significance, GraphPad Prism (GraphPad
Software, La Jolla, CA) or SigmaPlot (Systat Software, Inc., San Jose, CA) software
was used. Data composed of two groups were analyzed using the two-tailed Student’s
t-test or the Mann-Whitney U-test and presented in bar graphs depicting means ± SEM
or box and whisker plots depicting medians and quartiles. Data compared to a set
control value lacking variability were analyzed using the one-sample t-test (Dalgaard,
2008; Skokal and Rohlf, 1995) and presented in bar graphs.
Results
Down-regulation of Lpar6 leads to a reduction in OLG differentiation genes and
has no effect on OLG process network area
During the time of OLG differentiation, OLGs express LPA1-6. To evaluate the role of
LPA6 individually, primary OPCs, extracted from P2 rats, were transfected with siRNA
pools specifically silencing Lpar6 expression. Knockdown of gene expression was
confirmed by qRT-PCR, which revealed a reduction of roughly 50% (Fig. 4.1A).
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Importantly, down-regulation of Lpar6 was not associated with compensatory up or
down-regulation of any other receptors (LPA1-5) (Fig. 4.1A). In order to assess the role
of LPA6 on OLG differentiation, Cnp and Ugt8 gene expression levels were assessed.
Consequently, down-regulation of Lpar6 led to a reduction in both Cnp and Ugt8 mRNA
levels (Fig. 4.1B). Interestingly, however, the subsequent down-regulation in OLG
differentiation genes was not accompanied with an increase in the expression of an
inhibitor of differentiation, namely Egr1 (Fig. 4.1B). To assess the role of LPA6 in
morphological maturation of OLGs during differentiation, OLG process index was
evaluated upon knockdown of Lpar6. Reduction of Lpar6 did not significantly change
overall OLG process index when compared to control (Fig. 4.1C). Additionally, when
down-regulating Lpar6, LPA was unable to rescue OLG differentiation genes back to
control levels, although a slight increase in Ugt8 and Lpar6 expression was noted (Fig.
4.1D). These effects were not found to be associated with changes in cell survival or
proliferation as determined by immunostaining using antibodies specifically recognizing
the active (cleaved) form of caspase-3 or the Ki67 antigen (data not shown). These data
indicate that LPA6 is needed for proper OLG differentiation and can not be excluded
from the possible involvement in the ATX-LPA signaling axis.
In the developing zebrafish, LPA6 promotes myelin gene expression of plp1b
To further validate the role of LPA6 in OLG differentiation, we assessed its function in
the developing zebrafish, an emergent vertebrate model particularly suitable for in vivo
and developmental research (Best and Alderton, 2008; Fleming et al., 2010). In order to
examine the role of LPA6, it was necessary to verify the expression of both lpar6a and
lpar6b, two individual genes produced as a result of a genome duplication (Woods et
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al., 2000), both in whole zebrafish and OLGs extracted from zebrafish, at 48hpf. To
obtain an OLG enriched population from the developing zebrafish, we performed
Fluorescent Activated Cell Sorting (FACS) as introduced in Fig. 2.4., using
Tg(nkx2.2a:megfp;olig2:dsred2) fish. RNA extracted from FACS sorted OLG enriched
populations and whole zebrafish, at 48hpf, was used to verify gene expression of lpar6a
and lpar6b (Fig. 4.2A,B). To assess the role of lpar6a and lpar6b in OLG development,
we performed the Clustered Regularly Interspaced Short Palindromic Repeats
(CRISPR)/Cas9 genome editing technique. For these studies, we used the same
codon-optimized Cas9 with nuclear localization signals system as described in Fig. 2.1.
As shown in Fig. 4.2C-F, injection of guide RNAs against lpar6a and lpar6b genes and
in vitro transcribed, capped, polyadenylated nls-zCas9-nls RNA into one-cell stage
zebrafish embryos resulted in the generation of indel mutations over and upstream of
the CRISPR targeting sequence. These mutations resulted in reduced levels of lpar6a
and lpar6b mRNA (Fig. 4.2H), an effect that was not observed in uninjected zebrafish.
Most importantly, the CRISPR/Cas9-mediated reduction in lpar6a and lpar6b
expression was found associated with a decrease in the transcript levels for the later
stage OLG differentiation marker proteolipid protein (plp1b) (Fig. 4.2H). As shown in
Fig. 4.2G, injection of Cas9 mRNA with either of the guide RNAs was not found to be
associated with changes in the gross morphology of the embryos. The above-described
data, further support the role of LPA6 in OLG differentiation, and verify its involvement in
vivo.
LPA6 promoted progression along the lineage does not alter HDAC activity or
histone acetylation
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As previously described, early stages of the OLG lineage are seen to be regulated by
ATX’s lysoPLD activity, in association with, epigenetic modifications that result in
increased histone deacetylation (Marin-Husstege et al., 2002; Shen et al., 2005; He et al.,
2007; Shen et al., 2008; Liu and Casaccia, 2010; Takada and Appel, 2010; Swiss et al.,
2011). In order to assess if HDAC activity is affected by the down-regulation of Lpar6,
siRNA mediated knockdown of Lpar6 was performed on cells that were then subjected
to a fluorogenic HDAC activity assay. The reduction of Lpar6 did not significantly
change overall HDAC activity (Fig. 4.3A). It has been previously shown that HDAC
activity in differentiating OLGs is primarily directed to lysine residues of histone H3,
including the lysine residue on the tail of histone H3 at position 9 (H3K9) (Swiss et al.,
2011). To assess changes in acetylation at this site, cells treated, as depicted in
Fig. 4.1, were analyzed by immunocytochemistry, assessing O4+ OLGs with H3K9ac
nuclear staining, combined with confocal microscopy. Most importantly, siRNA mediated
down-regulation of Lpar6 did not significantly change the levels of H3K9ac (Fig. 4.3B).
These findings differ from the epigenetic changes seen regulated by the ATX-LPA
signaling axis and, thus, highlight LPA6 as a regulator of alternative signaling pathways
needed for OLG differentiation.
Discussion
Differentiation of OPCs into myelinating OLGs encompasses a complex sequence of
events including cell cycle exit, RNA processing, branching, synthesis of myelin proteins
and lipids and membranes wrapping around the axon (Raff, 2007; Simons and Trotter,
2007; Swiss et al., 2011). The mechanisms underlying many of these events are
attributed to extracellular factors and specific signaling pathways. ATX, specifically
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through its lysoPLD active site, is one extracellular factor that is needed for proper OLG
differentiation through its capacity to epigenetically modify the OLG genome. LPA, the
product of ATX’s lysoPLD active site, is an essential ligand needed to bind its receptors
on OLGs and activate such signaling cascades. The complexity of this regulation is
apparent as LPA can bind six different receptors, with converging signaling pathways.
Most importantly, little is known regarding the role of each receptor in OLG
development. Such information is needed to therapeutically target these receptors and
enhance OLG development pharmacologically. In an effort to understand the signaling
events governing gene expression changes during OLG differentiation, we examined
the role of LPA6. The data obtained from these studies reveal that LPA6 plays a novel
role in OLG gene regulation during differentiation. These studies are the first of their
kind and further enhance the importance of LPA signaling in OLG development.
We show for the first time that LPA6 is needed for OLG differentiation. Downregulation of Lpar6, and genetic mutation of lpar6a and lpar6b, leads to decreased
expression of OLG differentiation genes, Cnp and Ugt8, and myelin gene, plp1b,
respectively (Fig.4.1B; Fig4.2H). These results show a conserved role of LPA6, for which
OLG differentiation is dependent. Though reduction of Lpar6 decreased the expression
of OLG differentiation genes, it did not have an effect on the differentiation inhibitor,
Egr1 (Fig. 4.1B). The expression level of Egr1 is known to decrease as OLG
differentiation occurs and is followed by the up-regulation of genes involved in lipid
metabolism and myelination (Swiss et al., 2011). Importantly, Egr1 is a HDAC target
gene (Swiss et al., 2011), specifically seen regulated by HDAC1/2 (Wheeler et al.,
2015), and acetylation of lysine residues on the tail of histone H3 at position (H3K9ac) is
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a critical residue that has been linked to the transcription of Egr1 (Kubosaki et al., 2009;
Tur et al., 2010; Wang et al., 2010). These results are the first to indicate that gene
expression changes downstream of LPA6 differ from those seen described by Wheeler
et al., 2015. In this regard, the mechanisms associated with the activation of LPA6 may
be gene specific and work in conjunction with other signaling events to fine tune the
genome wide changes needed for proper OLG differentiation.
Interestingly, LPA added to cells with reduced Lpar6 expression were unable to
rescue differentiation genes back to control levels, however a slight increase was noted
in mRNA expression of Ugt8 and Lpar6 (Fig. 4.1D). These results show that LPA6 is
needed for proper OLG gene expression, although, another LPA receptor may also be
involved in gene regulation at this time. It is of note that the addition of LPA did not
affect gene expression levels of Cnp, thus, it is likely that the regulation of different OLG
differentiation genes is governed by different signaling mechanisms. Nevertheless,
these data suggest that OLG differentiation requires signaling via the activation of LPA6
and, as such, highlight a novel role for LPA6.
Moreover, the effects seen following siRNA mediated down-regulation of Lpar6,
were primarily changes in gene expression and were independent of morphological
aspects of OLG differentiation (Fig. 4.1C). Though LPA has been shown to increase
membrane formation in later stages of OLG development (Nogaroli et al., 2009b), it is
conceivable that these effects are a result of activation of a single, or a multitude of,
remaining LPARs. Further analysis on the signaling pathways, led by the activation of
different LPARs, will help delineate the specific roles they play in OLG development.
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Our previous studies showed that the ATX-LPA signaling axis activates HDAC1/2
activity to regulate gene expression changes needed for proper OLG differentiation
(Wheeler et al., 2015). In order to see if the signaling effects mediated downstream of
LPA6 were associated with the epigenetic changes previously described, HDAC activity
was assessed after reduction of Lpar6 expression. siRNA mediated Lpar6 downregulation did not alter overall HDAC activity (Fig. 4.3A). This finding outlines the notion
that LPA6 signaling does not involve HDAC regulation and differs from the ATX-LPAHDAC1/2 signaling events. HDAC activity in differentiating OLGs is primarily directed to
lysine residues of histones H4 and H3 including the lysine residue on the tail of histone
H3 at position 9 (H3K9) (Swiss et al., 2011). When assessing the acetylation of lysine 9
on Histone 3 (H3K9ac) in siRNA treated cells when compared to control, no change
was seen (Fig. 4.3B). H3K9ac is highly regulated by the activity of HDAC1/2, thus,
without direct targeting of this protein complex, changes in acetylation of siRNA treated
cells are likely to remain unchanged from control. These data validate the notion that
signaling via LPA6 does not activate HDAC1/2, and as such, effects the expression of
differentiation and myelin genes by a pathway different from the one described in
Chapter 2 (Wheeler et al., 2015).
Protein kinases have been identified as a bridge of communication between the
extracellular and intracellular environments (Flores et al., 2008; Fyffe-Maricich et al.,
2011; Guardiola-Diaz et al., 2012; Ishii et al., 2012; Narayanan et al., 2009; Tyler et al.,
2009). With regard to OLGs, mTOR was found to regulate OLG differentiation in vitro
(Tyler et al., 2009). Acting through its two effector complexes, mTOR complex 1
(mTORC1) and mTOR complex 2 (mTORC2), mTOR has been linked to the
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transcription and translation of genes (Laplante and Sabatini, 2013). Interestingly,
mTOR1 was found to play a major role in OLG differentiation, active myelination, and
proper myelin compaction on large caliber axons in the CNS (Bercury et al., 2014). As
signaling pathways involved in OLG differentiation begin to be understood, crosstalk
between such pathways will be further impacted. Interestingly, pharmacological
inhibition of the mTOR pathway has the ability to feedback and up-regulate the MAPK
(mitogen-activating protein kinase) pathway (Carracedo et al., 2008) linking the before
mentioned PI3K/Akt/mTOR pathway with that of the Ras/Raf/MEK/Erk pathway.
Importantly, and with regard to OLGs, both major signaling pathways, through
Akt/mTOR and MEK/Erk1/2, are necessary for full differentiation of OPCs to mature
OLGs in vitro (Dai et al., 2014). Moreover, LPA6 signaling is known to act through G
protein-coupled receptors G12/13 and Gi/o (Chun, 2013). Gi/o stands out as it initiates
protein kinase signaling events including the activation of the PI3K/Akt/mTOR pathway
and Ras/Raf/MEK/Erk pathways. Taken together, it is plausible that the gene
expression changes seen with down-regulation or genetic manipulation of LPA6 acts
through the crosstalk between such signaling pathways. Future studies are needed to
dissect these signaling events, however, these studies show that it is conceivable that
the changes in gene expression downstream of LPA6 signaling act, at least in part,
through protein kinase signaling.
Cumulatively, LPA6 stands out to be a novel LPA receptor governing gene
expression patterns during OLG development. The actions of LPA6 appear to be
conserved across species and display similar characteristics. Interestingly, Xenopus
embryos were found to express lpar6 and loss of function analysis showed disruption of
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neural development. Additionally, loss of function of Xenopus lpar6 showed similar
defects to that of loss of enpp2 (ATX) (Geach et al., 2014). Mutations found in the
human Lpar6 gene, however, do not show the same neural development phenotype
(Pasternack et al., 2008; Shimomura et al., 2008, 2009), and LPA6 KO mice remain
viable (mousephenotype.org). Nevertheless, LPA6 displays a unique role in OLG
differentiation and future studies will uncover the mechanistic effects of this novel
receptor.
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Figure 4.1. In rodent OLG cultures, siRNA mediated down-regulation of Lpar6
leads to a reduction in the levels of mRNAs encoding OLG differentiation genes,
but does not change the level of mRNA encoding the transcriptional OLG
differentiation inhibitor Egr1, or OLG process index. A, Bar graph depicting mRNA
levels for Lpar1-6 as determined by real-time reverse transcription (RT)-qPCR analysis.
Control (vehicle-treated) values were set to 100% (see horizontal line) and experimental
values were calculated accordingly B, Bar graph depicting mRNA levels for the OLG
differentiation genes Cnp and Ugt8 and the transcriptional inhibitor Egr1 as determined
by real-time RT-qPCR analysis. Control (vehicle-treated) values were set to 100% (see
horizontal line) and experimental values were calculated accordingly. C, Box and
whisker graph depicting process index levels for control and siRNA treated cells as
determined by immunostaining and morphology analysis. The plot depicts medians and
quartiles of three independent experiments. Whiskers represent the 10th and 90th
percentile. D, Bar graph depicting mRNA levels for the OLG differentiation genes Cnp,
Ugt8 and Lpar6 in siRNA treated cells +/- the addition of LPA, as determined by realtime RT-qPCR analysis (n=2). Control (vehicle-treated) values were set to 100% (see
horizontal line) and experimental values were calculated accordingly. Data shown in all
graphs represent means ± SEM. nsnot significant, *p≤0.05, **p≤0.0.
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Figure 4.2. In the developing zebrafish, CRISPR-Cas9-mediated mutagenesis of
lpar6a and lpar6b leads to a reduction in the mRNA levels for OLG marker gene,
plp1b. A,B, Representative images of agarose gels showing RNA expression of lpar6a
and lpar6b in whole fish (A) and FAC sorted OLGs (B). C,E, Representative images of
agarose gels showing DNA fragments upon Surveyor nuclease treatment of control
homoduplexes (c) and control/lpar6a (C) or control/lpar6b (E) homo/heteroduplexes.
Numbers on the left indicate DNA sizes in bp. Arrowheads indicate cleaved PCR
amplicon fragments at the expected sizes indicative of indel mutations generated by
genome editing. D,F, Representative images of sequencing traces obtained from
genomic DNA-derived PCR amplicons from control and Cas9 mRNA/sgRNA injected
zebrafish embryos. Arrows at the top of each trace indicate the location of the target
sequence, over and upstream of which a composite sequence trace indicates the
presence of indel mutations generated by genome editing. G, Representative brightfield
images of control (uninjected) and Cas9 mRNA/sgRNA injected embryos at 48 hpf. H,
Bar graphs illustrating mRNA levels for lpar6a, lpar6b and the OLG marker gene plp1b
in whole embryos as determined by real-time reverse transcription (RT)-qPCR analysis.
Control (uninjected embryos) values were set to 100% (see horizontal line) and
experimental values were calculated accordingly. Data shown represent means ± SEM.

102

103

Fig. 4.3. In rodent OLG cultures, down-regulation of Lpar6 does not effect HDAC
activity or nuclear histone acetylation at lysine residue 9 of Histone 3 (H3K9). A,
Bar graphs showing HDAC activity as determined by using the fluorogenic substrate
Boc-Lys(Ac)-AMC. Control (vehicle-treated) values were set to 100% and experimental
values were calculated accordingly. Data represent means ± SEM. nsnot significant. B,
Box and whisker plot depicting nuclear acetyl-H3K9 levels as assessed by determining
fluorescence intensities shown in arbitrary units (a.u.). The plot depicts medians and
quartiles of three independent experiments. Whiskers represent the 10th and 90th
percentile. nsnot significant
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Chapter 5
Introduction to HIV Neuropathology in the CNS
Introduction to HIV
HIV, a member of the lentivirus family, comes in two forms, HIV-1 and HIV-2.
HIV-2 is mainly found in Western Africa, with some cases arising in Europe and India
(de Silva et al., 2008), and rarely progresses to AIDS or HAND (HIV Associated
Neurological Disorders) (Rowland-Jones and Whittle, 2007). Thus, HIV infection
through HIV-1 predominates as the most common form found worldwide. If HIV infection
is left untreated, it can take roughly 10-12 years for AIDS to develop, a time period in
which HIV can cause serious harm to both the immune and nervous system. Over 33
million individuals are currently infected by HIV (Power et al., 2012) and the CDC
estimates 50,000 Americans will become infected with HIV each year.
The single-stranded RNA genome of HIV-1 encodes nine proteins comprising of
envelope (Env), cor (Gag), polymerase (Pol) and six accessory proteins including Tat
and Nef. HIV infection is initiated by the binding of the viral envelope protein, gp120 to
CD4 receptors located on the surface of host cell (Sattentau et al., 1986). This
interaction triggers a conformational change, which grants the entry of the virus genome
and proteins. Once the host cell is infected, HIV makes viral DNA using its RNA
genome template. Newly synthesized viral DNA can then integrate into the host genome
to form the provirus. Infected cells can either be latent, or actively transcribed to
produce the virus and viral proteins such as Tat.
cART (combination antiretroviral therapy), an HIV therapy created in 1996, has
advanced the longevity of patients suffering from the virus and has had some progress
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in aiding neurological pathogenesis, but falls short when treating HAND. Roughly 60%
of the HIV infected population suffers from HAND (Williams et al., 2009). Moreover,
AIDS remains the most common cause of dementia in non-aged individuals in the US.
Thus, it is critical that further examination of CNS neuropathology, such as HIVassociated dementia and moderate cognitive and motor diseases, should be addressed
so that proper therapies can be given.
CNS Neuropathology and HIV infected cells
As the survival rate and life expectancies for HIV+ patients have increased, so
has the incidence of HIV neuropathology. HIV can enter the CNS at early stages of
infection (Kramer-Hämmerle et al., 2005), through penetration of the Blood Brain Barrier
(BBB) (Bagasra et al., 1996), or by HIV-1 infected macrophages that infiltrate the CNS
and release the provirus (Merrill and Chen, 1991). Inflammation of the CNS induced by
HIV-1 infection further disrupts the integrity of the BBB, leading to supplementary HIV-1
entry and infection (Eugenin et al., 2011). The effect of HIV-1 on neuropathology has
gained increasing importance as it was reported that up to 70% of AIDS patients
develop neurological disorders (Jellinger et al., 2000; Maschke et al., 2000).
Additionally, children exposed to HIV infection were shown to display white matter
(WM), an area of the brain consisting mostly of glial cells and myelinated axons, atrophy
(Roy et al., 1992), and adult HIV+ patients demonstrated preferential damage to
cerebral WM and subcortical brain structures (Jernigan et al., 1993).
In occurrence with the abnormal appearance of WM and brain inflammation seen
in HIV infected patients, there is an increase in both microgliosis and astrogliosis (Esiri
et al., 1991). Infected microglia have been shown to secrete pro-inflammatory cytokines
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and chemokines in addition to HIV viral proteins, such as Tat, that exhibit toxicity to both
myelin and OLGs (Herbein et al., 2010; Sui et al., 2004; Tyor et al., 1992). Viral
proteins, such as Tat and gp120, can induce the production of toxic factors, including
ROS, (Chauhan et al., 2003; Hurley et al., 2003; King et al., 2006; Lipton, 1998; Nath
and Geiger, 1998) from infected glial cells in addition to further stimulating viral
replication and production.
OLGs, the myelin producing cells of the CNS, are very vulnerable to HIV
infection. Though lacking the expression of CD4, it has been reported that
galactosylceramide (previously introduced, UGT8, is the enzyme responsible for its
synthesis), expressed on the surface of OLGs can serve as an alternative receptor
mediating HIV infections (Albright et al., 1996; Harouse et al., 1991; Yahi et al., 1992). It
has not been concluded, however, that OLGs are in fact directly infected by HIV.
Nevertheless, it is apparent that OLGs can be injured by HIV infection as hyperplasia of
OLGs has been found in AIDS patients (Gyorkey et al., 1987) and, interestingly, HIV
induces activation of the death pathways, p53 and BAX in OLGs (Jayadev et al., 2007).
Accordingly, the effects of HIV on the CNS are quite significant with infection resulting in
progressive atrophy to WM areas alongside glial cell reactivity and infection, and toxic
factor release. A better understanding of the mechanisms that lead to injury in the CNS
will help predict future therapies that, when used in conjunction with cART, will prolong
survival, mental cognition and motor capabilities for patients.
HIV-1 Tat
Tat is an HIV viral protein that is essential for efficient viral transcription and
replication. It is synthesized at both early and late stages of viral replication and has a
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strong tendency to adhere to the surface of nearby cells. Tat is known to express a CCF
motif which can mimic the CC-chemokines that attract CCR2, CCR3, and CXCR4
expressing glial cells (Cardona et al., 2006). The mRNA of the Tat protein consists of
two coding exons, the first encoding amino acids 1-72, and the second encoding amino
acids 73-101. In most research laboratories working with Tat, such as the laboratories in
which we conducted Tat related studies, a recombinant truncated version of amino
acids 1-86 is used.
The cellular responses induced by Tat expression appear to be robust as it can
bind to many different receptors and cell surface markers. Tat can bind to chemokine
receptors, reportedly leading to increased intracellular calcium levels, as well initiate
iGluRs activation of the PLC, protein kinase C (PKC) and Gi/o pathway, leading to IP3dependent calcium release (Albini et al., 1998; Power et al., 1998; Song et al., 2003). In
machrophages, Tat-induced calcium signaling results in the production of proinflammatory cytokines and chemokines (Puri and Aggarwal, 1992), further promoting
inflammation. Microglia are also strongly affected by Tat as they appear to display a
decrease in cAMP levels needed to induce expression of neuroprotective substances as
well as an increase in their production of free radicals (Aloisi et al., 1999).
Other glial cells that fall victim to Tats influence are astrocytes. Tat activates
astrocyte production of pro-inflammatory cytokines and chemokines, further promoting
astroglial inflammatory responses (El-Hage et al., 2008; Zou et al., 2011). Additionally,
Tat has been reported to cause an increase in free radical and ROS production in OLGs
leading to process retraction and apoptosis (Fernández-Gamba et al., 2012;
Rathnasamy et al., 2011). Though there is limited research on the effects of Tat on OLG
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development and myelination, patients exhibiting symptoms associated with HAND
display both motor and cognitive impairments that can be linked to WM injury in the
CNS. It is imperative that we fully understand the dimensions in which HIV-1 and its
viral proteins, such as Tat, inflict on the CNS to cause such impairments. It is of upmost
importance to investigate the role of Tat on the development of the myelinating cells of
the CNS, OLGs, in an effort to repair its function and WM injuries seen in HIV infected
patients.
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Chapter 6
HIV-1 Tat Modulates ATX lysoPLD Activity and Oligodendrocyte Differentiation
(This chapter was submitted as a paper in ASN Neuro in April of 2016. Dr. Patrick Zou
and myself equally contributed to the work reported for this manuscript)
Introduction
Neurocognitive complications are frequently reported in HIV+ patients. Although
combined anti-retroviral therapy (cART) effectively blocks HIV replication in the central
nervous

system

(CNS)

and

profoundly

decreases

the

incidence

of

severe

neurocognitive impairments, such as HIV-associated dementia, ~50% of the HIVinfected population still develop various forms of milder neurocognitive deficits,
collectively called HIV-associated neurocognitive disorders (HAND) (Ellis et al., 2007;
McArthur et al., 2010). White matter injuries in HIV-infected patients are commonly
observed, and have been shown to correlate to HAND pathogenesis (Filippi et al., 2001;
Archibald et al., 2004; Pfefferbaum et al., 2007). Although cART can reduce the viral
load in the cerebrospinal fluid (CSF) to below detectable levels, its effect is limited with
regard to white matter damage and HAND (Yilmaz et al., 2006). This implies that toxic
factors released by previously infected CNS cells may inflict more damage than the
virus itself.
One candidate factor for HIV-induced white matter injury is the HIV-1 viral protein
transactivator of transcription (Tat), which was originally discovered as a key component
for efficient transcription of the HIV genome. Tat has been shown to be continuously
expressed and secreted by infected CNS cells, and can be detected in the CSF (Wang
et al., 2014) of HIV patients, even with cART (Johnson et al., 2013). Previously, we
have reported that Tat significantly decreases immature OLG viability (Zou et al., 2015).
110

Importantly, Tat exposure also reduced the extensive networks formed by fine,
branching processes that are typical for OLGs at this stage, suggesting Tat may also
inhibit immature OLG differentiation.
OLG development has been extensively studied and well characterized both in
vivo and in vitro. Newly formed oligodendrocyte progenitor cells (OPCs) migrate to their
targeted destination to differentiate into pre-myelinating OLGs that will ultimately evolve
into mature OLGs and myelinate axons. It is also well established that OLG
differentiation is controlled by the fine-tuning of both intrinsic factors, such as
transcriptional control and epigenetic regulation, and extracellular signals, including
growth factors and mitogens (Zuchero and Barres, 2013; Mitew et al., 2014). One
extracellular protein that has been shown to play a significant role in OLG development
is

Autotaxin

(ATX),

also

known

as

ENPP2,

phosphodiesterase-1α/ATX,

or

lysophospholipase D (lysoPLD), which is predominantly expressed and secreted by
OLG lineage cells (Zhang et al., 2014), and has been shown to play an important role in
OLG development. Previous studies in our lab have shown that ATX, via two functional
domains, promotes OLG differentiation along the lineage. The first domain, the
modulator of OLG remodeling and focal adhesion organization (MORFO) domain, was
found to promote the morphological maturation of OLGs (Dennis et al., 2005). The
second domain is an enzymatic lysoPLD-active site that generates the lipid signaling
molecule lysophosphatidic acid (LPA) (Tokumura et al., 2002; Umezu-Goto et al., 2002;
Nakanaga et al., 2010); it has been shown to promote OLG differentiation and
myelination by epigenetically regulating the expression of OLG differentiation genes
(Wheeler et al., 2015).
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Since both Tat and ATX affect immature OLGs, we hypothesized that Tat inhibits
OLG differentiation by interfering with the ATX-LPA signaling pathway. Our studies
shown here demonstrated that 18 hr Tat treatment led to a reduction in the process
network and OLG differentiation genes, Ugt8 and Cnp, expression. Although LPA by
itself did not affect OLG morphology, it protected OLGs from Tat-induced process
retraction, and rescued gene expression down-regulated by Tat. Tat treatment also
decreased ATX lysoPLD activity in vitro. Co-immunoprecipitation, using biotinconjugated Tat and V5-tagged ATX, revealed a potential physical interaction between
Tat and ATX, which may account for the reduced ATX lysoPLD activity in the presence
of Tat. Together, these results strongly suggest that, in addition to its effects on OLG
processes, Tat may physically bind to ATX, inhibiting ATX lysoPLD activity, and downregulate LPA signaling. Thus, Tat-ATX interactions have the potential to interfere with
OLG differentiation and also to block the protective effects of LPA on OLG process
morphology. Disrupting interactions between ATX and Tat may be a potential
therapeutic strategy for protecting HIV patients from white matter injury.
Materials and Methods
All animal procedures were performed strictly in compliance with protocols reviewed
and approved by the Virginia Commonwealth University Institutional Animal Care and
Use Committee (IACUC).
Pharmacological compounds. Lysophosphatidic acid (LPA; 18:1; Sigma, St. Louis,
MO) was dissolved in DMEM containing 0.1% fatty acid-free bovine serum albumin.
Recombinant Tat1-86 and biotin-conjugated Tat (ImmunoDx, LLC Woburn, MA) were
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dissolved in distilled water. In the experiments involving pharmacological compounds,
vehicle control refers to the solvent that is used to dissolve the compounds.
ATX-lysoPLD activity assay. ATX-lysoPLD activity was determined using the
fluorogenic assay previously described (Ferguson et al., 2006; Wheeler et al., 2015).
Concentrated (40x) conditioned medium, obtained via centrifugal filters (EMD Millipore,
Billerica, MA), from primary OLG cultures treated with vehicle control or Tat for 18hrs
and grown in phenol-red-free DMEM were incubated with 2.5 μM FS-3 substrate
(Echelon Biosciences Inc., Salt Lake City, UT) for 4 hr at 37°C. Alternatively,
concentrated (40x) conditioned medium from untreated primary OLG cultures grown in
phenol-red-free DMEM were incubated with vehicle control or Tat (100nM) and 2.5 μM
FS-3 substrate (Echelon Biosciences Inc., Salt Lake City, UT) for 4 hr at 37°C. Increase
in fluorescence with time was measured at an excitation wavelength of 485 nm and an
emission wavelength of 520 nm using a PHERAstar multimode microplate reader (BMG
LABTECH Inc. Cary, NC.).
RNA isolation and real-time RT-qPCR analysis. Isolation of RNA from control and
treated OLGs were performed as previously published (Wheeler et al., 2015).
The following unmodified mouse gene-specific primer pairs were used:
Cnp:
forward (5’-ATGCCCAACAGGATGTGGTG-3’),
reverse (5’-AGGGCTTGTCCAGGTCACTT-3’)
Ugt8:
forward (5’-AGGAGCTCTGGGGAGATTGC-3’),
reverse (5’-TTTGAATGGCCAAGCAGGTCA-3’)
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Atx:
forward (5’- GACCCTAAAACCATTATTGCTAA-3’),
reverse (5’-GGGAAGGTGCTGTTTCATGT -3’)
Lpar1:
forward (5’- GCCACCTGGCTGCTGCAGA -3’),
reverse (5’-GTGTCGATGAGGCCCTGCCG -3’)
Lpar2:
forward (5’- CTGTTCAGCCGCTCCTACCTGG -3’),
reverse (5’-GGCAGCTGACGTGCTCTCTGCCATAG -3’)
Lpar3:
forward (5’- ACGAGCTTCGTCCCCGTCCA -3’),
reverse (5’-ACGAGCTTCGTCCCCGTCCA -3’)
Lpar4:
forward (5’-GCCTTGGTACGTTCCCAAGCCATT-3’),
reverse (5’-AGTTGCAAGGCACAAGGTAATCGGG -3’)
Lpar5:
forward (5’-GGGACTAGAGGGGAGCTCACCGAA-3’),
reverse (5’- TAGCCTCTGGCTGGTGGCATCCTAG-3’)
Lpar6:
forward (5’-GTAAGCGCCAACGGCTCCA-3’),
reverse (5’-GTAAGCGCCAACGGCTCCCA -3’)
Pgk1: (as reference gene):
forward (5’- ATGCAAAGACTGGCCAAGCTAC-3’),
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reverse (5’-AGCCACAGCCTCAGCATATTC -3’)
RT-qPCR reactions with at least 2 technical replicates per sample were performed on a
CFX96 real-time PCR detection system (BioRad, Hercules, CA) using the iQ SYBR
Green Supermix (BioRad, Hercules, CA). PCR conditions were as follows: 95°C for 3
min followed by 40 cycles of 95°C for 15 s, 58°C for 30 s, and 95°C for 10 s. For all
primer pairs, melting curves were used to ensure specificity. Relative expression levels
were determined using the ΔΔCT method (Livak and Schmittgen, 2001).
Western Blot. Concentration of proteins extracted from cultured OLGs or brain
tissues were determined using a BCA protein assay kit (ThermoFisher Scientific,
Waltham, MA). Equal amounts of protein samples were loaded on a Criterion precast 420% gradient SDS gel (Bio-Rad, Hercules, CA), electrophoretically separated, and
probed with antibodies specific to 2',3'-cyclic-nucleotide 3'-phosphodiesterase (CNPase)
(Abcam, Cambridge, MA). Bound primary antibodies were detected with appropriate
IRDye secondary antibodies (1:3000, Li-COR, Lincoln, NE), and imaged using an
Odyssey Imager (Li-COR). Protein bands were quantified using Li-COR image studio
software.
Cell culture. Immature murine OLGs were cultured as previously described (Zou et
al., 2015). In brief, primary mixed glial cells isolated from brains of postnatal day 0 - 2
mouse pups irrespective of sex (CD-1, Charles River Laboratory, Wilmington, MA) were
plated in Dulbecco’s Modified Eagle’s Medium (DMEM) (Life Technologies, Carlsbad,
CA) supplied with fetal bovine serum (10%, Thermo Scientific Hyclone, Logan, UT),
glucose (6 g/L, Sigma, St. Louis, MO), Sodium Bicarbonate (0.13%, Life Technologies),
Penicillin/Streptomycin (1x, Life Technologies). Culture medium was refreshed every
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other day. At day 8, O2A/glial progenitor cells were collected from the mixed cultures
and re-plated on poly-L-lysine coated 12-well plates or cover slips, at a density of
250,000 cells/well or 15,000 cells/cover slip, and incubated in DMEM supplied with
CNTF (10 ng/ml, Peprotech, Rocky Hill, NJ), NAC (5 μg/ml, Sigma) and triiodothyronine
(15 nM, Sigma) for 2 days before further experiments.
Repeated measure paradigm. Repeated measurements of the morphology of
individual OLGs were performed as previously published (Zou et al., 2011). In brief,
OLGs were cultured in 12-well plates for 2 days before treatment with vehicle or 100 nM
Tat. Culture plates were then transferred to the environmental chamber (37°C, 5% CO2)
of a Zeiss Axio Observer Z1 system (Carl Zeiss Microscopy, LLC, Thornwood, NY).
Individual OLGs were randomly selected, and imaged hourly for 18 hrs. Images were
analyzed using the Zeiss Axiovision 4.8 software.
Immunostaining. O4 immunostaining was performed on live, unfixed cells. All other
immunostaining was performed after cells were fixed with 4% paraformaldehyde.
O4 monoclonal antibodies [1:20, grown from hybridoma cells in our lab (Knapp and
Hauser, 1996)] was applied at room temperature for 15 min. Goat anti-mouse IgM-Cy3
(1:1000, Millipore, Billerica, MA) was used to probe bound O4 antibodies. All LPA
receptor antibodies [Anti- LPAR1 (Abcam), LPAR2 and LPAR3 (Santa Cruz, Dallas,
TX), LPAR4 (Alomone labs, Hadassah Ein Kerem, Israel), and LPAR6 (Acris, San
Diego, CA)] were applied at 1:1000 at room temperature for 1 hr, and corresponding
secondary antibodies were conjugated to Alexa 488 (1:2000, Life Technologies) were
used as secondary antibodies. The cell nucleus was stained with the Hoechst 33342
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dye (1:2000, Life Technologies). Images were taken on a confocal microscope (Zeiss
LSM 700, Carl Zeiss, Thornwood, NY) and processed using Zeiss Zen 2010 software.
Co-immunoprecipitation. Dynabeads Protein G (1.5 mg/50 μl, Life Technologies)
was first mixed with primary antibodies (5 μg): non-specific mouse IgG, mouse anti-V5,
and rabbit anti-biotin, respectively (all from Abcam), and washed three times with PBS
at room temperature. Concentrated supernatant from a COS-7 cell line (500 μl) was
mixed with 5 μg biotin-conjugated Tat, and added to the Dynabeads-bound primary
antibodies and gently rocked overnight at 4°C. The next day, Dynabeads (with bound
proteins) were washed three times at room temperature with PBS before being
collection and then resuspended in loading buffer (2x Laemmli buffer, Bio-Rad), heat
denatured (95°C, 5 min) and loaded (40 µl/sample) to a 4 – 20% SDS-PAGE precast
gel (Bio-Rad) for Western blotting.
Results
Tat-induced decrease in immature OLG process networks, is reversed by LPA
An earlier study reported that immature OLGs exposed to HIV-1 Tat show
significantly decreased viability in vitro (Zou et al., 2015). In addition, surviving cells
exhibit abnormal morphology, indicating that the differentiation of these cells is
disrupted. To investigate the effect of Tat on the morphology of differentiating OLGs in
more detail, immature OLGs at 2 days in vitro were treated with vehicle or Tat for 18 hrs
before morphological analysis was performed. Compared to vehicle-treated OLGs, Tat
treatment led to a loss of fine, branched processes in as little as early as 4 hrs and this
continued throughout the 18 hr experimental period (Fig. 6.1). Statistical analysis from 4
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independent experiments (≥ 30 cells/treatment group) showed a significant decrease in
process network in Tat treated OLGs (Fig. 6.2).
Since LPA signaling has been shown to promote expression of genes involved in
OLG differentiation (Wheeler et al., 2015), we examined whether LPA could reverse Tat
induced reduction of the OLG process network. As shown in Fig. 6.2, the addition of 1
or 10 μM LPA does not affect the process network of OLGs. However, when added
concurrently with Tat, LPA completely blocked Tat-induced process retraction, thus
revealing a protective role of LPA against Tat-mediated effects on OLG process
network.
The effect of Tat to down-regulate Cnp and Ugt8 expression is reversed by LPA
The lysoPLD activity of ATX has been reported to regulate OLG gene expression
(Wheeler et al., 2015). Thus, we investigated whether gene expression in immature
OLGs was also affected. As seen in Fig. 6.3A, 18 hr Tat-treatment significantly
decreased the expression of the OLG differentiation genes Cnp and Ugt8. Interestingly,
Tat treatment did not alter Atx gene expression. Since the main function of ATX
lysoPLD activity is to produce the lipid signaling molecule LPA, we next examined
whether LPA could rescue the expression of genes down-regulated by Tat. The addition
of LPA completely rescued the expression of Cnp and Ugt8, but did not have any
significant effect on Atx expression (Fig. 6.3B). In addition, protein expression data from
Western blot analysis verified that Tat treatment decreased CNP expression, which was
reversed by the addition of LPA (Fig. 6.3C).
Expression of LPA receptors is not affected by Tat treatment
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Since the effects of Tat on immature OLG morphology and differentiation gene
expression can be rescued by LPA, we hypothesized that Tat interferes with the LPA
signaling pathway. To assess the LPA receptors (LPARs) expression profile in our
system, we performed immunostaining with antibodies specific to different LPARs in our
2 days in vitro immature OLGs. Results revealed the presence of LPA1-4 and LPA6 on
O4+ OLGs (Fig. 6.4A). To assess whether Tat alters LPAR expression, qRT-PCR was
performed on 18 hr Tat- or vehicle- treated OLGs. Our results showed that Tat
treatment had no effect on LPA1-6 gene expression on immature OLGs (Fig. 6.4B).
Tat decreases ATX lysoPLD activity
Since Tat did not affect the expression of LPARs in immature OLGs, we next
examined whether Tat disrupts LPA production. Extracellular LPA is predominantly
produced by the lysoPLD activity of ATX, which converts lysophosphatidylcholine (LPC)
to LPA by removing its choline group (Aoki et al., 2008). Thus, we assessed whether
Tat treatment alters ATX lysoPLD enzymatic activity in OLGs. Immature OLGs were
treated with vehicle or Tat for 18 hr before supernatant was collected for the ATX
lysoPLD activity assay. OLGs treated with Tat showed significantly lower ATX lysoPLD
activity in the supernatant during the 4 hr assay (Fig. 6.5A). The reduction of lysoPLD
activity was seen as a steady inhibition that led to a ~10% overall decrease across all
assay time points (Fig. 6.5B).
Physical interaction between Tat and ATX decreases ATX lysoPLD activity
Since Tat treatment did not alter Atx expression in OLGs, we next assessed
whether the reduced Atx lysoPLD activity was mediated by an interaction between Tat
and ATX. Vehicle or Tat was added to the supernatant collected from untreated primary
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OLG cultures immediately before ATX lysoPLD activity was assessed. In this
experimental paradigm, which bypassed any potential effect on cells, Tat directly and
significantly decreased ATX lysoPLD activity (Fig. 6.6A). We next hypothesized that
decreased ATX lysoPLD activity might be the result of a physical interaction between
Tat and ATX. To test this hypothesis, we performed co-immunoprecipitation using
biotin-conjugated Tat and V5-tagged ATX collected and concentrated from the
supernatant of a stably transfected COS-7 cell line (Dennis et al., 2012). As seen in Fig.
6B, V5-tagged ATX was detected in anti-biotin precipitates and vice versa, suggesting a
physical interaction between ATX and Tat. As a control for non-specific binding, neither
V5-tagged ATX nor biotin-conjugated Tat was detected in precipitates collected using a
mouse IgG1 monoclonal isotype control (Fig 6.6B, bottom panel). It has been previously
reported that cell-associated ATX, compared to secreted ATX, migrates slower during
SDS-PAGE due to differences in glycosylation (Jansen et al., 2005). Since we used
high density cultures of adherent cells to obtain cell culture supernatants of high ATX
concentration, the higher molecular weight ATX band (MW ~ 125 kDa) seen in Fig. 6.6B
likely represents cell-associated ATX derived from floating and/or damaged cells.
Discussion
White matter injury is frequently reported in HIV+ patients at all stages
(Gongvatana et al., 2009; Zhu et al., 2013; Ragin et al., 2015). The mammalian adult
CNS has been known to maintain a population of OLG precursor cells, which migrate to
the lesion site upon injury and differentiate into myelinating OLGs to replace the injured
OLGs and regenerate lost, damaged myelin (Polito and Reynolds, 2005; Kang et al.,
2010; Zuchero and Barres, 2013). Hence, it is interesting that white matter injury
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persists when HIV RNA is undetectable in the cerebrospinal fluid (Yilmaz et al., 2006;
Ragin et al., 2015). Our studies here showed that HIV-1 Tat, which is continuously
secreted by infected CNS cells, even in the absence of viral replication, inhibits the
lysoPLD activity of ATX, possibly via a potential physical interaction. The interaction
between Tat and ATX not only attenuates OLG differentiation, but also disrupts the
protective effects of LPA on OLG process morphology. Thus, targeting the interaction
between Tat and ATX may be a therapeutic strategy to promote recovery of white
matter injury in HIV patients.
OLG lineage cells are targets of HIV-1 Tat. Proliferation and migration of OLG
precursor cells, viability of immature OLGs, morphology, and myelin-like membrane
production of mature OLGs have all been reported to be disrupted by Tat both in vivo
and in vitro (Hahn et al., 2012; Zou et al., 2015). Our initial experiments found that
immature OLGs that survived 18 hr Tat treatment exhibit a decrease in process network
(Fig. 6.1). Although LPA by itself does not promote process outgrowth, it protects OLG
process network from Tat-induced damage (Fig. 6.2). Previously, we have reported that
early OLG differentiation is regulated by epigenetic mechanisms downstream of the
LPA signaling pathway (Wheeler et al., 2015). Consistently, gene expression studies
and Western blot analysis showed that OLG differentiation genes, Utg8 and Cnp, were
down regulated by Tat (Fig. 6.3). This Tat-induced down regulation of OLG
differentiation genes were also rescued with the addition of LPA (Fig. 6.3), strongly
supporting our hypothesis that Tat affects OLG differentiation by interrupting the LPA
signaling pathway. Additionally, Atx gene expression in OLGs treated with Tat and/or
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LPA was not significantly different from control (Fig. 6.3), suggesting the LPA rescue of
Cnp and Ugt8 gene expression was not attributed to an increase in Atx expression.
There are six bona fide LPARs, all of which are found on OLGs, with LPAR1
being the most abundantly expressed (Zhang et al., 2014). Our experiments showed
that 18 hr Tat exposure did not affect the expression of any LPAR gene in OLGs. Thus,
the finding that LPA rescues both Tat-induced down regulation of OLG differentiation
genes Ugt8 and Cnp (Fig. 5), and the decrease of OLG process networks (Fig. 6.2),
strongly indicates that Tat might alter LPA production rather than LPAR expression.
In the CNS, LPA is predominantly produced by the lysoPLD activity of ATX.
Although Tat did not affect Atx gene expression, supernatant collected from Tat-treated
OLGs showed significantly decreased ATX lysoPLD activity. Since physical interactions
between proteins may lead to an altered conformation and function, we hypothesized
that Tat interacts with ATX, thus inhibiting its lysoPLD activity and production of LPA.
Our experiments showed that ATX lysoPLD activity was significantly decreased when
Tat was added directly to the supernatant collected from untreated OLGs. Further, when
biotin-conjugated Tat was added to the supernatant collected from a COS-7 cell line,
that stably expresses V5-tagged ATX, the two proteins were precipitated together.
These results strongly implicate that Tat, by binding to ATX, inhibits ATX lysoPLD
activity and LPA production. The crystal structures of Tat and ATX reveal that both
proteins

contain

cysteine-rich

domains,

indicating

the

possibility

of

forming

intermolecular disulfide bonds (Tahirov et al., 2010; Nishimasu et al., 2011; Gu et al.,
2014).

It

is

worth

mentioning

that

the

V5-tagged

ATX

used

in

the

co-

immunoprecipitation was collected from the supernatant of a stably transfected cell line.
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Thus, the concentration of ATX cannot be effectively determined, and may exceed the
physiological concentration of ATX in vivo. Additionally, both Tat and ATX have been
reported to physically interact with integrin receptors (Hausmann et al., 2011; Urbinati et
al., 2012), introducing the possibility that the binding between Tat and ATX may require
participation of other components. Further studies are required to better characterize
the affinity and stoichiometry of the ATX-Tat interaction, as well as whether this
interaction requires additional adaptor proteins. Alternatively, it is reported that Tat1-72
and Tat1-86 can efficiently enter certain cells via endocytosis (Mann and Frankel, 1991).
It is also thus conceivable that Tat enters the cell and interferes with the secretion of
ATX, leading to decreased ATX lysoPLD activity in Tat-treated OLGs. In brief, the study
reported here can be summated by our proposed working model (Fig. 6.7). The viral
protein Tat, via its proposed interaction with ATX’s lysoPLD active site, reduces the
expression of OLG differentiation genes and interrupts the protective role of LPA on
OLG morphology.
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Figure 6.1: HIV-1 Tat decreases immature OLG process networks. Sample phase
contrast images of immature OLGs treated with vehicle- or 100 nM Tat at 0, 2, 4, 6, 12
and 18 hr. While normal growth was observed in vehicle-treated OLGs, Tat treatments
leads to decreased process network, especially after 4 hr.
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Figure 6.2: LPA protects OLGs from Tat-induced process retraction. (A)
Representative images of Vehicle-, Tat-, LPA- and Tat + LPA- treated OLGs shown by
O4+ immunostaining (Scale bar = 10 μm). (B) OLGs treated with 100 nM Tat showed
significantly decreased process network at 18 hr. LPA at 1 or 10 μM rescued the
decreased OLG process network induced by 100 nM Tat. LPA by itself at both
concentrations has no effect on OLG process network. (*** p<0.001 vs. 100 nM Tat;
One-Way ANOVA followed by post-hoc Bonferroni’s test, N=4 individual experiments, ≥
30 cells were counted for each N).
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Figure 6.3: OLG differentiation genes are down-regulated with Tat treatment. (AB) Quantitative RT-PCR gene expression analysis of vehicle, Tat and LPA treated
immature OLGs. (A) Immature OLGs treated with Tat for 18 hr showed decreased
expression of Ugt8 and Cnp. Tat treatment has no effect on expression of Atx. (B) Tatinduced decrease of Ugt8 and Cnp expression can be rescued by adding LPA to
culturing medium. Current addition of Tat and LPA also has no effect on Atx expression.
(C) Western blot showed that 18 hr Tat treatment decreases protein expression of Cnp
in immature OLGs, which can also be reversed by LPA (*: p<0.05 vs. Control. For Fig.
3A & 3B: student’s t-test, N=5; For Fig 3C. One-Way ANOVA followed by post hoc
Bonferroni’s test, N=4 individual experiments).
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Figure 6.4: Expression of LPA receptors are not affected by Tat treatment. (A)
Immunostaining showing LPA1-4 and LPA6 are found on O4+ immature OLGs at 2 div
(days in vitro) (Scale bar = 10 µm). (B) qRT-PCR gene expression data showing LPA1-6
expression in OLGs is not altered by Tat treatment. The mean value for vehicle-treated
OLGs was set to 100% (horizontal line) and values for Tat-treated cells were calculated
accordingly. (student’s t-test; N=4 individual experiments).
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Figure 6.5: Tat decreases ATX lysoPLD activity. ATX lysoPLD activity assay was
performed using supernatant collected from 18 hr Tat- or vehicle-treated primary
immature OLGs. (A) Tat-treatment significantly decreases overall lysoPLD activity. (B)
The mean value of the lysoPLD activity of supernatant from vehicle-treated OLGs was
set to 100% (horizontal line). Treat cells with Tat leads to ~10-15% drop of lysoPLD
activity at all time points examined [*: p<0.05 vs. control; Two-way ANOVA (Tat, Time)
followed by post-hoc bonferroni’s test, N=5 individual experiments].
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Figure 6.6: Physical interaction of TAT and ATX alters ATX activity. (A) Adding Tat
to the supernatant collected from untreated primary OLG cultures significantly
decreased the ATX lysoPLD activity when compared with control [* p<0.05, vs. Control;
Two-way ANOVA (Tat, Time) followed by post hoc Bonferroni’s test, N=4 individual
experiments]. (B) Concentrated supernatant collected from a stably transfected Cos7
cell line that secrets V5-tagged ATX was mixed with biotin-conjugated Tat, and
immunoprecipitated (IP) with antibodies specific to V5 (left panels) or biotin (right
panels) and processed for Western blot (WB) for biotin (bottom panels) or V5 (top
panels), respectively. Mouse IgG has no known specificity was used as negative
control. While nothing was detected from msIgG precipitates, V5-tagged ATX was
detected in anti-Biotin precipitates, and vice versa.
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Figure 6.7: Proposed model for effects of Tat on immature OLG differentiation. Tat
interacts with ATX, decreasing its lysoPLD activity and subsequent LPA production.
Changes in LPA prevent the protective ability of LPA towards Tat-induced retraction of
OLG process network area and the differentiation promoting ability to regulated OLG
genes, Ugt8 and Cnp.
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Chapter 7
Final Conclusions
In the CNS, OLGs repeatedly wrap their membranes around axons to form a highly
compacted multilayered myelin sheath to ensure proper signaling in the CNS. The
importance of the myelin sheath becomes apparent in diseases where it is injured or its
function is impaired such as in MS and WM associated injuries found in HIV+ patients.
In such cases, a better understanding of OLG differentiation is necessary to further
recognize how to stimulate repair under pathological conditions. Focal areas of
demyelination characterize MS in the CNS and cells with the potential to myelinate have
been found present within MS lesions, however, remyelination remains inefficient, likely
due to a block in OLG differentiation within the context of the lesioned CNS environment
(Chang et al., 2002b; Kuhlmann et al., 2008c; Wolswijk, 2002). Additionally, there is WM
atrophy and OLG impairment in the brains of HIV+ infected individuals (Sarma et al.,
2014; Sclafani et al., 1997). In general, OLG differentiation requires changes in gene
expression. Current knowledge underlying these molecular mechanisms is limited and
represents a major hurdle in identifying therapeutic targets suitable for stimulating OLG
differentiation and myelination under conditions as they are found in MS and HIV+
infection. Thus, the focus of the experiments outlined in this dissertation was to
characterize a novel molecular mechanism governing changes in gene expression as
they occur during OLG differentiation, i.e. mechanisms mediated by the extracellular
protein ATX. In investigating this novel mechanism, additional roles of ATX were also
revealed. The data obtained bring new knowledge to the field and will aid in the full
understanding of how to stimulate repair of the myelin sheath after injury.
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In the context of the demyelinating disease, MS, ATX mRNA and protein levels have
been found reduced (Comabella and Martin, 2007), thus suggesting that promoting
OLG differentiation under such pathological conditions may require the activation of the
molecular mechanisms mediated by ATX. In this regard, ATX plays an important role in
initiating the signaling pathways regulating gene expression changes during OLG
differentiation. Specifically, these changes are mediated through the activity of its
functionally active domain, the lysoPLD active site. More mechanistically, ATX’s
lysoPLD activity regulates HDAC1/2 activity and gene expression. Such a
differentiation-promoting role of ATX via its lysoPLD active site and via activation of
HDAC1/2 is supported by data in which the inhibition of ATX’s lysoPLD activity by
HA130 and S32826 both decreased overall HDAC activity, seen in vivo and in vitro
(Figs. 2.4,6), and increased histone acetylation of lysine 9 on Histone 3 (H3K9ac) (Fig.
2.7). Conversely, OLGs treated with LPA, the enzymatic product of ATX’s lysoPLD
activity, showed an increase in HDAC activity (Fig. 2.6D). Furthermore, inhibition of the
lysoPLD active site kept expression levels of Ugt8 and Cnp down-regulated and
maintained elevated Egr1 expression, thus inhibiting progenitor cells from differentiating
(Fig. 2.5D). In the zebrafish, genetic manipulation of atx, as well as specific inhibition of
the lysoPLD active site, led to a reduction in both cldnk and plp1b expression (Figs.
2.1,2,3). In support of the hypothesis that HDAC1/2 activation is downstream of the
ATX-LPA signaling cascade, inhibiting HDAC1/2, but not HDAC6, kept OLG
differentiation genes, Ugt8 and Cnp down-regulated and in a progenitor state; an effect
that could not be rescued by the addition of LPA (Fig. 2.8B,C). Thus, LPA, formed via
the lysoPLD active site of ATX, is essential in OLG differentiation as it enhances
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HDAC1/2 activity and ultimately regulates the gene expression changes needed for
proper OLG development (Fig. 2.9).
Although several extracellular signaling molecules, ATX included, are known to
be essential for OLG differentiation (Mitew et al., 2014), the intracellular regulators are
poorly understood. With regard to the data outlined in Chapter 2, the mechanism(s) by
which the ATX- LPA axis activates HDAC1/2 activity, needed for OLG differentiation,
has yet to be discovered. Previously, it has been reported that LPA induction of HDAC
activity is blocked by inhibiting receptor activation with pertussis toxin (Ishdorj et al.,
2008). The A-protomer of pertussis toxin ADP-ribosylates the α subunits of
heterotrimeric Gi/o proteins, resulting in the receptors uncoupling from the Gi/o proteins.
The uncoupling of GPCR from the Gi/o proteins disrupts the communication between the
receptor and the effector signaling cascades (Mangmool and Kurose, 2011). All current
LPA receptors couple to Gi/o (Chun, 2013). Thus, the inability of LPA to activate HDAC
activity through Gi/o, reveals the possible involvement of signaling pathways initiated by
Gi/o in OLG differentiation. Although LPA6 signals through Gi/o, data outlined in Chapter
4 reveal the unlikelihood that this receptor activates HDAC1/2 signaling during OLG
differentiation. It is possible, however, that the signaling pathways, downstream of LPA6
and the ATX-LPA signaling axis, converge and together mediate gene expression
changes. Interestingly, LPA also failed to induce HDAC activity when LPA1 expression
was reduced by siRNA (Ishdorj et al., 2008). These findings, together with the maLPA1null mice studies, in which LPA1 plays a role in the later stages of OLG development,
and not during early OPC differentiation (Garcia-Diaz et al., 2015), proves it unlikely that
activation via LPA1 stimulates HDAC1/2 activity during OPC differentiation.
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Nonetheless, these experiments provide insight to possible signaling pathways linking
the ATX-LPA axis to HDAC1/2 regulation of gene expression changes needed for OLG
differentiation. Key players seen in the converging signaling cascades downstream of
LPA receptors are protein kinases.
Signaling via protein kinases acts to connect the extracellular environment to the
intracellular environment. As diverse protein signaling cascades are initiated via the
activation of LPARs/Gi/o, it is possible that activation of HDAC1/2 is a result of protein
kinase activity. Interestingly, hyperphosphorylation of HDAC1 and HDAC2 leads to a
slight, but significant, increase in deacetylase activity (de Ruijter et al., 2003). HDAC1
has been reported to be phosphorylated by casein kinase 2 (CK2), cAMP-dependent
protein kinase, and protein kinase G(Cai et al., 2001). HDAC2, however, is
phosphorylated uniquely by protein kinase CK2 in vitro (Tsai and Seto, 2002). Thus,
CK2 presents itself as an interesting protein kinase involved in the regulation of both
HDAC1 and 2. Though initially considered to be a “constitutively active” protein, it is now
understood that activated Akt can phosphorylate CK2 (Nguyen and Mitchell, 2013).
Additionally, CK2 has been recorded to physically associate with Akt (Guerra, 2006),
phosphorylate Akt on Ser129 (Di Maira et al., 2005), contribute to Akt activation (Di
Maira et al., 2009), and interact with Akt within Wnt/β-catenin signaling (Ponce et al.,
2011). In association with Akt, activation of the PI3K/Akt/mTOR pathway has recently
been shown to trigger phosphorylation of HDAC1 in breast cancer cells (Citro et al.,
2015). Interestingly, the PI3K/Akt/mTOR pathway is one of the signaling pathways
initiated by Gi/o activation. As such, activation and interaction of the PI3K/Akt/mTOR
pathway with CK2 may contribute to the regulation of HDAC1/2. This hypothesis,
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however, will need further examination to pinpoint the exact mechanisms leading the to
epigenetic changes initiated via the ATX-LPA axis observed during OLG differentiation.
Targeting individual LPA receptors, and the signaling pathways by which they alter
gene expression, is a conceivable approach to trigger differentiation of OLGs. Thus, a
better understanding of the functions of individual LPA receptors involved in OLG
differentiation are needed. In researching the effect of the under-investigated LPA6 in
OLG differentiation, it was found that LPA6 is critically involved in the regulation of OLG
differentiation genes, Cnp and Ugt8, in vitro (Fig 4.1) and myelin gene, plp1b, in vivo
(Fig. 4.2). Though initially seen to parallel results seen when inhibiting the lysoPLD
domain of ATX, and revealing a potential receptor downstream of the ATX-LPA axis, it
was later revealed that gene expression changes induced by down-regulation of Lpar6
somewhat differed from those that are epigenetically modulated.
Taking a closer look, the signaling events of the ATX-LPA-HDAC1/2 axis and those
downstream of LPA6 appear to have different effects on OLG gene regulation.
Reduction of Lpar6 expression by roughly 50%, maintained the down-regulated
expression of OLG differentiation genes, Ugt8 and Cnp (Fig. 4.1B), however, the
expression of Cnp did not reach the same level of down-regulation as seen when
inhibiting the lysoPLD active site (Fig. 2.5D). Most intriguingly, down-regulation of Lpar6
did not have an effect on the expression of OLG differentiation inhibitor, Egr1 (Fig.
4.1B), whereby, inhibition of the lysoPLD active site caused Egr1 expression to remain
elevated (Fig. 2.5D). Of utmost importance is the data revealing that the downregulation of Lpar6 does not effect HDAC activity (Fig. 4.3). In line with these findings,
no change was found in the acetylation of lysine 9 on Histone 3 (H3K9ac) in siRNA
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treated cells compared to control (Fig. 4.3). The data further exemplify the differences in
signaling through the ATX-LPA-HDAC1/2 axis and through LPA6.
One factor that remained consistent was the finding that following the inhibition of
ATX’s lysoPLD active site and by the siRNA mediated down-regulation of Lpar6,
primary changes were found in gene expression and were independent of
morphological aspects of OLG differentiation. Neither treatment had a significant effect
on the process morphology of OLGs (Supp. Fig. 8.1;Fig.4.1C). As OLGs develop along
the lineage, alterations in both gene expression and cytoskeletal maturation are seen.
The studies outlined in this dissertation reveal that both the ATX-LPA-HDAC1/2 and
LPA6 signaling pathways influence immediate gene expression changes in OLG
differentiation rather than directly mediating cytoskeletal changes. It is plausible,
however, that changes in morphology could result as a consequence of the changes in
gene expression.
The discrepancies seen between targeting the lysoPLD active site and LPA6 were
initially hypothesized to be the result of experimental timing differences. In this context,
experimentation using siRNA prolongs the time in which OLGs are exposed to mitogens
(in order to ensure proper knockdown of the gene) and though the time frame from
mitogen removal remains consistent, it is plausible that subsets of these OPCs are
differentiated. It is understood that there is a short time window in which HDAC1/2 play
a crucial role in the differentiation phase of OLG development. Data outlined in this
dissertation further confirms this role and links it to the extracellular signaling of LPA, by
way of ATX’s lysoPLD active site. It is conceivable, however, that if siRNA experiments
targeted a subset of OPCs that were past the differentiation stage, differences would be
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seen in gene expression and could underlie the variances seen in Cnp and Egr1
expression levels. To address this idea, Egr1 expression was analyzed following the
same experimental timeline seen in siRNA experiments, whereby OLGs were subjected
to mitogens for an additional 24hrs before treatment with HA130 (ATX lysoPLD active
site inhibitor). Egr1 expression remained up-regulated (Supp. Fig. 8.2), as was seen
previously in Chapter 2, thereby dispensing the experimental timeline as a confounding
factor contributing to the changes seen between the ATX-LPA-HDAC1/2 and LPA6
pathways.
An alternative, and more plausible, hypothesis elucidating divergent gene
expression patterns, is notion that signaling events downstream of LPA6 differ from the
ATX-LPA-HDAC1/2 pathway, in that they do not activate epigenetic players. LPA6
exerts its effects through the activation of Gα12/13 and Gαi/o (Chun, 2013). Though many
signaling pathways are found downstream of Gα12/13 and Gαi/o, recently the
PI3K/Akt/mTOR pathway has been shown to play a role in OLG development and
myelination (Flores et al., 2008; Narayanan et al., 2009; Sherman et al., 2012).
Specifically, mTOR, a serine threonine protein kinase, regulates OLG differentiation in
vitro (Tyler et al., 2009). mTOR exists in two functionally distinct complexes, mTORC1
and mTORC2, which are more classically known to be associated with the regulation of
translation, but have recently been found to play a role in the regulation of gene
transcription (Bercury et al., 2014; Cunningham et al., 2007; Laplante and Sabatini,
2013). While there is a tight balance between the activity of mTORC1 and mTORC2 in
OLG differentiation, it has recently been found that signaling through mTORC1 is critical
for the regulation of OLG differentiation and myelination (Bercury et al., 2014).
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Interestingly, ablation of Raptor, a protein component of mTORC1, reduced both protein
and gene expression levels of CNP and PLP in the corpus callosum and spinal cord
(Bercury et al., 2014). Though UGT8 was not analyzed in these studies, reduction of
CNP and PLP, seen with the loss of mTORC1, parallels the reduction in Cnp and plp1b
found by down-regulation or genetic manipulation of LPA6. Additionally, Raptor has
been shown to physically bind to and regulate how YY1 binds to gene promoters
(Cunningham et al., 2007). This finding is particularly interesting with regard to OLGs,
because YY1 has been shown to be essential for OLG progenitor differentiation (He et
al., 2007).
Furthermore, multiple signaling pathways are often coordinately regulated by
extensive crosstalk and the pharmacological inhibition of the mTOR pathway can
feedback to up-regulate the MAPK (mitogen-activating protein kinase) pathway
(Carracedo et al., 2008). These studies link the PI3K/Akt/mTOR pathway with that of the
Ras/Raf/MEK/Erk pathway. In evaluating the crosstalk between these two pathways
(both found downstream of Gαi/o), Dai et al., 2014 found that both major signaling
pathways, through Akt/mTOR and MEK/Erk1/2, are necessary for full differentiation of
OPCs to mature OLGs in vitro. Though these studies primarily focused on the
expression of MBP, it does not exclude the possibility that these signaling events are
initiated by the activation of LPA6. As previously discussed, the PI3K/Akt/mTOR
pathway plays a role in the phosphorylation of HDAC1 (Citro et al., 2015), and there is
reason to hypothesize that protein kinases play a role in the epigenetic changes
regulated by the ATX-LPA axis. Though LPA6 does not appear to activate HDAC
activity, as seen regulated by the ATX-LPA axis, it is plausible that there is crosstalk
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between the two signaling pathways that regulate overall gene expression changes
needed for proper OLG differentiation. Taken together, there are many implications that
protein kinase signaling, downstream of Gi/o, play a role in OLG differentiation and
further studies revealing a possible association with LPA6 and the ATX-LPA axis will
further elucidate the importance of LPA signaling in OLG development.
In brief, it is unlikely that the ATX-LPA-HDAC1/2 axis acts through LPA6 to activate
the epigenetic changes needed for proper OLG differentiation. It is plausible, however,
that LPA6, works in conjunction with the ATX-LPA-HDAC1/2 signaling cascades to fine
tune gene expression changes needed for proper development. It is also conceivable
that the activation of LPA6, by LPA, is a result of an alternative, LPA-producing source.
ATX has been shown to be dispensable for hair follicle morphogenesis (Grisanti et al.,
2013) and LPA6 is essential for the maintenance of human hair growth (Pasternack et
al., 2008, 2009). The ligand, LPA, needed to stimulate LPA6 for hair growth, however, it
not a product of ATX, but rather by PA-PLA1 (Inoue et al., 2011). Thereby, we cannot
rule out the possibility that other sources of LPA may stimulate LPA6 in OLG
differentiation.
ATX is involved in a wide range of physiological mechanisms including, but not
limited to, lymphocyte homing (Knowlden and Georas, 2014), hyperoxic lung injury
(Nowak-Machen et al., 2015), cancer motility (Jankowski, 2011) and the formation of the
vasculature by vasculognesis and angiogenesis (Kleger et al., 2011). The role of ATX is
becoming more evident as further research is conducted, however, a great deal of
information is yet to be uncovered regarding this extracellular protein. Studies present in
this dissertation display one of the newest discoveries regarding ATX, its subsequent

146

interaction with HIV-1 viral protein Tat. As seen in chapter 6, Tat has a negative effect
on the differentiation of OLGs, both by down-regulating OLG differentiation genes and
causing process retraction (Fig.6.1,2,3). As Tat is considered a “sticky” protein that
binds many receptors, it was initially suspected that Tat binds LPA receptors and alters
their expression. To our surprise, Tat had no effect on the expression of LPA1-6 (Fig.
6.4). Looking further, the addition of LPA, formed via ATX’s lysoPLD domain, was able
to rescue the effects of Tat on OLG mRNA expression and protected OLGs against Tat
induced process retraction (Fig. 6.2,3). Thus, implying that Tat interferes with LPA
signaling, which as outlined in this dissertation, is now known to play a large role in OLG
differentiation. Rather than binding to LPA receptors on OLG, the negative effects of Tat
are a result of a protein-protein interaction with ATX that results in the reduction of
ATX’s lysoPLD activity (Fig.6.5,6). Hence, Tat released in HIV-1 individuals limits the
protective properties of ATX lysoPLD active site on OLG differentiation and could
attribute to the WM injuries seen in infected patients. These data provide another novel
role of ATX in pathological conditions found in the injured CNS and exemplifies the
importance of this protein in OLG differentiation.
To conclude, the data outlined in this dissertation, reveal novel molecular
mechanisms, that are mediated by ATX and LPA6, and are critically involved in the
regulation of OLG differentiation; providing insight into innovative therapeutic targets
suitable for stimulating remyelination under pathologic conditions such as those found in
MS as well as HIV+ patients (Fig. 7.1). These studies are the first of their kind revealing
the importance of the understudied LPA6 in OLG differentiation, a finding that could lead
to the creation of novel therapeutic drugs. Additionally, ATX was found to interact with
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the viral protein, Tat, a unique discovery that may lead to future breakthroughs
pinpointing the increasingly important role of ATX in glial biology. Further investigation
into the epigenetic pathways that regulate OLG gene expression, LPAR expression and
signaling, as well as ATX-Tat interactions may reveal important information regarding
development that can be used when developing and testing future therapeutic
approaches.

148

149

Figure 7.1. Schematic cartoon representing effects of ATX’s lysoPLD active site in
development and pathology. Development: LPA, formed via the lysoPLD active site
of ATX binds to one or more of the LPA receptors, LPA1-5, on OLGs, to activate
HDAC1/2 and regulate gene expression changes needed for OLG differentiation. LPA
signaling through LPA6 likely acts through a different signaling pathway(s) (possibly
through Akt/mTOR and/or MEK/Erk1/2) to regulate gene expression changes. LPA
formed via PA-PLA1 may be the ligand for LPA6 signaling. Pathology: LPA acts as a
protectant against HIV-Tat induced decreases in process network area of OLGs. LPA
can also rescue the effect of HIV-Tat on OLG differentiation genes. At the same time,
HIV-Tat can block the generation of LPA by negatively affecting ATX’s lysoPLD activity.
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Chapter 8
Supplemental Figures, Data and Protocols
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Supplemental Figure 8.1: Inhibition of ATX’s lysoPLD active site does not change
overall process network area of OLGs. Box and whisker plot depicting process
network area of OLGs for HA130 treated cells as determined by immunostaining and
morphology analysis. The plot depicts medians and quartiles of three independent
experiments. Whiskers represent the 10th and 90th percentile.
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Supplemental Figure 8.2. Egr1 remains up-regulated with HA130 treatment after
72hr. Bar graph depicting mRNA levels for transcriptional inhibitor Egr1 as determined
by real-time reverse transcription (RT)-qPCR analysis. OLGs were treated with
mitogens for 48hr before the addition of HA130 or DMSO control for an additional 24hr.
Control (DMSO-treated) values were set to 100% and experimental values were
calculated accordingly. Data shown represent means ± SEM. *p≤0.05.
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Supplemental Figure 8.3. LPA1-4 inhibitor can be rescued by LPA, but not at the
same magnitude as seen with rescue of the ATX lysoPLD active site alone. A.
Timeline depicting when cells were removed from mitogens and treated. B. Box and
whisker plot depicting Ugt8 mRNA gene expression of OLGs treated with BrP-LPA
(Inhibitor of LPA1-4) or HA130 (ATX lysoPLD Inhibitor) +/- the addition of LPA as
determined by qRT-PCR analysis. The plot depicts medians and quartiles of three
independent experiments. Whiskers represent the 10th and 90th percentile. Control
(DMSO-treated) values were set to 100% and experimental values were calculated
accordingly. Data shown represent means ± SEM. #p≤0.05, *p≤0.05.
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Figure 8.4: The effect of TAT on ATX lysoPLD activity has regional differences.
(A-F) Tat expression was induced for 10 days before animals were sacrificed and
different regions of the mouse brain were dissected. (A-C) ATX lysoPLD activity in
proteins extracted from whole brain, midbrain or frontal cortex were not affected by 10day Tat expression. (D-E) In hippocampus or striatum, expression of Tat for 10 days
significantly increases ATX lysoPLD activity. (F) ATX lysoPLD activity was significantly
decreased by 10-day Tat expression in cerebellum. (G-I) Astrocytes from whole brain,
hippocampus and cerebellum were cultured and treated with 100 nM Tat. ATX lysoPLD
activity from astrocytes of all three areas was increased with Tat exposure. [A-F: *,&:
p<0.05 vs. Tat-; G-I: * p<0.05 vs. Control; Two-way ANOVA (Tat, Time) followed by
post-hoc Bonferroni’s test, N=3].
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A2B5 Immunopanning for Oligodendrocytes
Preparation of A2B5 plates: (10 pups/150mm plate)
• Obtain 3 Falcon 150 x 15mm (non tissue culture) plates and put a line on the side of
the plate with a sharpie (will help to ensure all areas of plate are washed)
• Prepare IgM (-20° freezer in purple box reading IgM) in 50mM Tris/HCL (pH 9.5).
Add 12.5ml IgM to dish followed by 25ml Tris HCL (1x). Make sure the liquid covers
the entire bottom of the dish.
• Put in 4°C T.C. Fridge O/N– keep sterile!! If a shorter time is needed, incubate in
37°C for 2-3hrs
• Remove (do not wash) IgM and replace with A2B5 supernatant media (-80° freezer
on bottom left, place in water bath to defrost and centrifuge 1.5 X 1,000 for 3 min).
• Add A2B5 with 30ml pipette, 10ml for each plate. Then add 10ml of DMEM/Ab/FCS
to each plate.
• Incubate O/N at 4°C
Set Up
• Remove plates from 4°C and wash 2x with PBS (sterile) and incubate 37°C/CO2
until required
• Obtain sterilization pouch filled with scissors and scalpel and filter paper pouch from
the bottom drawer of the bench (with the microscope on top).
o Big Scissor- cut the heads from the body
o Middle Scissor- remove brain from skull
o Small Scissor- remove meninges and mince in HANKS solution
• Obtain filter (blue- 40 micron) from the top drawer of the bench with the microscope
on top
• Put 5 50ml tubes in hood (one for digestion, two for washing and two to hold mixed
glia that will be given to Dr. Cabral’s lab)
• Put DNase on ice and put trypsin in the water bath
• If using coverslips: put coverslips in ethanol and then sterile water and let them dry
in the hood on white filter paper (middle drawer of bench in the middle of T.C.)
• UV everything in hood for about 10 min while getting the pups (5th floor rat room)
Procedure:
• Go to fifth floor to get pups, make sure to bring a box down to the animal room.
• Weigh pups on the T.C. scale and record weight
• Remove heads from pups using big scissor and put bodies in a plastic bag. Put
heads on a petri dish on ice.
• Extract brains (whole) from P2-P4 pups Cut from the brain stem up to the nose,
open skull and extract the whole brain. Place the brain on filter paper, remove the
cerebellum, and carefully drag the brain along the paper to remove excess blood.
Once clean place and mince in 60mm petri dish containing 5ml HANKS (T.C. fridge).
Use a razor blade to further mince the brains. Wash plate with HANKS – final
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volume + 10ml.
Add minced brains to a 50ml tube- using the extra HANKS to obtain every cell.
Add enzymes (2.5mL trypsin and 100ml DNAse I) incubate for 15 min at 37°C (swirl
around every 5 minutes), stirring every 5min.
Add fibronectin (human) to coverslips or wells. 1:10 dilution. Place in incubator for at
least 30 minutes.
Discard of paper towel and carcases in the freezer in T.C.
Wash scissors with water and then D.I. water and lay on paper towel.
Inactivate enzymes: add equal volume DMEM/10% FCS to cells taken from water
bath
Centrifuge cells at 1.2 x 1000 rpm for 3 min. Pour off supernatent, unless giving the
astrocytes to another lab.
Re-suspend pellet in 10ml DMEM/FCS. Aspirate with 16g, big (x5) and 22g, small
(x3) needles to achieve single cell suspension. Needles are found on the bottom
drawer of T.C. bench with microscope on top. Syringes are above the weigh station10ml volume.
Increase volume of cell suspension. If you have three plates, add to final volume of
30ml, then add 30ml again for 10ml on each plate. Plate out evenly among panning
plates (Mix 1 cell:1 media with DMEM/FCS per plate)
Incubate 30 min at 37°C/CO2
Then, remove/discard media (mostly containing unwanted astrocytes and glial cells)
Wash plates 2x with 1X PBS (discard washes)
Wash cells off plates (x2) with 10mL DMEM/FCS. Check on microscope to ensure
majority of cells are removed from plate. About 10 washes/quarter, physically force
the cells off the dish and into the media.
Collected cells: pass through FALCON 40mm cell strainer (top drawer of bench
with microscope on top- blue), centrifuge and re-suspend in 10mL
Differential adhesion: 10 min at 37°C/CO2 on non-TC (not cell star, 1 on ice and 1
in hood) 100mm dish.
Fibronectin Removal- during the 10 minute incubation, remove fibronectin from the
plates and add 50ul of PBS for a total of 2 washes. Leave in PBS until add media.
Make Media- Make sure to use FCS free media and add T3,N2, PDGF or bFGF.
Collect media and count cells- vacuum out media and add 1ml FCS free media.
Get a microcentrifuge tube and put 18ul of trypan blue in the tube. This dye will go
into cells that are dead. Then add 2ul of the resuspended pellet in 1ml of your
desired media. Take about 10ul of the dye and cells and put into cell counter. Count
all squares at the top left, right, lower left and right.
Plate out cells: (1-5x104 /well/100ml) in 24 well cluster plate
Incubate for 30 min (minimum) at 37°C/CO2 in DMEM/FCS
Add 400ml media/well and incubate overnight (O/N)

Medium- T3, N2- TC working aliquots box
bFGF and PDGF in -20°- things that make oligos proliferate box
T.C.- DNase- bottom right rack (-20°)
Trypsin- bottom left rack (-20°, 15ml tube)
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Preparation of zebrafish embryos for FACS
*Need a negative control (non-fluorescent embryos) for setting the FACS machine
*Do not use more than ~150 embryos per tube (50-60 is best)
*Works for 48hpf, 72hpf and 4dpf zebrafish
1. Dechorionate embryos and place in 1.5mL eppendorf tubes
2. Anesthetize with MESAB (Tricaine)
3. De-yolk embryos in 100uL calcium-free Ringer’s solution; pipette up and down
with 200uL pipette (x20-50 depending on how many embryos in tube)
4. Let sit on ice for 2min
5. Spin down (quick spin), remove liquid and wash with 1X PBS (x2)
6. Prepare 1mL (per number of tubes needed) of trypsin-EDTA 0.25% + 5mg/mL
collagenase + 100uL DNase. Will need separate tubes for different samples or if
have a very large number of embryos. (Have also used 500uL volume and
seems to work fine)
7. Add 200uL of trypsin/collagenase/DNase mix to each tube of embryos and
aspirate with 20-gauge needle in a 1mL syringe (x10); add the remaining 800uL
of solution and aspirate again with 20-gauge needle (x5)
8. Incubate in 30C water bath for 15min. At end of 15min aspirate again with 26gauge needle (x5-10). Aspirate more if needed.
9. Spin at 3000rpm for 2min in +4 centrifuge, remove liquid and wash with 1mL icecold 5%GS/PBS then spin again. Note when removing liquid from tube: If pellet is
very snotty and begins to suck up immediately, collect snotty pellet and put in a
new tube then empty the rest of liquid and put pellet back into original tube and
wash. This part can be tricky so be careful to not discard pellet.
10. At end, re-suspend pellet in 500uL ice-cold 5%GS/PBS and aspirate with 26gauge needle (x5-10). If using multiple tubes, divide the 500uL 5%GS/PBS
volume between tubes, aspirate, then combine into one tube at end with a final
volume of 500uL). If first time doing protocol, verify that method has worked by
running through a 40um cell strainer.
11. Collect cells from sorter in 500uL Trizol for RNA extraction or lysis buffer for
protein extraction.
12.
Collagenase type 2 (Worthington 4174): Fisher # NC9870009
Trypsin-EDTA 0.25% (1x) (Gibco) Invitrogen # 25200-056
DNase I, type II Sigma D4527
Calcium-free Ringer’s solution (recipe from the zebrafish book)
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Acetyl-Histone 3-Lysine 9 (H3K9ac) Staining of OLGs
04+
1. Fix with 4% Para for 10min (40µl)
2. Wash with PBS 3X5min (80µl)
3. Block with Media >30min
4. Primary Ab- 04 (make sure to spin down before add to cells) (60µl), leave overnight
at 4°C
5. Wash with PBS 3X5min (80µl)
6. Add secondary Ab at a dilution of 1:250 for 1hr RT (IgM 488)
7. Wash with PBS 3X5min (80µl)
Acetyl Histone 3 Lysine 9
1. Optional fix with 4% Para for 10min
2. Wash with PBS 3X5min (80µl)
3. Permeabilize with 1%/0.4M Sucrose/1XPBS for 10 min (important step to make sure
Ab can penetrate cell)
4. Wash with PBS 3X5min (80µl)
5. Block with media > 30min (50-60ul)
6. Add H3K9ac Ab at 1:400 O/N at 4°C
7. Wash with PBS 3X5min (80µl)
8. Add secondary Ab at a dilution of 1:250 for 1hr RT (Alexa Fluor Anti Rb)
9. Wash with PBS 3X5min (80µl)
Hoechst
1. Add Hoechst Stain for 10 min (50µl)
2. Wash with PBS 3X5min (80µl)
*Add vectoshield to slides and place coverslip on top. Use clear nail polish to seal the
edges.
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Protein Assay
1. Add 100ul Total Cell Extract Buffer + 2AB- Protease + Phosphatase Inhibitor
Cocktail (1:100) (per 1X106 cells) to each well
Total Cell Extract Buffer
Reagent
20mM Hepes pH 7.0
150mM NaCl
10mM KCL
1mMMgCl2
20%Glycerol
1% Triton X-100

Volume (250ml)
5mL (1M)
4.38g (2.19)
2.5mL (1M)
250ul (1M)
50ml (1M)
2.5ml

Volume (100ml)
2mL (1M)
1.75g (0.86)
74mg (1mL-1M)
20mL
1mL

2.
3.
4.
5.

Plate on ice and rock for 2 min
Use scraper to remove cells from plate
Spin down
Diluting Samplesa. 10xà 2.5µl sample + 22.5µl of PBS
b. 5x à 5.0µl sample + 20µl of PBS
6. ABS Reagents

Tube
Stock
A
B
C
D
E
F
G
Blank

Vol. BSA
300ul (stock)
375 (stock)
325 (stock)
175 (A)
325 (B)
325 (D)
325 (E)
100ul (F)
-

Vol. 1X BSA
125µl (1:4)
325µl (1:2)
175µl (1:2)
325µl (1:2)
325µl (1:2)
325µl (1:2)
400µl (1:5)
25

Final
2000
1500
1000
750
500
250
125
25
-

a. Amount= Samples (ex. 6) X 2= 12
b. BSA= 9 X 3 = 27
c. Total= 39, add another to make 40
d. 200ul of ABC reagents/well= 200µl X 40= 8000µl
e. A= 25 (.25 x 8000 = 2.0 X 2= 4.0ml)
f. B =24 (.24 x 8000 =1.920 X 2 = 3.840ml)
g. C=1 (.1 x 8000 = 80 x 2 = .160ml)
h. Total of 50 parts or 8mls in a 15ml tube, vortex and wait to react.
i. Add 200µl to BSA first and samples last.
7. Make plate
a. BSA samples- start from left to right: Stock, A,B,C,D,E,F,G,Blank. Add to
first three wells. Add 25µl of BSA
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b. Diluted samples- start from left to right and in 4th and 5th rows. Add 25ul of
sample
8. Incubate at 37°C in dark room for 1hr
9. Leave at RT for 15 min
10. Measure concentration on Pherastar under protein assay protocol
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IP Lab Data Analysis for Acetyl Histone 3 Lysine 9 Stain
`
Image Analysis 1
Username: Fuss lab
Password: 0825
Image Analysis 2
Username: Babette
Password: oligo
1. Obtain picture from the Q drive convert pictures to tif from Zen software. Open—
File---Export—Save to Natalie Preetha folder
2. Convert the picture to .tif by opening ZEN and export the picture in .tif 12 bit and
then save
3. Note units of measurements-pixel dimensions under scaling x
4. Under IP Lab open .tif file
5. Analyze- define XY units. Set 1 pixel=0.106 micrometers-add name or scroll
down to find AcetylH3.
6. Analyze-set acetyl H3 –uncheck calibration bar
7. Analyze-segmentation-Blue
8. segment color-magenta set min- ~840covers nucleus w/o holes and max-4094
(threshold applied to each image in the same way)
9. Math-split color channels-RGB – can use this to determine min/max
10. Enhance – edit color table-monochrome may be easier to view
11. Red-min-264
12. Analyze- Segmentation- Componenta. blue min-840 AND Red min-264
b. For NOT- select AND reverse
c. Must have blue and red checked- should now give a magenta color over
nucleus.
13. Analyze-Measure Segments-magenta segment-gives average intensity and area
of RBG
14. To remove oligos that you do no want to be analyzed use the eraser tool
15. Set measurements-sum, min, max, mean, shape for area, limit-to filter out
16. Measurement options-erase failing criteria
a. include interior holes
b. include a side and vertical margin (left+top)
c. outline-number
17. Max number-can have a limit
18. Analyze –measure segments ROI- gives table which gives individual
19. Sort by Area under set neasurements-3
20. Qualify segments-Magenta segments-table summarizes -gives average
21. Open multiple images
22. Edit-transfer attributes of original image-length units transfer to all or specific
image
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23. Analyze-segmentation-done
24. Analyze-quantify segments-summary will be added to same table
25. If need to erase non oligodendrocytes: Use erase tool-double click to choose
pixels and then quantify
26. Click on X to export table to excel
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ATX lysoPLD Activity Assay
1. For fish studies using protein extracted from whole zebrafish:
Prepare samples:
Dechorionate zebrafish and anesthetize with MESAB (at least 100μL/mL)
Quick wash embryos with 1x PBS (ensure they are anesthetized! – may take
a couple of minutes)
• Remove yolk sacs:
• Suspend fish in ice-cold Ringer’s solution (116mM NaCl; 2.9mM KCl; 1.8mM
CaCl2; 5mM HEPES, pH 7.2) + 1mM EDTA + protease inhibitors
• Pipette up and down with 200μl pipette ~10x-30x; liquid will become cloudy
• Quick spin to collect fish at bottom of tube
• Wash with ice-cold Ringer’s solution, quick spin, remove then add more
Ringer’s solution (x3) until solution is clear and can see fish (they should look
thin and stringy due to removal of yolk sac-can check under microscope to
see if most of yolk has been removed)
• Quick spin and remove solution
• Quick wash with 1X PBS then add 1X PBS at ~1μl/embryo + protease
inhibitor
• Homogenize with electronic pestle (~3sec/10μL) and spin 10,000rpm for 3min
at +4°C
• Transfer supernatant to fresh 1.5mL tube (keep homogenate on ice at all
times!!)
• Measure concentration with nanodrop “Protein A280”; Aliquot, label tubes and
store at -80C
2. For all OLG samples, you must obtain OLG supernatant in PHENOL-FREE
media. Spin down the supernatant to concentrate protein levels. Make sure you
start the activity assay with the same amount in all conditions. Do not dilute
samples from tissue culture- there is already a small amount of ATX being
secreted
3. Make master mixes for each sample (triplicates) in separate eppendorf
tubes (all reagents multiply by 3.3)
• Dilute samples in 1xPBS to a final volume of 115.5μL (35μL x 3.3):
100μg/100µL x 3.3 = 330μg total
• Do not forget to include a blank: 1X PBS only (no sample)
• Dilute FS-3 substrate from stock solution of 1 mM (in 1XPBS) to 50 µM in
reaction buffer (stock for assay) (Echelon L-2000)
• Working FS-3 concentration can vary from 0.5 to 5 µM.
• We currently use 2.5μM final in a volume of 5μL per reaction x 3.3 = 16.5μL
per sample master mix
• (New FS-3 should be reconstituted to a stock concentration of 1mM in 1X
PBS, not dH2O!)
4. In a black 96 well plate (Corning #3991), pipette the following reagents per well
(done in triplicates). Be sure to add FS-3 last!
•
•
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Volume Volume (x3.3)

Reagent

35μL

115.5μL

Sample + 1X PBS

10μL

33μL

FAF-BSA

50μL

165μL

Rxn Buffer

5µL

16.5µL

FS-3 substrate

[Stock]

[Final]

10 mg/mL 1 mg/mL
50 µM

2.5 µM

5. Read samples in the PHERAstar - Set to 37°C (turn on incubator in PHERAstar
several minutes before reading to allow to warm up). Incubation time can vary
depending on enzyme activity and concentration.
Settings:
• Protocol name: ATX Activity Assay – Fluorescence (Do not change settings
so can compare different runs)
• Excitation = 494nm / Emission = 520nm
• Cycle time: 600sec (10 min); Number of flashes per well: 10
• Focal height and gain have already been set on this machine for this type of
plate and samples, do not change!
• Focal height: 5.0mm; Gain: 110 (set to 20% maximum so signal will not
saturate)
6. Incubator will not shut off on its own. After the run is over, take the plate out and
shut off incubator because if plate left in overnight, all wells will evaporate into
machine!
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RNA extraction from whole zebrafish
1. Dechorionate zebrafish embryos and transfer to a 1.5mL tube
2. Anthesthetize with MESAB (42uL/mL system water) and wait ~5-10min – check
that fish are no longer swimming around by inverting tube a few times **All steps
involving Trizol should be performed in fume hood!** (Trizol is located in 4C
refridgerator)
3. Remove system water and add ~200uL Trizol and homogenize with electronic
pestle for a few seconds until embryos are in solution (be careful with
homogenizer and make sure Trizol does not spill out of tube) (Note: can store
homogenized embyros in Trizol at -80C if cannot finish protocol)
4. Add 300uL more of Trizol and vortex to completely mix – total volume = 500uL.
Incubate samples at RT for 5min
5. Add 100uL of chloroform. Cap tubes securely and shake vigorously by hand for
15sec and incubate at RT for 2-3min
6. Centrifuge at 12,000xg for 15 min at 4C. Mixture will separate into a lower red
(phenol/chloroform phase), a white interphase and a clear aqueous phase. RNA
is located in this top aqueous phase (volume is ~60% of total volume)
7. Transfer aqueous phase only to a new tube and precipitate RNA by adding
250uL isopropanol. Incubate at RT for 10min and spin at 12,000xg for 10min at
4C (The RNA will form a gel-like pellet on side of tube)
8. Remove supernatant and wash pellet with 500uL 75% ethanol. Mix sample by
vortexing
9. Centrifuge at 7500xg for 5min at 4C
10. Remove as much supernatant as possible without disturbing RNA pellet and let
air dry for 5-10min (leave caps open)
11. Elute in RNase-free dH2O (~20-100uL dH2O)
12. Measure concentration on nanodrop label tubes and store at -80C
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Image Analysis
Username: Fusslab
Password: 0825
Software: IP lab
Q drive for pictures
Dennis_VCU script for analysis- don’t save anything to the script
1. Get image (TIF) of interest from Q drive. Make sure to take only one cell with one
nucleus. Always take pictures that were taken with 40X magnification.
2. Free hand the region of interest using the dotted tool. Trace around the cell,
leaving out anything not connected to the cell.
3. Go to the MATH tab and split color channels. Keep under RGB, and get rid of
blue.
4. Click RUN- segmentation.
5. Create own threshold, mask to select the processes, and move min slider back
and forth.
6. Receive measurement results: sum of the threshold value, mean/area
7. The top number is the network area and the bottom is the process index
8. * If you have a big gap- it may count as 2 cells and give 4 numbers. If you know
that it is part of the same cell, you can add the numbers.
9. Go back to the free hand tool and draw around the cell body, make sure the
nucleus is covered.
10. With receive 2 numbers- make sure they are the same! Subtract the cell body
from the whole cell measurement.
11. * If the cell body is below 50- the program will not be able to measure it.
12. Go to FILE- EXPORT-EXCELL
13. Put Measurement Results in sheet 1 of excel.
Jameel EZ- enable macros
1. Set cursor to A1-column 1 (blank)
2. Tools- MACRO-MACROS-RUN
3. Take 4 numbers and put horizontally
4. Highlight all horizontal numbers
5. Use the filter cone, drop down menu and get rid of the blanks
6. Copy 1st three columns
7. Clear contents and paste into H2
8. NA/PI/Cell Body
9. Copy formula from old experiment
10. NA PI complexity- take average from each column and paste values in column O.
11. Normalize to control cells
12. The average of the normalized cells should all equal 100.
13. Highlight three column: net area/ proc are/ complexity and the avg/ NA norm/PI
norm/NC
14. Go back to treated cells and copy
170

15.
16.
17.
18.

Take the average and this number is compared to 100 (control)
Never want number to be 0.
Take figures and go to sigmaplot and measure standard error, etc.
Use about 30-35 cells per experiment and have an N of at least 3, may need 4
or 5.
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